[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 175
1. Maillo A, Orfao A, Espinosa AB, Sayagués JM, Merino M, Sousa P, Lara M, Tabernero MD: Early recurrences in histologically benign/grade I meningiomas are associated with large tumors and coexistence of monosomy 14 and del(1p36) in the ancestral tumor cell clone. Neuro Oncol; 2007 Oct;9(4):438-46

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early recurrences in histologically benign/grade I meningiomas are associated with large tumors and coexistence of monosomy 14 and del(1p36) in the ancestral tumor cell clone.
  • Tumor recurrence is the major clinical complication in meningiomas, and its prediction in histologically benign/grade I tumors remains a challenge.
  • In this study, we analyzed the prognostic value of specific chromosomal abnormalities and the genetic heterogeneity of the tumor, together with other clinicobiological disease features, for predicting early relapses in histologically benign/grade I meningiomas.
  • A total of 149 consecutive histologically benign/grade I meningiomas in patients who underwent complete tumor resection were prospectively analyzed.
  • Similarly, histologically benign/grade I meningiomas showing coexistence of monosomy 14 and del(1p36) in the ancestral tumor cell clone displayed a higher frequency of early relapses.
  • In fact, coexistence of -14 and del(1p36) in the ancestral tumor cell clone, together with tumor size, represented the best combination of independent prognostic factors for the identification of those patients with a high risk of an early relapse.
  • Our results indicate that patients with large histologically benign/grade I meningiomas carrying monosomy 14 and del(1p36) in their ancestral tumor cell clone have a high probability of relapsing early after diagnostic surgery.
  • [MeSH-major] Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 14 / genetics. Meningeal Neoplasms / genetics. Meningioma / genetics. Neoplasm Recurrence, Local / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 1997 Jul;28(7):779-85 [9224744.001]
  • [Cites] Brain Pathol. 1990 Sep;1(1):19-24 [1688296.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14719-24 [9405679.001]
  • [Cites] Cancer. 1998 Jun 1;82(11):2262-9 [9610708.001]
  • [Cites] Arq Neuropsiquiatr. 1997 Sep;55(3A):431-7 [9629361.001]
  • [Cites] Mayo Clin Proc. 1998 Oct;73(10):936-42 [9787740.001]
  • [Cites] Ann Genet. 1998;41(3):164-75 [9833072.001]
  • [Cites] Neuropathol Appl Neurobiol. 1998 Dec;24(6):441-52 [9888154.001]
  • [Cites] Cancer Genet Cytogenet. 1999 Apr 15;110(2):103-10 [10214357.001]
  • [Cites] Oncogene. 1999 Apr 1;18(13):2231-9 [10327069.001]
  • [Cites] Acta Neurochir (Wien). 1999;141(9):921-32 [10526073.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1957 Feb;20(1):22-39 [13406590.001]
  • [Cites] Am J Clin Pathol. 2005 May;123(5):744-51 [15981814.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7121-6 [16103061.001]
  • [Cites] Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):772-80 [16467088.001]
  • [Cites] In Vivo. 2006 Mar-Apr;20(2):271-5 [16634530.001]
  • [Cites] Clin Cancer Res. 1999 Nov;5(11):3569-77 [10589773.001]
  • [Cites] J Neurosurg. 2000 Mar;92(3):401-5 [10701525.001]
  • [Cites] Clin Neuropathol. 2000 Nov-Dec;19(6):259-67 [11128617.001]
  • [Cites] J Neurooncol. 2000 Dec;50(3):207-13 [11263500.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Jun;60(6):628-36 [11398839.001]
  • [Cites] Cancer. 2001 Jul 15;92(2):377-85 [11466693.001]
  • [Cites] Am J Pathol. 2001 Aug;159(2):661-9 [11485924.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] Cytometry. 2002 Jun 15;50(3):153-9 [12116338.001]
  • [Cites] Cancer Genet Cytogenet. 2003 Jan 15;140(2):99-106 [12645646.001]
  • [Cites] BMC Cancer. 2003 Mar 4;3:6 [12614485.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3285-95 [12947064.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Jan 15;148(2):123-8 [14734222.001]
  • [Cites] J Clin Pathol. 2004 Oct;57(10):1033-7 [15452155.001]
  • [Cites] Histopathology. 1993 Oct;23(4):349-53 [8300070.001]
  • [Cites] Neurosurgery. 1993 Dec;33(6):955-63 [8134008.001]
  • [Cites] J Formos Med Assoc. 1994 Feb;93(2):145-52 [7912586.001]
  • [Cites] Acta Neurochir (Wien). 1994;126(2-4):53-8 [8042555.001]
  • [Cites] Genes Chromosomes Cancer. 1994 Apr;9(4):296-8 [7519053.001]
  • [Cites] Rom J Neurol Psychiatry. 1994 Oct-Dec;32(4):237-51 [7779743.001]
  • [Cites] Cancer Res. 1995 Oct 15;55(20):4696-701 [7553651.001]
  • [Cites] Cancer Genet Cytogenet. 1995 Dec;85(2):101-4 [8548731.001]
  • [Cites] Oncogene. 1996 Apr 4;12(7):1417-23 [8622857.001]
  • [Cites] Neurosurgery. 1996 Jul;39(1):2-7; discussion 8-9 [8805134.001]
  • [Cites] J Neurosurg Sci. 1996 Mar;40(1):17-23 [8913957.001]
  • [Cites] Oncogene. 1997 Feb 6;14(5):611-6 [9053860.001]
  • [Cites] J Mol Diagn. 2004 Nov;6(4):316-25 [15507670.001]
  • [Cites] J Neurosurg. 1983 Jan;58(1):51-6 [6847909.001]
  • [Cites] Acta Neuropathol. 1983;61(2):130-4 [6637397.001]
  • [Cites] J Neurosurg. 1984 Jan;60(1):52-60 [6689728.001]
  • [Cites] J Neurosurg. 1985 Jan;62(1):18-24 [3964853.001]
  • [Cites] Surg Neurol. 1986 Mar;25(3):233-42 [3945904.001]
  • [Cites] Cancer Genet Cytogenet. 1986 May;22(1):63-8 [3456829.001]
  • [Cites] J Neurosurg. 1986 Aug;65(2):168-71 [3723173.001]
  • [Cites] Neurochirurgie. 1986;32(2):129-34 [3724942.001]
  • [Cites] Cancer Genet Cytogenet. 1987 May;26(1):127-41 [3470128.001]
  • [Cites] Clin Neuropathol. 1989 Jan-Feb;8(1):41-4 [2706843.001]
  • [Cites] Acta Neurochir (Wien). 1989;100(3-4):104-7 [2589115.001]
  • [Cites] J Neurosurg. 1992 Oct;77(4):616-23 [1527622.001]
  • [Cites] J Med Assoc Thai. 1997 Jul;80(7):473-8 [9277078.001]
  • (PMID = 17704362.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1994101
  •  go-up   go-down


2. Wrobel G, Roerig P, Kokocinski F, Neben K, Hahn M, Reifenberger G, Lichter P: Microarray-based gene expression profiling of benign, atypical and anaplastic meningiomas identifies novel genes associated with meningioma progression. Int J Cancer; 2005 Mar 20;114(2):249-56
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microarray-based gene expression profiling of benign, atypical and anaplastic meningiomas identifies novel genes associated with meningioma progression.
  • To identify gene expression profiles associated with human meningiomas of different World Health Organization (WHO) malignancy grades, we analyzed 30 tumors (13 benign meningiomas, WHO grade I; 12 atypical meningiomas, WHO grade II; 5 anaplastic meningiomas, WHO grade III) for the expression of 2,600 genes using cDNA-microarray technology.
  • Receiver operator curve (ROC) analysis with a cutoff value of 45% selection probability identified 37 genes with decreased and 27 genes with increased expression in atypical and anaplastic meningiomas, compared to benign meningiomas.
  • Supervised classification of the tumors did not reveal specific expression patterns representative of each WHO grade.
  • However, anaplastic meningiomas could be distinguished from benign meningiomas by differential expression of a distinct set of genes, including several ones associated with cell cycle regulation and proliferation.
  • [MeSH-major] Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Meningeal Neoplasms / genetics. Meningioma / genetics. Oligonucleotide Array Sequence Analysis

  • Genetic Alliance. consumer health - Meningioma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2004 Wiley-Liss, Inc.
  • (PMID = 15540215.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


3. Saceda-Gutiérrez JM, Isla-Guerrero AJ, Pérez-López C, Ortega-Martínez R, Gómez de la Riva A, Gandia-González ML, Gutiérrez-Molina M, Rey-Herranz JA: [Solitary fibrous tumors of the meninges: report of three cases and literature review]. Neurocirugia (Astur); 2007 Dec;18(6):496-504
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Solitary fibrous tumors of the meninges: report of three cases and literature review].
  • [Transliterated title] Tumor fibroso solitario meníngeo: descripción de tres casos y revisión de la literatura.
  • We report 3 patients with fibrous solitary tumor of meningeal location where we described the histological study, as well as evolution after the surgical treatment.
  • Checking the literature the tumor is indistinguishable clinical and radiolocally of the typical meningioma, doing necessary the use of inmunohistochemistry to do the differential diagnosis, where positiveness for CD34 and the negativeness for EMA define the fibrous solitary tumor.
  • It is about a benign tumor, where total removing is the principal factor in prognosis, nevertheless there are cases of local recurrences and long-distance metastasis.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningeal Neoplasms / radiography. Solitary Fibrous Tumors / pathology. Solitary Fibrous Tumors / radiography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18094909.001).
  • [ISSN] 1130-1473
  • [Journal-full-title] Neurocirugía (Asturias, Spain)
  • [ISO-abbreviation] Neurocirugia (Astur)
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 46
  •  go-up   go-down


Advertisement
4. Aghi M, Barker FG 2nd: Benign adult brain tumors: an evidence-based medicine review. Prog Neurol Surg; 2006;19:80-96
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign adult brain tumors: an evidence-based medicine review.
  • BACKGROUND: Benign adult brain tumors can be managed conservatively or using surgery, radiation, or medicines.
  • While randomized comparisons assessing tumor recurrence, quality of life, or survival are the ideal means of comparing treatments, it can be difficult to recruit patients to such trials and lengthy follow-up periods are needed because of the slowly progressive natural history of these tumors.
  • METHODS: Review of the literature on benign adult brain tumors using evidence-based standards and focusing on meningiomas, pituitary adenomas, and vestibular schwannomas, which together represent the majority of WHO grade 1 adult brain tumors.
  • RESULTS: Nearly all studies of benign adult brain tumors were of relatively poor quality (level 3 or poorer).
  • CONCLUSIONS: While randomized clinical trials comparing conservative management, surgery, radiation, and medical management of benign adult benign tumors are unlikely to occur, there is some level 3 evidence that can assist in their treatment.
  • [MeSH-major] Brain Neoplasms / therapy. Evidence-Based Medicine
  • [MeSH-minor] Adenoma / therapy. Adult. Humans. Meningeal Neoplasms / therapy. Meningioma / therapy. Neuroma, Acoustic / therapy. Neurosurgical Procedures. Phototherapy. Pituitary Neoplasms / therapy. Radiosurgery

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17033148.001).
  • [ISSN] 0079-6492
  • [Journal-full-title] Progress in neurological surgery
  • [ISO-abbreviation] Prog Neurol Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 58
  •  go-up   go-down


5. Mori Y, Kondo T, Iwakoshi T, Kida Y, Kobayashi T, Yoshimoto M, Hasegawa T: Malignant lymphoma arising in the cerebral parenchyma adjacent to a parasagittal meningioma. Neurol Med Chir (Tokyo); 2006 Aug;46(8):398-400
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Two separate tumors were identified with quite different histological features.
  • The extra-axial tumor was identified as benign transitional meningioma and the intra-axial tumor as diffuse large cell type malignant lymphoma.
  • However, development of new different tumors is possible, although thought to be rare.
  • [MeSH-major] Brain Neoplasms / complications. Brain Neoplasms / pathology. Lymphoma / complications. Lymphoma / pathology. Meningeal Neoplasms / complications. Meningeal Neoplasms / pathology. Meningioma / complications. Meningioma / pathology

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16936461.001).
  • [ISSN] 0470-8105
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


6. Scherer K, Johnston J, Panda M: Dural based mass: malignant or benign. J Radiol Case Rep; 2009;3(11):1-12

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dural based mass: malignant or benign.
  • Cerebral angiogram demonstrated a parafalcine mass supplied by the middle meningeal artery.
  • Embolization of the middle meningeal artery with craniotomy for excision of the suspected meningioma was performed.
  • Dural metastatic tumors mimicking meningiomas is an uncommon phenomenon, particularly when the primary location is the colon.
  • This paper additionally discusses the differentiation of benign dural based tumors like meningiomas from malignant findings.
  • Multiple adjunct studies can differentiate meningiomas from metastatic tumor.
  • The definitive diagnosis is based on histopathology.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 2002 Dec;33(12):1211-26 [12514791.001]
  • [Cites] AJNR Am J Neuroradiol. 2003 Feb;24(2):225-33 [12591638.001]
  • [Cites] Neurol Med Chir (Tokyo). 2004 Jun;44(6):317-20 [15253548.001]
  • [Cites] Acta Cytol. 1981 Sep-Oct;25(5):461-79 [7025541.001]
  • [Cites] Acta Cytol. 1981 Nov-Dec;25(6):599-610 [6947665.001]
  • [Cites] Neurosurgery. 1986 Nov;19(5):820-3 [3785633.001]
  • [Cites] J Neurosurg Sci. 1987 Jan-Mar;31(1):33-6 [3625287.001]
  • [Cites] Neuroradiology. 1993;35(4):272-3 [8492892.001]
  • [Cites] Neurol Med Chir (Tokyo). 1994 Feb;34(2):108-10 [7514757.001]
  • [Cites] Neurosurg Clin N Am. 1996 Jul;7(3):345-67 [8823768.001]
  • [Cites] Surg Neurol. 2002 Sep-Oct;58(3-4):241-5 [12480230.001]
  • [Cites] Otol Neurotol. 2002 Nov;23(6):975-9 [12438865.001]
  • [Cites] J Neurooncol. 2002 Jul;58(3):193-9 [12187955.001]
  • [Cites] Arch Pathol Lab Med. 2001 Jul;125(7):880-7 [11419971.001]
  • [Cites] Australas Radiol. 2005 Dec;49(6):497-500 [16351616.001]
  • [Cites] Clin Neurol Neurosurg. 1997 May;99(2):135-7 [9213059.001]
  • [Cites] Neurologist. 2006 Jan;12(1):48-52 [16547447.001]
  • [Cites] J Neurooncol. 2005 Oct;75(1):57-61 [16215816.001]
  • [Cites] Neurochirurgie. 1999 May;45(2):160-3 [10448659.001]
  • [Cites] J Neurosurg. 1998 Oct;89(4):552-8 [9761048.001]
  • (PMID = 22470624.001).
  • [ISSN] 1943-0922
  • [Journal-full-title] Journal of radiology case reports
  • [ISO-abbreviation] J Radiol Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3303278
  • [Keywords] NOTNLM ; Dural based mass / meningioma / metastatic dural based lesions
  •  go-up   go-down


7. Monleón D, Morales JM, Gonzalez-Segura A, Gonzalez-Darder JM, Gil-Benso R, Cerdá-Nicolás M, López-Ginés C: Metabolic aggressiveness in benign meningiomas with chromosomal instabilities. Cancer Res; 2010 Nov 1;70(21):8426-34
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metabolic aggressiveness in benign meningiomas with chromosomal instabilities.
  • Meningiomas are often considered benign tumors curable by surgery, but most recurrent meningiomas correspond to histologic benign tumors.
  • Because alterations in chromosome 14 among others have suggested clinical aggressiveness and recurrence, determining both the molecular phenotype and the genetic profile may help distinguish tumors with aggressive metabolism.
  • Genetic analysis showed a subgroup of histologic benign meningioma with chromosomal instabilities.
  • According to the metabolic profiles, these tumors had increased energy demand, higher hypoxic conditions, increased membrane turnover and cell proliferation, and possibly increased resistance to apoptosis.
  • Taken together, our results identify distinct metabolic phenotypes for otherwise benign meningiomas based on cytogenetic studies and global metabolic profiles of intact tumors.
  • Measuring the metabolic phenotype of meningioma intact biopsies at the same time as histopathologic analysis may allow the early detection of clinically aggressive tumors.
  • [MeSH-major] Chromosomal Instability. Chromosome Aberrations. Meningeal Neoplasms / genetics. Meningioma / genetics. Metabolome / genetics
  • [MeSH-minor] Cytogenetic Analysis. Humans. In Situ Hybridization, Fluorescence. Magnetic Resonance Spectroscopy. Neoplasm Staging. Tumor Cells, Cultured

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] ©2010 AACR.
  • (PMID = 20861191.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


8. Bracey TS, Hilton DA, Sulkin T, Smith ME: A meningeal myofibroblastic neoplasm related to solitary fibrous tumour and associated with a malignant neuroblastic element. J Clin Pathol; 2010 Feb;63(2):180-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A meningeal myofibroblastic neoplasm related to solitary fibrous tumour and associated with a malignant neuroblastic element.
  • BACKGROUND: Solitary fibrous tumour (SFT) is a rare mesenchymal tumour now described at many locations, including the meninges.
  • Intracranial SFT closely resembles meningioma clinically and radiologically, and, like meningioma, reports of meningeal SFT suggest a relatively benign behaviour after complete resection.
  • CLINICAL PRESENTATION: The case is reported of a 60-year-old man with an anterior cranial fossa meningeal-based mass, which was resected.
  • Recurrence of the tumour with extracranial extension 9 years later resulted in death of the patient.
  • Histological examination revealed similar biphasic epithelioid and spindled CD34-immunopositive appearance to the earlier tumour, but in addition showed a high-grade element resembling olfactory neuroblastoma.
  • CONCLUSION: This case report is of a meningeal-based mesenchymal neoplasm with histological similarities to SFT.
  • In addition, recurrence of the tumour with a high-grade neuroblastic element has, to our knowledge, not previously been described in SFT.
  • [MeSH-major] Esthesioneuroblastoma, Olfactory / pathology. Meningeal Neoplasms / pathology. Solitary Fibrous Tumors / pathology
  • [MeSH-minor] Fatal Outcome. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / radiography. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20154042.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


9. Kang SG, Yoo DS, Cho KS, Kim DS, Chang ED, Huh PW, Kim MC: Coexisting intracranial meningeal melanocytoma, dermoid tumor, and Dandy-Walker cyst in a patient with neurocutaneous melanosis. Case report. J Neurosurg; 2006 Mar;104(3):444-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coexisting intracranial meningeal melanocytoma, dermoid tumor, and Dandy-Walker cyst in a patient with neurocutaneous melanosis. Case report.
  • Primary intracranial melanocytic and dermoid tumors are also benign congenital lesions that usually arise from the leptomeninges and are formed by the inclusion of cutaneous ectoderm at the time of neural tube closure.
  • The authors describe a patient with coexisting intracranial meningeal melanocytoma, NCM with Dandy-Walker malformation, and intraventricular dermoid tumor.
  • [MeSH-major] Dandy-Walker Syndrome / complications. Dermoid Cyst / pathology. Melanoma / pathology. Melanosis / complications. Meningeal Neoplasms / pathology. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Neurocutaneous melanosis.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16572661.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


10. Pollock BE: Stereotactic radiosurgery of benign intracranial tumors. J Neurooncol; 2009 May;92(3):337-43
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stereotactic radiosurgery of benign intracranial tumors.
  • Stereotactic radiosurgery is a frequently performed procedure for patients with benign intracranial tumors.
  • Benign tumors are good candidates for radiosurgery because they are generally non-invasive, are well visualized by magnetic resonance imaging, and their slow rate of proliferation makes conventional radiation dose fractionation unnecessary.
  • [MeSH-major] Adenoma / surgery. Meningeal Neoplasms / surgery. Meningioma / surgery. Neuroma, Acoustic / surgery. Pituitary Neoplasms / surgery. Radiosurgery

  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 2004 Mar;100(3):438-44 [15035279.001]
  • [Cites] Neurosurgery. 2005 Jun;56(6):1254-61; discussion 1261-3 [15918941.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Feb;90(2):800-4 [15562021.001]
  • [Cites] J Neurosurg. 2007 May;106(5):833-8 [17542527.001]
  • [Cites] J Neurosurg. 2002 Nov;97(5):1091-100 [12450031.001]
  • [Cites] Neurosurgery. 2008 Jan;62(1):53-8; discussion 58-60 [18300891.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Oct 1;54(2):500-4 [12243828.001]
  • [Cites] J Neurosurg. 2000 Dec;93 Suppl 3:90-5 [11143270.001]
  • [Cites] Neurosurgery. 2006 Aug;59(2):255-66; discussion 255-66 [16883166.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Jul;88(7):3105-12 [12843150.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Mar 15;55(4):1000-5 [12605979.001]
  • [Cites] Neurosurgery. 2005 Apr;56(4):699-705; discussion 699-705 [15792508.001]
  • [Cites] Neurosurgery. 2002 Nov;51(5):1153-9; discussion 1159-61 [12383360.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1983 Sep;46(9):797-803 [6352865.001]
  • [Cites] Neurosurgery. 2002 Dec;51(6):1373-79; discussion 1379-80 [12445342.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1957 Feb;20(1):22-39 [13406590.001]
  • [Cites] J Neurosurg. 1998 Dec;89(6):933-8 [9833818.001]
  • [Cites] J Neurosurg. 1998 Jun;88(6):1002-8 [9609294.001]
  • [Cites] Neurosurgery. 2008 Jun;62(6):1271-6; discussion 1276-8 [18824993.001]
  • [Cites] J Neurosurg. 2005 Aug;103(2):206-9 [16175847.001]
  • [Cites] Neurosurgery. 1995 Jan;36(1):215-24; discussion 224-9 [7708162.001]
  • [Cites] J Neurosurg. 2001 Sep;95(3):435-9 [11565865.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Mar;85(3):1287-9 [10720077.001]
  • [Cites] Neurosurgery. 2008 Jun;62(6):1262-9; discussion 1269-70 [18824992.001]
  • [Cites] Neurosurgery. 2003 Mar;52(3):517-24; discussion 523-4 [12590675.001]
  • [Cites] J Neurosurg. 2006 Nov;105(5):657-61 [17121123.001]
  • [Cites] J Neurosurg. 2000 Dec;93 Suppl 3:14-8 [11143231.001]
  • [Cites] Neurosurgery. 2008 Sep;63(3):435-40; discussion 440-2 [18812954.001]
  • [Cites] J Neurosurg. 2007 Jun;106(6):980-7 [17564168.001]
  • [Cites] Neurosurgery. 2006 Jul;59(1):77-85; discussion 77-85 [16823303.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):845-51 [17379451.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Aug 1;62(5):1427-31 [16029803.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Aug;90(8):4483-8 [15899958.001]
  • [Cites] Acta Chir Scand. 1951 Dec 13;102(4):316-9 [14914373.001]
  • [Cites] N Engl J Med. 1998 Nov 12;339(20):1426-33 [9811917.001]
  • [Cites] Neurosurgery. 2001 Nov;49(5):1029-37; discussion 1037-8 [11846894.001]
  • [Cites] Neurosurgery. 2007 Jan;60(1):60-5; discussion 65-6 [17228253.001]
  • [Cites] J Neurosurg. 2002 Jul;97(1):65-72 [12134934.001]
  • [Cites] J Neurosurg. 2006 Jun;104(6):876-83 [16776330.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Sep 1;36(2):275-80 [8892449.001]
  • [Cites] Neurosurgery. 2008 Sep;63(3):427-33; discussion 433-4 [18812953.001]
  • [Cites] J Neurosurg. 2000 Dec;93 Suppl 3:62-7 [11143265.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Apr 1;55(5):1177-81 [12654424.001]
  • [Cites] Neurosurgery. 2005 May;56(5):927-35; discussion 927-35 [15854240.001]
  • [Cites] Cancer. 2007 Aug 15;110(4):854-60 [17599761.001]
  • [Cites] Mayo Clin Proc. 1998 Oct;73(10):936-42 [9787740.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Apr 1;70(5):1325-9 [18029107.001]
  • [Cites] Otol Neurotol. 2002 Jul;23(4):534-41 [12170158.001]
  • (PMID = 19357960.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 48
  •  go-up   go-down


11. Wibom C, Mörén L, Aarhus M, Knappskog PM, Lund-Johansen M, Antti H, Bergenheim AT: Proteomic profiles differ between bone invasive and noninvasive benign meningiomas of fibrous and meningothelial subtype. J Neurooncol; 2009 Sep;94(3):321-31
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteomic profiles differ between bone invasive and noninvasive benign meningiomas of fibrous and meningothelial subtype.
  • However, some tumors may, despite their benign appearance, display invasive growth behavior.
  • These tumors constitute a difficult clinical problem to handle.
  • Tumor tissue from 13 patients with fibrous (6 invasive and 7 noninvasive) and 29 with meningothelial (10 invasive and 19 noninvasive) grade I meningiomas were analyzed by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI).
  • By analyzing the protein spectra in benign meningiomas we could differentiate between invasive and noninvasive growth behavior in both fibrous and meningothelial meningiomas of grade I.
  • [MeSH-major] Bone Neoplasms / metabolism. Bone Neoplasms / secondary. Meningeal Neoplasms / pathology. Meningioma / pathology. Neoplasm Invasiveness / pathology. Proteomics

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Proteome Res. 2005 May-Jun;4(3):698-708 [15952716.001]
  • [Cites] Cancer Res. 2006 Oct 15;66(20):10199-204 [17047085.001]
  • [Cites] Cancer Sci. 2007 Feb;98(2):201-13 [17233837.001]
  • [Cites] Neurosurgery. 2008 Jan;62(1):53-8; discussion 58-60 [18300891.001]
  • [Cites] J Proteome Res. 2007 Jun;6(6):2113-20 [17428078.001]
  • [Cites] Cancer Biol Ther. 2007 Mar;6(3):343-5 [17471020.001]
  • [Cites] Prostate. 2004 Sep 1;60(4):325-31 [15264244.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Apr 5;292(3):587-92 [11922607.001]
  • [Cites] Anticancer Res. 2004 Jul-Aug;24(4):2319-24 [15330178.001]
  • [Cites] J Neurosurg. 2007 Nov;107(5):905-12 [17977259.001]
  • [Cites] Acta Neurol Scand. 1993 Mar;87(3):243-7 [8475698.001]
  • [Cites] Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:139-46 [16515582.001]
  • [Cites] Prog Neurol Surg. 2007;20:142-9 [17317982.001]
  • [Cites] J Urol. 2005 Jan;173(1):73-8 [15592032.001]
  • [Cites] Anal Chem. 2008 Jan 1;80(1):115-22 [18027910.001]
  • [Cites] Electrophoresis. 2000 Apr;21(6):1164-77 [10786889.001]
  • [Cites] Strahlenther Onkol. 2006 Nov;182(11):635-40 [17072520.001]
  • [Cites] Surg Neurol. 1997 Nov;48(5):501-6 [9352816.001]
  • [Cites] Neurosurgery. 2007 Dec;61(6):1194-8; discussion 1198 [18162898.001]
  • [Cites] J Neurosurg. 2006 Jul;105(1):60-4 [16871881.001]
  • [Cites] Cancer Biol Ther. 2007 Mar;6(3):391-6 [17264672.001]
  • [Cites] Neuropathology. 2007 Oct;27(5):407-12 [18018472.001]
  • [Cites] Br J Cancer. 2006 Jun 19;94(12):1853-63 [16736004.001]
  • [Cites] J Neurosurg. 1983 Sep;59(3):461-6 [6310067.001]
  • [Cites] J Clin Neurosci. 2001 May;8 Suppl 1:44-8 [11386825.001]
  • [Cites] Neurosurg Focus. 2007;23(4):E3 [17961040.001]
  • [Cites] Gynecol Oncol. 2006 Feb;100(2):247-53 [16229881.001]
  • [Cites] Clin Chem. 2006 Nov;52(11):2103-6 [16990423.001]
  • [Cites] Clin Chem. 2005 Jan;51(1):102-12 [15613711.001]
  • [Cites] Clin Cancer Res. 2008 Feb 15;14(4):1002-14 [18281532.001]
  • [Cites] Stereotact Funct Neurosurg. 2005;83(1):45-51 [15860936.001]
  • (PMID = 19350207.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


12. Stavrinou P, Magras I, Stavrinou LC, Zaraboukas T, Polyzoidis KS, Selviaridis P: Primary extracerebral meningeal glioblastoma: clinical and pathological analysis. Cent Eur Neurosurg; 2010 Feb;71(1):46-9
Genetic Alliance. consumer health - Glioblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary extracerebral meningeal glioblastoma: clinical and pathological analysis.
  • Primary meningeal gliomas are uncommon tumors in the subarachnoid space, their primary characteristic being the absence of any obvious connection to the brain parenchyma.
  • Rarely, they are quite malignant and assume a bulky, well circumscribed appearance rendering the differential diagnosis from other CNS neoplasms difficult.
  • At surgery, the outer layer of the dura mater was intact and there was a clear brain-tumor interface without obvious pial disruption.
  • Histological examination showed a biphasic pattern consisting of benign connective tissue intermingled with bundles of what seemed to be a glioblastoma.
  • The tumor was identified as a primary meningeal glioblastoma.
  • This time, the pathological findings of the tumor were those of a typical glioblastoma multiforme.
  • We discuss the origin of the initial neoplasm and also the differential diagnosis that needs to include meningioma, aggressive glioblastoma infiltrating the dura and a recently recognized bimorphic CNS tumor: the desmoplastic glioblastoma.
  • [MeSH-major] Glioblastoma / pathology. Glioblastoma / surgery. Meningeal Neoplasms / pathology. Meningeal Neoplasms / surgery
  • [MeSH-minor] Dura Mater / pathology. Glial Fibrillary Acidic Protein / metabolism. Humans. Ki-67 Antigen / metabolism. Male. Middle Aged. Neoplasm Recurrence, Local

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Georg Thieme Verlag KG Stuttgart * New York.
  • (PMID = 20175027.001).
  • [ISSN] 1868-4912
  • [Journal-full-title] Central European neurosurgery
  • [ISO-abbreviation] Cent Eur Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; 0 / Ki-67 Antigen
  •  go-up   go-down


13. El-Khashab M, Koral K, Bowers DC, Johnson-Welch S, Swift D, Nejat F: Intermediate grade meningeal melanocytoma of cervical spine. Childs Nerv Syst; 2009 Apr;25(4):407-10
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intermediate grade meningeal melanocytoma of cervical spine.
  • BACKGROUND: Meningeal melanocytoma is a rare, benign melanotic tumor of the leptomeninges, which occurs anywhere in the cranial or spinal regions but most commonly in supratentorial and thoracic spine regions.
  • The literature on this entity consists of case reports; therefore, there is no agreement on the most effective therapy of this tumor, although total excision seems to be the best therapeutic option.
  • CASE HISTORY: We report a 17-year-old girl with intermediate grade meningeal melanocytoma involving the C6 nerve root with spinal cord compression resulted in progressive tetraparesis.
  • The tumor was removed subtotally through cervical laminotomy followed by rapid improvement of most neurological deficits.
  • This tumor was unusual because of its very hyperintense homogenous signal on T1-weighted images, invasion of the arachnoid membrane, and extension into the neural foramina.
  • Black dots on the surface of the cord were thought to represent an organized blood clot until the frozen section suggested a melanocytic tumor.
  • DISCUSSION: We discuss the distinction of meningeal melanocytoma from other melanocytic tumors of the leptomeninges.
  • CONCLUSION: Melanocytic tumors should be considered in the differential diagnosis when a hyperintense lesion of the leptomeninges is identified on T1-weighted images or a very dark mass similar to charcoal or organized hematoma is found in the surgical field.
  • The best management is complete tumor resection, but radiotherapy is reserved in cases of subtotal resection and multiple lesions.
  • Locally aggressive nature of tumor and possibility of recurrence warrant regular follow-up.
  • [MeSH-major] Cervical Vertebrae. Medulloblastoma / pathology. Meningeal Neoplasms / pathology. Spinal Cord Neoplasms / pathology
  • [MeSH-minor] Adolescent. Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging. Meninges / pathology. Meninges / surgery. Spinal Cord / pathology. Spinal Cord / surgery. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Neck Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Neurol. 2003 Mar;59(3):200-10 [12681556.001]
  • [Cites] J Neurosurg. 2004 Mar;100(3 Suppl Spine):287-90 [15029918.001]
  • [Cites] Am J Surg Pathol. 1999 Jul;23(7):745-54 [10403296.001]
  • [Cites] Neurosurgery. 1992 Nov;31(5):958-61 [1436425.001]
  • [Cites] AJNR Am J Neuroradiol. 1991 Mar-Apr;12 (2):315-6 [1902034.001]
  • [Cites] AJNR Am J Neuroradiol. 1996 Jan;17(1):55-60 [8770250.001]
  • [Cites] J Neurosurg Spine. 2007 May;6(5):451-4 [17542513.001]
  • [Cites] Neurosurgery. 1992 Nov;31(5):945-8 [1436422.001]
  • [Cites] Childs Nerv Syst. 2006 Jun;22(6):556-61 [16491422.001]
  • [Cites] J Neurosurg. 1998 May;88(5):890-4 [9576259.001]
  • [Cites] AJNR Am J Neuroradiol. 1997 Jan;18(1):180-2 [9010539.001]
  • [Cites] J Neurosurg. 2001 Oct;95(2 Suppl):225-31 [11599841.001]
  • (PMID = 19139906.001).
  • [ISSN] 1433-0350
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


14. Nakasu S, Fukami T, Jito J, Nozaki K: Recurrence and regrowth of benign meningiomas. Brain Tumor Pathol; 2009;26(2):69-72

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrence and regrowth of benign meningiomas.
  • However, even benign meningiomas sometimes show relatively rapid growth and may recur after total removal.
  • We investigated 135 benign meningiomas, of which 120 were totally removed (Simpson's grade I-III).
  • On the other hand, the histological features of sheet-like growth, prominent nucleoli, and necrosis did not correlate with recurrence, because they were relatively rare in grade I tumors.
  • The patients with recurrent or residual tumors did not always receive adjuvant treatment.
  • Including subtotally treated tumors, the retreatment rate was 9.8% at 10 years and 25.6% at 20 years.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningioma / pathology. Neoplasm Recurrence, Local / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19856217.001).
  • [ISSN] 1861-387X
  • [Journal-full-title] Brain tumor pathology
  • [ISO-abbreviation] Brain Tumor Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


15. Wang Y, Kang L, Xiao L: Infrequent bilateral orbital tumors and simulating lesions: the experience of a Chinese institute. Jpn J Ophthalmol; 2009 Nov;53(6):629-34

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infrequent bilateral orbital tumors and simulating lesions: the experience of a Chinese institute.
  • RESULTS: The number and percentage of lesions in each general category were leukemia lesions in eight patients (19.5%), metastatic tumors in seven (17%), optic nerve and meningeal tumors in six (14.6%), secondary tumors in six (14.6%), peripheral nerve lesions in four (9.8%), inflammatory lesions in four (9.8%), and vasculogenic, histiocytic, and miscellaneous lesions, each in two patients (4.9%).
  • Of all cases, 51.2% were benign and 48.8% were malignant.
  • Of the 15 patients with either metastatic tumors or blood disorders, two (13.3%) had a history of primary neoplasm at presentation.
  • Through the combination of history, bilateral ocular manifestations, radiologic findings, and systemic examinations, the correct diagnosis can be made, which is valuable for early identification of both metastasis and blood disorders.
  • [MeSH-major] Orbital Neoplasms / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ophthalmology. 2002 Apr;109(4):753-6 [11927435.001]
  • [Cites] Surv Ophthalmol. 2004 May-Jun;49(3):281-99 [15110666.001]
  • [Cites] Am J Ophthalmol. 1967 Apr;63(4):723-6 [6022244.001]
  • [Cites] Arch Ophthalmol. 2005 Oct;123(10 ):1443-5 [16219741.001]
  • [Cites] Arch Ophthalmol. 1971 Jun;85(6):673-5 [5562786.001]
  • [Cites] Ophthal Plast Reconstr Surg. 1994 Dec;10(4):283-6 [7865452.001]
  • [Cites] Ophthal Plast Reconstr Surg. 2001 Sep;17 (5):346-54 [11642491.001]
  • [Cites] Acta Chir Plast. 2003;45(2):49-51 [12921259.001]
  • [Cites] AJNR Am J Neuroradiol. 2001 Nov-Dec;22(10):1963-9 [11733333.001]
  • [Cites] Ophthalmology. 1990 Nov;97(11):1519-31 [2255524.001]
  • [Cites] Arch Ophthalmol. 1990 Jan;108(1):80-3 [2105089.001]
  • [Cites] Br J Ophthalmol. 1992 Dec;76(12):755-7 [1486082.001]
  • [Cites] Acta Haematol. 1989;81(2):80-5 [2496555.001]
  • [Cites] Surv Ophthalmol. 1992 Nov-Dec;37(3):167-83 [1475751.001]
  • [Cites] Ophthalmology. 2003 Oct;110(10):2019-30 [14522782.001]
  • [Cites] Eye (Lond). 2008 Jul;22(7):980-1 [18049485.001]
  • [Cites] Ophthalmology. 2002 Mar;109(3):537-41 [11874758.001]
  • [Cites] Am J Ophthalmol. 1990 Aug 15;110(2):153-9 [2198811.001]
  • [Cites] Ophthal Plast Reconstr Surg. 2007 Mar-Apr;23(2):87-93 [17413619.001]
  • [Cites] Ophthalmology. 1997 Apr;104(4):683-94 [9111264.001]
  • [Cites] Arch Ophthalmol. 1984 Nov;102(11):1606-11 [6497741.001]
  • (PMID = 20020243.001).
  • [ISSN] 1613-2246
  • [Journal-full-title] Japanese journal of ophthalmology
  • [ISO-abbreviation] Jpn. J. Ophthalmol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


16. Kubo O, Chernov M, Izawa M, Hayashi M, Muragaki Y, Maruyama T, Hori T, Takakura K: Malignant progression of benign brain tumors after gamma knife radiosurgery: is it really caused by irradiation? Minim Invasive Neurosurg; 2005 Dec;48(6):334-9
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant progression of benign brain tumors after gamma knife radiosurgery: is it really caused by irradiation?
  • Malignant transformation of benign neoplasm after radiosurgery is usually diagnosed based on the initial presence of benign tumor, its exposure to ionizing radiation, elapsed time from radiation exposure to malignant progression, and different histological characteristics or growth rate of the regrowing tumor comparing with those originally treated.
  • Three presented cases fulfilled these diagnostic criteria; however, it seems that progression of the tumors (schwannoma, meningioma, chordoma) resulted from the natural course of the disease, rather than represented side effects of gamma knife radiosurgery.
  • Evaluation of the proliferative potential of the benign neoplasm before radiosurgical treatment either directly, if tumor sampling is available, or indirectly, by calculation of the tumor growth rate and/or analysis of the data of the metabolic imaging (PET, MRS) is important for identification of "aggressive" subtypes, precise prediction of prognosis, and confirmation of the radiation-induced malignant transformation in cases of tumor regrowth.
  • [MeSH-major] Brain Neoplasms / surgery. Cell Transformation, Neoplastic / radiation effects. Chordoma / surgery. Meningeal Neoplasms / surgery. Meningioma / surgery. Neoplasms, Radiation-Induced / physiopathology. Neurilemmoma / surgery. Radiosurgery / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16432782.001).
  • [ISSN] 0946-7211
  • [Journal-full-title] Minimally invasive neurosurgery : MIN
  • [ISO-abbreviation] Minim Invasive Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


17. Poliani PL, Sperli D, Valentini S, Armentano A, Bercich L, Bonetti MF, Corriero G, Brisigotti M, Quattrone A, Lanza PL: Spinal glioneuronal tumor with neuropil-like islands and meningeal dissemination: histopathological and radiological study of a pediatric case. Neuropathology; 2009 Oct;29(5):574-8
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spinal glioneuronal tumor with neuropil-like islands and meningeal dissemination: histopathological and radiological study of a pediatric case.
  • Cerebral and spinal location of glioneuronal tumors have been recently described as a novel type of primary CNS neoplasia.
  • A distinctive rare form of glioneuronal tumors with neuropil-like islands (GTNI) have been reported to occur in the adult cerebrum, whereas spinal GTNI localization is extremely rare.
  • In the present report we describe a case of a 15-month-old child with a spinal GTNI of the cervical region and meningeal dissemination.
  • Histologically the tumor was composed of round, small neurocytic-like cells arranged around eosinophilic neuropil cores and embedded in a diffuse fibrillar glial component forming prominent "rosetted" neuropil islands displaying strong immunoreactivity for neuronal markers.
  • Nevertheless, due to their exceptional rarity, the natural history of these lesions is not yet fully understood, but spinal GTNI seems to have an unfavorable clinical course despite their benign histopathological features, which must be taken into account for appropriate treatment and follow-up of the patient.
  • [MeSH-major] Brain Neoplasms / secondary. Meningeal Neoplasms / secondary. Neoplasms, Nerve Tissue / pathology. Spinal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19077041.001).
  • [ISSN] 1440-1789
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


18. Perrini P, Caniglia M, Pieroni M, Castagna M, Parenti GF: Malignant transformation of intramedullary melanocytoma: case report. Neurosurgery; 2010 Sep;67(3):E867-9; discussion E869
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Meningeal melanocytomas are low-grade primary melanocytic tumors with benign histological features and a favorable clinical prognosis.
  • Transition from meningeal melanocytoma to primary melanoma of the central nervous system is exceptionally rare, with only 5 cases having been previously reported.
  • Two years later, the tumor recurred locally, and the patient underwent additional surgery to remove the intramedullary mass.
  • The histological findings of the tumor were consistent with an intramedullary malignant melanoma.
  • CONCLUSION: The malignant transformation of melanocytic tumors of the central nervous system may occur years after surgical treatment, and its incidence remains unknown.
  • Emphasis should be placed on the importance of careful and continued follow-up monitoring of the tumor.
  • [MeSH-major] Cell Transformation, Neoplastic / pathology. Melanoma / pathology. Meningeal Neoplasms / pathology. Nevus, Pigmented / pathology. Spinal Cord Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20657325.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Colombo F, Casentini L, Cavedon C, Scalchi P, Cora S, Francescon P: Cyberknife radiosurgery for benign meningiomas: short-term results in 199 patients. Neurosurgery; 2009 Feb;64(2 Suppl):A7-13

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyberknife radiosurgery for benign meningiomas: short-term results in 199 patients.
  • OBJECTIVE: To present initial, short-term results obtained with an image-guided radiosurgery apparatus (CyberKnife; Accuray, Inc., Sunnyvale, CA) in a series of 199 benign intracranial meningiomas.
  • All patients were either symptomatic and/or harboring growing tumors.
  • Ninety-nine tumors involved the cavernous sinus; 28 were in the posterior fossa, petrous bone, or clivus; and 29 were in contact with anterior optic pathways.
  • Twenty-two tumors involved the convexity, and 21 involved the falx or tentorium.
  • Tumor volumes varied from 0.1 to 64 mL (mean, 7.5 mL) and radiation doses ranged from 12 to 25 Gy (mean, 18.5 Gy).
  • In 150 patients with lesions larger than 8 mL and/or with tumors situated close to critical structures, the dose was delivered in 2 to 5 daily fractions.
  • The tumor volume decreased in 36 patients, was unchanged in 148 patients, and increased in 7 patients.
  • [MeSH-major] Meningeal Neoplasms / surgery. Meningioma / surgery. Radiosurgery / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Recurrence, Local / surgery. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19165077.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Pfister C, Ritz R, Pfrommer H, Bornemann A, Tatagiba MS, Roser F: Are there attacking points in the eicosanoid cascade for chemotherapeutic options in benign meningiomas? Neurosurg Focus; 2007;23(4):E8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Are there attacking points in the eicosanoid cascade for chemotherapeutic options in benign meningiomas?
  • Enzymes of the arachidonic acid (AA) cascade such as cyclooxygenase (COX)-2 or 5-lipoxygenase (5-LO) are upregulated in a number of epithelial tumors, but to date there are hardly any data about the expression of these markers in meningiomas.
  • RESULTS: Sixty (63%) of 95 benign meningiomas, 21 (88%) of 24 atypical meningiomas, all five malignant meningiomas, and all normal human cortex samples displayed high COX-2 immunoreactivity.
  • [MeSH-major] Eicosanoids / metabolism. Meningeal Neoplasms / metabolism. Meningioma / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17961045.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Eicosanoids; 0 / PTGER4 protein, human; 0 / RNA, Messenger; 0 / Receptors, Prostaglandin E; 0 / Receptors, Prostaglandin E, EP4 Subtype; EC 1.13.11.34 / Arachidonate 5-Lipoxygenase; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases
  •  go-up   go-down


21. Kollová A, Liscák R, Novotný J Jr, Vladyka V, Simonová G, Janousková L: Gamma Knife surgery for benign meningioma. J Neurosurg; 2007 Aug;107(2):325-36
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gamma Knife surgery for benign meningioma.
  • OBJECT: Meningioma is the most frequent benign tumor treated with Gamma Knife surgery (GKS); however, the assessment of its efficacy and safety in slow-growing tumors is an ongoing process, requiring analysis of long-term results.
  • The median tumor volume was 4.4 cm3 (range 0.11-44.9 cm3).
  • The median tumor margin dose to the 50% isodose line was 12.55 Gy (range 6.5-24 Gy).
  • The volume of treated tumors decreased in 248 cases (69.7%), remained the same in 99 (27.8%), and increased in nine (2.5%).
  • The actuarial tumor control rate was 97.9% at 5 years post-GKS.
  • RESULTS: A significantly higher incidence of tumor volume increase was observed in men compared with women and in tumors treated with a margin dose lower than 12 Gy.
  • Significant risk factors for edema included an age greater than 60 years, no previous surgery, perilesional edema before radiosurgery, a tumor volume greater than 10 cm3, a tumor location in the anterior fossa, and a margin dose greater than 16 Gy.
  • A minimum margin dose of 12 to 16 Gy seems to represent the therapeutic window for benign meningiomas with a high tumor control rate in a mid-term follow-up period.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningeal Neoplasms / surgery. Meningioma / pathology. Meningioma / surgery. Radiosurgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Male. Middle Aged. Retrospective Studies. Time Factors. Treatment Outcome. Tumor Burden

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17695387.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Tabernero MD, Maillo A, Gil-Bellosta CJ, Castrillo A, Sousa P, Merino M, Orfao A: Gene expression profiles of meningiomas are associated with tumor cytogenetics and patient outcome. Brain Pathol; 2009 Jul;19(3):409-20

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profiles of meningiomas are associated with tumor cytogenetics and patient outcome.
  • Cytogenetic analysis is a powerful tool for predicting recurrence in meningiomas, even among histologically benign/grade I tumors.
  • Despite this, no study has been reported in which the impact of tumor cytogenetics on the gene expression profiles (GEP) has been analyzed in meningiomas.
  • Here, we analyzed the GEP of 47 tumors and correlated them with the most clinical relevant cytogenetic subgroups of meningiomas, as confirmed through the analysis of 172 patients.
  • Additionally three normal meningeal samples were also studied.
  • Overall, our results show a clear association between the clinically relevant cytogenetic subgroups of meningiomas including diploid tumors (n = 18), isolated -22/22q- (n = 12), del(1p36) alone (n = 4) and complex karyotypes associated with del(1p36) and/or -14q (n = 13) and their GEP.
  • Accordingly, based on the expression of 85 genes (40 of which were coded in the altered chromosomes used for patient stratification) the cytogenetic class of the tumor could be predicted with an error of <1%, a clear association being found between the GEP and patient outcome (P = 0.03) but not tumor histopathology.
  • [MeSH-major] Cytogenetic Analysis. Gene Expression Profiling. Meningeal Neoplasms / genetics. Meningioma / genetics. Neoplasm Recurrence, Local / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18637901.001).
  • [ISSN] 1750-3639
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  •  go-up   go-down


23. Askoxylakis V, Zabel-du Bois A, Schlegel W, Debus J, Huber P, Milker-Zabel S: Patterns of failure after stereotactic radiotherapy of intracranial meningioma. J Neurooncol; 2010 Jul;98(3):367-72
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of 411 patients with intracranial meningioma treated with radiotherapy at our institution, 22 patients with local tumor progression diagnosed by magnetic resonance imaging (MRI) after radiotherapy (RT) were identified and further investigated.
  • Median recurrence-free survival was 46 months for patients with benign meningioma (WHO grade I) and 31.5 months for patients with higher-grade meningioma (WHO grade II/III).
  • Median time to local tumor progression and site of local recurrence significantly depended on histological grade of meningioma.
  • Regarding site of failure, improvement of dose coverage for benign meningiomas and dose escalation for high-grade tumors might further improve therapy outcome.
  • [MeSH-major] Meningeal Neoplasms / surgery. Meningioma / surgery. Radiosurgery / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Feb 1;55(2):362-72 [12527049.001]
  • [Cites] Neurosurg Rev. 2008 Oct;31(4):421-30; discussion 430 [18521636.001]
  • [Cites] Cancer. 1993 Aug 1;72(3):639-48 [8334619.001]
  • [Cites] J Neurosurg. 1999 May;90(5):823-7 [10223446.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):858-63 [17379447.001]
  • [Cites] Crit Rev Oncol Hematol. 2008 Aug;67(2):153-71 [18342535.001]
  • [Cites] J Clin Oncol. 2001 Aug 1;19(15):3547-53 [11481362.001]
  • [Cites] Cancer Radiother. 1999 Jul-Aug;3(4):311-7 [10486542.001]
  • [Cites] Strahlenther Onkol. 2006 Nov;182(11):635-40 [17072520.001]
  • [Cites] Neurosurgery. 1997 Feb;40(2):238-44; discussion 245-7 [9007855.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Jul 30;29(5):1147-55 [8083085.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2009 Sep;36(9):1407-16 [19319527.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Dec 1;45(5):1315-24 [10613328.001]
  • [Cites] Methods Enzymol. 2007;435:297-321 [17998060.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Mar 1;61(3):809-16 [15708260.001]
  • [Cites] J Neurosurg. 1985 Jan;62(1):18-24 [3964853.001]
  • [Cites] Zentralbl Neurochir. 2008 Feb;69(1):14-21 [18393160.001]
  • [Cites] Radiologe. 1998 Mar;38(3):228-34 [9577869.001]
  • (PMID = 20012910.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. McGregor JM, Sarkar A: Stereotactic radiosurgery and stereotactic radiotherapy in the treatment of skull base meningiomas. Otolaryngol Clin North Am; 2009 Aug;42(4):677-88
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Meningiomas are the most common nonglial brain tumors.
  • They tend to be slow growing and benign and can reach substantial sizes before becoming symptomatic.
  • Location of a meningioma within the cranial vault may make complete surgical resection unlikely; tumors arising from the dura of the skull base are particularly challenging.
  • They may be used as adjuncts to surgery or as alternative modalities in the treatment of these complex tumors.
  • [MeSH-major] Meningioma / radiotherapy. Meningioma / surgery. Neoplasm Recurrence, Local / pathology. Radiosurgery / methods. Skull Base Neoplasms / radiotherapy. Skull Base Neoplasms / surgery
  • [MeSH-minor] Biopsy, Needle. Cranial Irradiation / adverse effects. Cranial Irradiation / methods. Dose-Response Relationship, Radiation. Female. Humans. Immunohistochemistry. Male. Meningeal Neoplasms / mortality. Meningeal Neoplasms / pathology. Meningeal Neoplasms / radiotherapy. Meningeal Neoplasms / surgery. Neoplasm Invasiveness / pathology. Neoplasm Staging. Prognosis. Radiation Injuries / prevention & control. Radiotherapy Dosage. Risk Assessment. Stereotaxic Techniques. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19751872.001).
  • [ISSN] 1557-8259
  • [Journal-full-title] Otolaryngologic clinics of North America
  • [ISO-abbreviation] Otolaryngol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 34
  •  go-up   go-down


25. Smith JS, Lal A, Harmon-Smith M, Bollen AW, McDermott MW: Association between absence of epidermal growth factor receptor immunoreactivity and poor prognosis in patients with atypical meningioma. J Neurosurg; 2007 Jun;106(6):1034-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Because multiple growth factor receptors have been identified in these tumors, the authors sought to assess the capacity of the expression patterns of a subset of these receptors to stratify meningioma cases.
  • METHODS: Eighty-four meningiomas were analyzed, including 36 benign, 29 atypical, and 19 malignant lesions.
  • Survival analyses were performed using follow-up data obtained in patients with newly diagnosed tumors.
  • Immunoreactivity for EGFR was observed in 47% of benign, 48% of atypical, and 42% of malignant tumors.
  • Staining for BFGFR was identified in 89% of benign, 97% of atypical, and 95% of malignant lesions.
  • Mean MIB-I indices for benign, atypical, and malignant cases were 3.6 (range 0.5-15.3), 8.2 (range 1.5-23.1) and 18.3 (range 1.0-55.8), respectively.
  • This association was not evident in cases of benign or malignant meningiomas.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningeal Neoplasms / surgery. Meningioma / pathology. Meningioma / surgery. Receptor, Epidermal Growth Factor / metabolism

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17564176.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins c-sis; 0 / Receptors, Fibroblast Growth Factor; 103107-01-3 / Fibroblast Growth Factor 2; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


26. Rao G, Klimo P Jr, Jensen RL, MacDonald JD, Couldwell WT: Surgical strategies for recurrent craniofacial meningiomas. Neurosurgery; 2006 May;58(5):874-80; discussion 874-80
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Recurrent cranial base meningiomas are among the most difficult tumors to treat surgically.
  • Although they are histologically benign, these tumors often invade through the cranial base into the infratemporal and pterygopalatine fossae.
  • We reviewed our experience with these tumors to describe the natural history of these lesions as well as provide a possible treatment paradigm.
  • The original site of tumor was the sphenoid wing in four patients, the middle fossa in two patients, and the left frontal region in one patient.
  • The average interval between the most recent tumor resection and recurrence into the face was 9.9 years.
  • [MeSH-major] Facial Neoplasms / surgery. Meningeal Neoplasms / surgery. Meningioma / surgery. Neoplasm Recurrence, Local / surgery. Skull Base Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16639321.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Simis A, Pires de Aguiar PH, Leite CC, Santana PA Jr, Rosemberg S, Teixeira MJ: Peritumoral brain edema in benign meningiomas: correlation with clinical, radiologic, and surgical factors and possible role on recurrence. Surg Neurol; 2008 Nov;70(5):471-7; discussion 477
Genetic Alliance. consumer health - Edema.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peritumoral brain edema in benign meningiomas: correlation with clinical, radiologic, and surgical factors and possible role on recurrence.
  • METHODS: Sixty-one patients with benign meningiomas were chosen for surgical treatment by the Group of Brain Tumors and Metastasis of the Department of Neurosurgery.
  • Tumors located in the cavernous sinus, tuberculum sellae, foramen magnum, ventricles, and petroclival region were excluded.
  • CONCLUSION: Peritumoral brain edema may be related to the invading potential of meningiomas and may play a role in the recurrence potential of the tumor.
  • [MeSH-major] Brain Edema / complications. Meningeal Neoplasms / pathology. Meningeal Neoplasms / surgery. Meningioma / pathology. Meningioma / surgery. Neoplasm Recurrence, Local / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18586307.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Monleón D, Morales JM, Gonzalez-Darder J, Talamantes F, Cortés O, Gil-Benso R, López-Ginés C, Cerdá-Nicolás M, Celda B: Benign and atypical meningioma metabolic signatures by high-resolution magic-angle spinning molecular profiling. J Proteome Res; 2008 Jul;7(7):2882-8
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign and atypical meningioma metabolic signatures by high-resolution magic-angle spinning molecular profiling.
  • Meningiomas are neoplasms that arise from the leptomeningeal covering of the brain and spinal cord, accounting for 15%-20% of CNS tumors.
  • The WHO classifies meningiomas into three histological grades: benign, atypical, and anaplasic in accordance with the clinical prognosis.
  • Sometimes, meningiomas with histological diagnosis of benign meningioma show clinical characteristics of atypical meningioma.
  • In this context, high-resolution magic-angle spinning (HR-MAS) spectroscopy of intact tissue from brain tumor biopsies has shown great potential as a support diagnostic tool.
  • In this work, we show differences between benign and atypical meningiomas in HR-MAS molecular profiles of meningioma biopsies.
  • Glutamine and glutamate, which are related to glutathione metabolism and have been associated with tumor recurrence, are also increased in atypical meningiomas.
  • Other metabolites associated with tumor malignancy that show statistically significant differences between benign and atypical meningiomas include phosphocholine and phosphoethanolamine.
  • Overall, this work suggests that the additional information obtained by NMR metabolomics applied to biopsies of human meningiomas may be useful for assessing tumor grade and determining optimum treatment strategies.
  • [MeSH-major] Meningeal Neoplasms / metabolism. Meningioma / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Female. Gene Expression Profiling. Humans. Magnetic Resonance Spectroscopy. Male. Middle Aged. Principal Component Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18507434.001).
  • [ISSN] 1535-3893
  • [Journal-full-title] Journal of proteome research
  • [ISO-abbreviation] J. Proteome Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


29. Bozkurt SU, Ayan E, Bolukbasi F, Elmaci I, Pamir N, Sav A: Immunohistochemical expression of SPARC is correlated with recurrence, survival and malignant potential in meningiomas. APMIS; 2009 Sep;117(9):651-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Meningioma is a common neoplasm that constitutes almost 30% of all primary central nervous system tumors and is associated with inconsistent clinical outcomes.
  • The extracellular matrix proteins play a crucial role in meningioma cell biology and are important in tumor cell invasion and in progression to malignancy.
  • The aim of this study was to evaluate the expression of SPARC with proliferation index, p53 reactivity in WHO grade 1 (benign), grade 2 (atypical) and grade 3 (anaplastic) meningiomas and correlate with clinical features of the patients, including location of the tumor, recurrence of the tumor and survival of patients.
  • We studied 111 meningiomas, 69 being benign, 34 being atypical and eight being anaplastic meningiomas of various histological types.
  • Immunohistochemical scores of SPARC were determined as the sum of frequency (0-3) and intensity (0-3) of immunolabeling of the tumor cells.
  • A high immunohistochemical score (4-6) for SPARC was more frequent in atypical and in anaplastic meningiomas than in benign meningiomas (p < 0.01).
  • MIB-1 proliferation index showed significant association between tumor grades in meningiomas (p < 0.01).
  • At the end of a follow-up period of 47.53 +/- 25.04 months, 30 tumors recurred.
  • A high SPARC expression was significantly associated with tumor recurrence (p = 0.02).
  • [MeSH-major] Meningeal Neoplasms / metabolism. Meningioma / metabolism. Osteonectin / metabolism
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Cell Proliferation. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Ki-67 Antigen / metabolism. Male. Middle Aged. Prognosis. Recurrence. Tumor Suppressor Protein p53 / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19703125.001).
  • [ISSN] 1600-0463
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Osteonectin; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


30. Kalamarides M, Hunter-Schaedle K, Blakeley J, Allen J, Babovic-Vuskanovic D, Belzberg A, Bollag G, Chen R, DiTomaso E, Golfinos J, Harris G, Jacob A, Kalpana G, Karajannis M, Korf B, Kurzrock R, Law M, McClatchey A, Packer R, Roehm P, Rubenstein A, Slattery W 3rd, Tonsgard JH, Welling DB, Widemann B, Yohay K: Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2. Clin Cancer Res; 2009 Aug 15;15(16):5032-5039
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Neurofibromatosis type 2 (NF2) is a rare autosomal dominant disorder associated primarily with bilateral schwannomas seen on the superior vestibular branches of the eighth cranial nerves.
  • Significant morbidity can result from surgical treatment of these tumors.
  • Meningiomas, ependymomas, and other benign central nervous system tumors are also common in NF2.
  • [MeSH-minor] Animals. Auditory Brain Stem Implants. Cochlear Implants. Drug Evaluation, Preclinical / methods. Drug Evaluation, Preclinical / trends. Humans. Meningeal Neoplasms / therapy. Meningioma / therapy. Time Factors

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Neurofibromatosis type 2.
  • MedlinePlus Health Information. consumer health - Clinical Trials.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Oncol. 2002 Mar;20(3):475-82 [11836557.001]
  • [Cites] Curr Biol. 2006 Apr 4;16(7):702-9 [16581517.001]
  • [Cites] J Med Genet. 2007 Jul;44(7):424-8 [17307835.001]
  • [Cites] Hum Gene Ther. 2006 Jan;17(1):20-30 [16409122.001]
  • [Cites] Genes Dev. 2000 Jul 1;14(13):1617-30 [10887156.001]
  • [Cites] J Med Genet. 2008 Jun;45(6):332-9 [18285426.001]
  • [Cites] J Neurosurg. 2000 May;92(5):766-70 [10794289.001]
  • [Cites] Brain Pathol. 2008 Jan;18(1):62-70 [17924978.001]
  • [Cites] Laryngoscope. 2007 Jun;117(6):1069-72 [17545869.001]
  • [Cites] Nat Cell Biol. 2006 Jan;8(1):27-36 [16341207.001]
  • [Cites] Genes Dev. 2005 Oct 1;19(19):2265-77 [16204178.001]
  • [Cites] Neoplasia. 2002 Nov-Dec;4(6):501-9 [12407444.001]
  • [Cites] Oncogene. 2009 Feb 12;28(6):854-65 [19029950.001]
  • [Cites] J Med Genet. 1992 Dec;29(12 ):841-6 [1479598.001]
  • [Cites] Genes Dev. 1999 Apr 15;13(8):978-86 [10215625.001]
  • [Cites] Genes Dev. 2002 May 1;16(9):1060-5 [12000789.001]
  • [Cites] Otol Neurotol. 2005 Jul;26(4):733-40 [16015177.001]
  • [Cites] Otol Neurotol. 2008 Jan;29(1):58-68 [18199958.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Oct;60(10):994-1003 [11589430.001]
  • [Cites] Otol Neurotol. 2005 Jan;26(1):93-7 [15699726.001]
  • [Cites] J Neurosurg. 2002 Jun;96(6):1063-71 [12066908.001]
  • [Cites] Am J Hum Genet. 2002 Oct;71(4):715-23 [12235555.001]
  • [Cites] Neurology. 2002 Dec 10;59(11):1759-65 [12473765.001]
  • [Cites] Am J Otol. 1998 Sep;19(5):638-43 [9752973.001]
  • [Cites] J Neurooncol. 1996 Sep;29(3):197-205 [8858525.001]
  • [Cites] Neurosurgery. 2008 Jun;62(6):1314-9; discussion 1319-20 [18824998.001]
  • [Cites] Neurology. 2007 Feb 27;68(9):643-7 [17215493.001]
  • [Cites] Br J Cancer. 2007 Sep 3;97(5):577-81 [17726450.001]
  • [Cites] Stat Med. 1999 Aug 15;18(15):1905-42 [10532877.001]
  • [Cites] Am J Hum Genet. 2007 Apr;80(4):805-10 [17357086.001]
  • [Cites] Neurology. 2000 Jan 11;54(1):71-6 [10636128.001]
  • [Cites] Br J Neurosurg. 2005 Feb;19(1):5-12 [16147576.001]
  • [Cites] J Cell Biol. 2007 Jun 4;177(5):893-903 [17548515.001]
  • [Cites] Lancet Neurol. 2006 Dec;5(12):1045-54 [17110285.001]
  • (PMID = 19671848.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NIDCD NIH HHS / DC / K08 DC009288
  • [Publication-type] Consensus Development Conference; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Number-of-references] 36
  • [Other-IDs] NLM/ NIHMS707923; NLM/ PMC4513640
  •  go-up   go-down


31. Strassner C, Buhl R, Mehdorn HM: Recurrence of intracranial meningiomas: did better methods of diagnosis and surgical treatment change the outcome in the last 30 years? Neurol Res; 2009 Jun;31(5):478-82
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrence of intracranial meningiomas: did better methods of diagnosis and surgical treatment change the outcome in the last 30 years?
  • OBJECTIVE: Meningiomas are benign intracranial tumors growing from the arachnoid cap cells.
  • Although their behavior is usually benign, they tend to recur even after total removal, and their recurrence is dependent on different aspects.
  • We compared the outcome of these patients after operation and the different methods of radiation therapy and chemotherapy with the data from Buhl (1994), who analysed 661 patients with intracranial meningioma who were operated on in the Department of Neurosurgery, University of Essen, Essen, Germany, between 1968 and 1988, to find out whether better methods of diagnosis like magnetic resonance imaging scans, magnetic resonance spectroscopy, post-operative radiation therapy and chemotherapy have an influence on the recurrence and outcome after surgical treatment.
  • Complete removal of the tumor was possible in 86.7% in both studies.
  • After removal of a recurrent meningioma, the mortality declined from 20 to 12.5%.
  • [MeSH-major] Meningeal Neoplasms / diagnosis. Meningeal Neoplasms / therapy. Meningioma / diagnosis. Meningioma / therapy
  • [MeSH-minor] Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Radiosurgery. Time Factors. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19500450.001).
  • [ISSN] 0161-6412
  • [Journal-full-title] Neurological research
  • [ISO-abbreviation] Neurol. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


32. Korhonen K, Parkkila AK, Helen P, Välimäki R, Pastorekova S, Pastorek J, Parkkila S, Haapasalo H: Carbonic anhydrases in meningiomas: association of endothelial carbonic anhydrase II with aggressive tumor features. J Neurosurg; 2009 Sep;111(3):472-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carbonic anhydrases in meningiomas: association of endothelial carbonic anhydrase II with aggressive tumor features.
  • In this study, the authors evaluate the expression of CA II and IX in meningiomas and assess their relationship to patient age, tumor type and grade, tumor sex hormone receptor status, tumor cell proliferation, and tumor recurrence.
  • RESULTS: Immunohistological staining with CA II and IX was assessed in 443 primary and 67 recurrent tumor specimens.
  • Of these samples, 455 were benign (WHO Grade I), 49 atypical (Grade II), and 6 malignant (Grade III).
  • Endothelial cells in 14.8% of the tumors stained positively for CA II.
  • Tumor cells were positive for CA IX in 11.6% of the cases.
  • Endothelial CA II expression correlated with increasing histological grade (p=0.002), and tumor proliferation rates were higher in CA II+ versus CA II- cases (p=0.002).
  • Androgen receptor-negative tumors were found to be CA II+ significantly more often than androgen receptor-positive tumors (p=0.001).
  • [MeSH-major] Carbonic Anhydrase II / analysis. Meningeal Neoplasms / enzymology. Meningioma / enzymology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19216648.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Androgen; EC 4.2.1.- / Carbonic Anhydrase II; EC 4.2.1.1 / Carbonic Anhydrases
  •  go-up   go-down


33. Kondziolka D, Flickinger JC, Lunsford LD: The principles of skull base radiosurgery. Neurosurg Focus; 2008;24(5):E11
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Stereotactic radiosurgery is commonly used for selected patients with benign cranial base tumors.
  • The goal of radiosurgery is cessation of tumor growth and preservation of neurological function.
  • [MeSH-major] Cranial Irradiation / methods. Radiosurgery / methods. Skull Base Neoplasms / surgery
  • [MeSH-minor] Brain Stem / physiopathology. Brain Stem / surgery. Cerebellar Neoplasms / surgery. Cerebellopontine Angle / surgery. Cranial Nerve Injuries / prevention & control. Decompression, Surgical. Diagnostic Imaging. Humans. Meningeal Neoplasms / surgery. Meningioma / surgery. Neurilemmoma / surgery. Patient Selection

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18447740.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 16
  •  go-up   go-down


34. Chang SW, Gore PA, Nakaji P, Rekate HL: Juvenile intradural chordoma: case report. Neurosurgery; 2008 Feb;62(2):E525-6; discussion E527
Genetic Alliance. consumer health - Chordoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: We report the youngest known case of a prepontine intradural chordoma.
  • These tumors are exceedingly rare.
  • Close follow-up is warranted because we postulate that this tumor exists in a biological continuum between benign notochordal hamartomatous remnants and typical invasive chordomas.
  • [MeSH-major] Chordoma / pathology. Chordoma / surgery. Dura Mater / pathology. Dura Mater / surgery. Meningeal Neoplasms / pathology. Meningeal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18382292.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Al-Khalaf HH, Lach B, Allam A, Hassounah M, Alkhani A, Elkum N, Alrokayan SA, Aboussekhra A: Expression of survivin and p16(INK4a)/Cdk6/pRB proteins and induction of apoptosis in response to radiation and cisplatin in meningioma cells. Brain Res; 2008 Jan 10;1188:25-34
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although meningiomas represent the most common class of tumors of the central nervous system, the molecular events underlying their genesis and development are still not well defined, and therapeutic approaches based on the genetics of these tumors are currently lacking.
  • In addition, we present evidence that the level of the anti-apoptosis survivin protein is high in these benign tumors.
  • [MeSH-major] Apoptosis / physiology. Cyclin-Dependent Kinase 6 / metabolism. Cyclin-Dependent Kinase Inhibitor p16 / metabolism. Meningeal Neoplasms / metabolism. Meningioma / metabolism. Microtubule-Associated Proteins / metabolism. Neoplasm Proteins / metabolism. Retinoblastoma Protein / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Agents / pharmacology. Cell Line, Tumor. Cisplatin / pharmacology. Female. Flow Cytometry. Humans. Hydroxyurea / pharmacology. Immunoblotting. Inhibitor of Apoptosis Proteins. Male. Middle Aged. Proto-Oncogene Proteins c-bcl-2 / drug effects. Proto-Oncogene Proteins c-bcl-2 / metabolism. Proto-Oncogene Proteins c-bcl-2 / radiation effects. Radiotherapy. Signal Transduction / drug effects. Signal Transduction / physiology. Up-Regulation / drug effects. Up-Regulation / physiology. Up-Regulation / radiation effects. bcl-2-Associated X Protein / drug effects. bcl-2-Associated X Protein / metabolism. bcl-2-Associated X Protein / radiation effects

  • Genetic Alliance. consumer health - Meningioma.
  • Hazardous Substances Data Bank. HYDROXYUREA .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18048012.001).
  • [ISSN] 0006-8993
  • [Journal-full-title] Brain research
  • [ISO-abbreviation] Brain Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / BIRC5 protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Retinoblastoma Protein; 0 / bcl-2-Associated X Protein; EC 2.7.11.22 / CDK6 protein, human; EC 2.7.11.22 / Cyclin-Dependent Kinase 6; Q20Q21Q62J / Cisplatin; X6Q56QN5QC / Hydroxyurea
  •  go-up   go-down


36. Rockhill J, Mrugala M, Chamberlain MC: Intracranial meningiomas: an overview of diagnosis and treatment. Neurosurg Focus; 2007;23(4):E1

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracranial meningiomas: an overview of diagnosis and treatment.
  • Meningiomas are extraaxial central nervous system tumors most often discovered in middle to late adult life, and are more often seen in women.
  • Ninety percent of meningiomas are benign, 6% are atypical, and 2% are malignant.
  • For the majority of incompletely resected or recurrent tumors not previously irradiated, radiotherapy is administered.
  • [MeSH-major] Meningeal Neoplasms / diagnosis. Meningeal Neoplasms / therapy. Meningioma / diagnosis. Meningioma / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17961033.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 62
  •  go-up   go-down


37. Isobe N, Oki S, Murakami T, Ooyama S, Kureshima M, Kurokawa Y: [A case of atypical meningioma with Lhermitte-Duclos disease]. No Shinkei Geka; 2005 Dec;33(12):1229-35
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lhermitte-Duclos disease is known as an uncommon disease that characterized by a slowly progressive tumor of the cerebellar hemisphere.
  • The patient had angioma of the left breast and bilateral benign struma, no typical manifestation of Cowden syndrome.
  • Removal of the frontal tumor caused the convulsion was subsequently performed.
  • After the operation, radiation therapy was not done because of the total removal of tumor and intension on patient side.
  • However, we should continuously take account to not only the recurrence of meningioma but also the enlargement of the cerebellar lesion and the complication of malignant tumors in whole body.
  • [MeSH-major] Cerebellar Neoplasms / complications. Ganglioneuroma / complications. Meningeal Neoplasms / complications. Meningioma / complications

  • Genetic Alliance. consumer health - Lhermitte-Duclos disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16359035.001).
  • [ISSN] 0301-2603
  • [Journal-full-title] No shinkei geka. Neurological surgery
  • [ISO-abbreviation] No Shinkei Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


38. Ong L, Ferrucci S: Tuberculum sellae meningioma associated with lymphomatoid papulosis. Optometry; 2005 Mar;76(3):165-75
MedlinePlus Health Information. consumer health - Vision Impairment and Blindness.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We present a case of a tuberculum sellae meningioma concurrent with lymphomatoid papulosis, a T-cell lymphomatoid skin disorder.
  • CONCLUSION: Meningiomas are generally benign tumors that can cause symptoms if vital structures are compromised.
  • Altered visual function and optic atrophy may be the only presentation of intracranial and orbital tumors.
  • Lymphomatoid papulosis (LyP) is a rare cutaneous disorder involving infiltrating clonal T-cells that has been associated with disseminated lymphomatic skin tumors.
  • [MeSH-major] Lymphomatoid Papulosis / complications. Meningeal Neoplasms / complications. Meningioma / complications. Optic Atrophy / etiology. Sella Turcica / pathology. Vision Disorders / etiology

  • Genetic Alliance. consumer health - Lymphomatoid papulosis.
  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15786635.001).
  • [ISSN] 1529-1839
  • [Journal-full-title] Optometry (St. Louis, Mo.)
  • [ISO-abbreviation] Optometry
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Wernicke AG, Dicker AP, Whiton M, Ivanidze J, Hyslop T, Hammond EH, Perry A, Andrews DW, Kenyon L: Assessment of Epidermal Growth Factor Receptor (EGFR) expression in human meningioma. Radiat Oncol; 2010;5:46
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: This study explores whether meningioma expresses epidermal growth factor receptor (EGFR) and determines if there is a correlation between the WHO grade of this tumor and the degree of EGFR expression.
  • RESULTS: Eighty-five samples of meningioma were classified in accordance with World Health Organization (WHO) criteria: benign 57/85 (67%), atypical 23/85 (27%), and malignant 5/85 (6%).
  • A significant association was determined when the benign and the atypical samples were compared to the malignant with respect to the SP (p = 0.009).
  • While there was a range of the IHS for the benign and the atypical histologic subtypes, malignant tumors exhibited the lowest score and were statistically different from the benign and the atypical specimens (p < 0.001).
  • EGFR expression is greatest in benign meningiomas and may serve a potential target for therapeutic intervention with selective EGFR inhibitors.
  • [MeSH-major] Meningeal Neoplasms / metabolism. Meningioma / metabolism. Receptor, Epidermal Growth Factor / metabolism
  • [MeSH-minor] Humans. Immunoenzyme Techniques. Neoplasm Staging. Prognosis. Tissue Array Analysis

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1984 Feb;44(2):753-60 [6318976.001]
  • [Cites] Curr Pharm Des. 2007;13(33):3358-67 [18045190.001]
  • [Cites] Surg Neurol. 1986 Mar;25(3):233-42 [3945904.001]
  • [Cites] Cancer Res. 1986 May;46(5):2545-50 [3697993.001]
  • [Cites] Acta Neurochir (Wien). 1986;83(1-2):62-6 [3492089.001]
  • [Cites] Cancer Res. 1987 Apr 15;47(8):2172-6 [3493842.001]
  • [Cites] Neurosurgery. 1987 Apr;20(4):525-8 [3587542.001]
  • [Cites] Pol J Pathol. 1998;49(3):145-9 [9810172.001]
  • [Cites] J Neuropathol Exp Neurol. 1999 Jul;58(7):697-701 [10411339.001]
  • [Cites] J Neurooncol. 2005 Jul;73(3):219-23 [15980972.001]
  • [Cites] N Engl J Med. 2005 Oct 20;353(16):1659-72 [16236737.001]
  • [Cites] N Engl J Med. 2006 Feb 9;354(6):567-78 [16467544.001]
  • [Cites] J Neurosurg. 2007 Jun;106(6):1034-40 [17564176.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 Aug;15(2):299-304 [3403313.001]
  • [Cites] Cancer. 1988 Nov 15;62(10):2139-44 [3052782.001]
  • [Cites] Cancer. 1990 Jul 1;66(1):152-5 [2354402.001]
  • [Cites] Cancer Invest. 1991;9(5):553-62 [1933488.001]
  • [Cites] J Endocrinol Invest. 1992 Jan;15(1):31-7 [1560188.001]
  • [Cites] Br J Neurosurg. 1993;7(2):197-9 [8388222.001]
  • [Cites] Surg Gynecol Obstet. 1993 Nov;177(5):488-96 [8211601.001]
  • [Cites] J Neurosurg. 1994 Feb;80(2):195-201 [8283256.001]
  • [Cites] Hum Pathol. 1994 Feb;25(2):146-53 [8119714.001]
  • [Cites] Crit Rev Oncol Hematol. 1995 Jul;19(3):183-232 [7612182.001]
  • [Cites] J Neurol. 1995 Oct;242(10):683-8 [8568531.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Mar 1;34(4):809-15 [8598357.001]
  • [Cites] Cancer. 1996 Sep 15;78(6):1284-92 [8826952.001]
  • [Cites] Br J Cancer. 1996 Oct;74(8):1253-7 [8883413.001]
  • [Cites] Anticancer Res. 1997 Jan-Feb;17(1B):769-74 [9066618.001]
  • [Cites] Neuropeptides. 1997 Jun;31(3):217-25 [9243517.001]
  • [Cites] J Neurosurg. 1997 Aug;87(2):315-23 [9254099.001]
  • [Cites] Acta Oncol. 1998;37(3):285-9 [9677101.001]
  • [Cites] Cancer Res. 2002 Dec 15;62(24):7350-6 [12499279.001]
  • [Cites] Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2002 Aug;24(4):427-9 [12905669.001]
  • [Cites] Acta Neuropathol. 2004 Aug;108(2):135-42 [15148612.001]
  • [Cites] J Neurosci Res. 1982;8(2-3):491-507 [6296418.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Lung Cancer. 2007 Aug;57 Suppl 2:S18-23 [17686441.001]
  • [Cites] Expert Opin Pharmacother. 2007 Oct;8(15):2579-92 [17931092.001]
  • [Cites] Clin Colorectal Cancer. 2007 Oct;6 Suppl 2:S42-6 [18021486.001]
  • [Cites] Drugs. 2007;67(17):2585-607 [18034592.001]
  • [Cites] Curr Cancer Drug Targets. 2007 Nov;7(7):650-65 [18045070.001]
  • [Cites] J Neurosurg. 1985 Jan;62(1):18-24 [3964853.001]
  • (PMID = 20509969.001).
  • [ISSN] 1748-717X
  • [Journal-full-title] Radiation oncology (London, England)
  • [ISO-abbreviation] Radiat Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  • [Other-IDs] NLM/ PMC2890616
  •  go-up   go-down


40. Mattozo CA, De Salles AA, Klement IA, Gorgulho A, McArthur D, Ford JM, Agazaryan N, Kelly DF, Selch MT: Stereotactic radiation treatment for recurrent nonbenign meningiomas. J Neurosurg; 2007 May;106(5):846-54
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In all, 52 tumors were treated.
  • All histological sections were reviewed and reclassified according to World Health Organization (WHO) 2000 guidelines as benign (Grade I), atypical (Grade II), or anaplastic (Grade III) meningiomas.
  • After initial treatment, 22 new tumors required treatment using SRS or SRT; 17 (77%) of them occurred inside the original resection cavity.
  • [MeSH-major] Meningeal Neoplasms / surgery. Meningioma / surgery. Neoplasm Recurrence, Local / surgery. Radiosurgery
  • [MeSH-minor] Adult. Aged. Cell Transformation, Neoplastic / pathology. Disease Progression. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasms, Multiple Primary / diagnosis. Neoplasms, Multiple Primary / pathology. Neoplasms, Multiple Primary / surgery. Reoperation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17542529.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Korhonen K, Salminen T, Raitanen J, Auvinen A, Isola J, Haapasalo H: Female predominance in meningiomas can not be explained by differences in progesterone, estrogen, or androgen receptor expression. J Neurooncol; 2006 Oct;80(1):1-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hormonal status was determined in 510 tumor samples.
  • 443 samples were from primary meningiomas and 67 from recurrent tumors.
  • Of the samples, 455 were benign (WHO grade I), 49 atypical (grade II), and 6 malignant (grade III).
  • Of the primary tumor samples, 88% were progesterone receptor positive, 40% were positive for estrogen and 39% for androgen receptors.
  • Estrogen positive tumor samples had significantly higher proliferation index than estrogen negative samples.
  • [MeSH-major] Meningeal Neoplasms / metabolism. Meningioma / metabolism. Receptors, Androgen / metabolism. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Neurol. 1987 Apr;27(4):319-22 [3824137.001]
  • [Cites] Neurosurgery. 1993 Aug;33(2):212-7; discussion 217-8 [8367042.001]
  • [Cites] Clin Neuropharmacol. 1984;7(4):363-7 [6509448.001]
  • [Cites] J Neurosurg. 1997 Jan;86(1):113-20 [8988089.001]
  • [Cites] Brain Pathol. 1993 Jul;3(3):255-68 [8293185.001]
  • [Cites] Acta Neurochir (Wien). 1992;115(1-2):20-30 [1595392.001]
  • [Cites] Cancer Res. 1993 Mar 15;53(6):1312-6 [8443810.001]
  • [Cites] J Neurosurg. 1995 Mar;82(3):453-60 [7861224.001]
  • [Cites] J Pathol. 1992 Dec;168(4):357-63 [1484317.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1992 Jun;55(6):486-90 [1619417.001]
  • [Cites] Hum Pathol. 2001 Sep;32(9):970-5 [11567227.001]
  • [Cites] Histopathology. 2003 Sep;43(3):280-90 [12940781.001]
  • [Cites] Neurosurgery. 1995 Jul;37(1):92-7 [8587697.001]
  • [Cites] Neurosurgery. 2003 Jun;52(6):1327-33; discussion 1333-4 [12762878.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1958 May;21(2):89-91 [13539648.001]
  • [Cites] Arch Neurol. 1987 Feb;44(2):209-15 [3545159.001]
  • [Cites] J Neurosurg. 1991 Jun;74(6):861-6 [2033444.001]
  • [Cites] J Clin Pathol. 2004 Oct;57(10):1033-7 [15452155.001]
  • [Cites] J Neurosurg. 1990 Nov;73(5):750-5 [2213165.001]
  • [Cites] J Neurosurg. 2003 Nov;99(5):848-53 [14609164.001]
  • [Cites] J Neurooncol. 1993 Jan;15(1):75-7 [8455065.001]
  • [Cites] J Neurosurg. 1993 Mar;78(3):456-62 [8433149.001]
  • [Cites] Clin Cancer Res. 2000 Sep;6(9):3570-5 [10999746.001]
  • [Cites] Surg Neurol. 1986 May;25(5):436-40 [3961659.001]
  • [Cites] Neurosurgery. 1995 Sep;37(3):478-82; discussion 483 [7501113.001]
  • [Cites] Neurosurgery. 1995 Dec;37(6):1049-55 [8584144.001]
  • [Cites] Neurosurgery. 1997 Nov;41(5):1152-9 [9361071.001]
  • [Cites] J Pathol. 1994 Dec;174(4):275-82 [7884589.001]
  • [Cites] J Neurosurg. 1994 Mar;80(3):527-34 [8113866.001]
  • [Cites] Neurosurgery. 2003 Jul;53(1):62-70; discussion 70-1 [12823874.001]
  • [Cites] J Neurosurg. 1986 Jul;65(1):99-107 [3712034.001]
  • [Cites] Cancer. 1994 Jul 15;74(2):679-85 [8033047.001]
  • [Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]
  • [Cites] Surg Neurol. 1986 Mar;25(3):233-42 [3945904.001]
  • [Cites] Gynecol Oncol. 1990 Sep;38(3):396-406 [2172119.001]
  • [Cites] J Neurosurg. 2000 Jul;93(1):132-5 [10883917.001]
  • [Cites] Cancer. 2002 Mar 15;94(6):1626-35 [11920521.001]
  • [Cites] J Surg Oncol. 1986 Mar;31(3):182-3 [3724170.001]
  • [Cites] J Neurosurg. 1994 Nov;81(5):765-73 [7523635.001]
  • [Cites] Hum Pathol. 1998 Feb;29(2):140-5 [9490273.001]
  • [Cites] Hum Pathol. 1998 Dec;29(12):1420-7 [9865827.001]
  • [Cites] J Neurosurg. 1990 Nov;73(5):743-9 [2213164.001]
  • [Cites] Neuropathol Appl Neurobiol. 1998 Dec;24(6):441-52 [9888154.001]
  • [Cites] Surg Neurol. 1985 Sep;24(3):245-9 [4023903.001]
  • [Cites] Acta Neuropathol. 1996;91(5):504-10 [8740231.001]
  • [Cites] Acta Neurochir Suppl. 1996;65:50-3 [8738495.001]
  • [Cites] J Neurosurg. 2000 Mar;92(3):401-5 [10701525.001]
  • [Cites] Endocrinology. 1994 Jul;135(1):107-12 [8013342.001]
  • [Cites] J Neurosurg. 1994 Aug;81(2):184-7 [8027799.001]
  • [Cites] Surg Neurol. 1995 Mar;43(3):230-3; discussion 234 [7792684.001]
  • [Cites] J Neurooncol. 1999 Apr;42(2):109-16 [10421067.001]
  • [Cites] Neurology. 1975 Aug;25(8):705-12 [1171403.001]
  • (PMID = 16703453.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Receptors, Androgen; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  •  go-up   go-down


42. van Tilborg AA, Al Allak B, Velthuizen SC, de Vries A, Kros JM, Avezaat CJ, de Klein A, Beverloo HB, Zwarthoff EC: Chromosomal instability in meningiomas. J Neuropathol Exp Neurol; 2005 Apr;64(4):312-22
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Approximately 60% of sporadic meningiomas are caused by inactivation of the NF2 tumor suppressor gene on chromosome 22.
  • Cytogenetic analysis shows that meningiomas caused by inactivation of the NF2 gene can be divided into tumors that show monosomy 22 as the sole abnormality and tumors with a more complex karyotype.
  • Unexpectedly and regardless of genotype, a subgroup of tumors was observed with an average number of 44.9 chromosomes and little variation in the number of chromosomes per metaphase spread.
  • In cultured cells of all tumor groups, bi- and multinucleated cells were seen, as well as anaphase bridges, residual chromatid strings, multiple spindle poles, and unseparated chromatids, suggesting defects in the mitotic apparatus or kinetochore.
  • Thus, we conclude that even a benign and slow-growing tumor like a meningioma displays chromosomal instability.
  • [MeSH-major] Chromosomal Instability. Meningeal Neoplasms / genetics. Meningioma / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15835267.001).
  • [ISSN] 0022-3069
  • [Journal-full-title] Journal of neuropathology and experimental neurology
  • [ISO-abbreviation] J. Neuropathol. Exp. Neurol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


43. Beseoglu K, Knobbe CB, Reifenberger G, Steiger HJ, Stummer W: Supratentorial meningeal melanocytoma mimicking a convexity meningioma. Acta Neurochir (Wien); 2006 Apr;148(4):485-90
MedlinePlus Health Information. consumer health - Moles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Supratentorial meningeal melanocytoma mimicking a convexity meningioma.
  • OBJECTIVE AND IMPORTANCE: Meningeal melanocytomas are rare benign neuro-ectodermal tumors arising from melanocytic cells in the leptomeninges.
  • Thus, most reported cases of meningeal melanocytomas are located in the posterior fossa and the spinal cord, respectively.
  • CLINICAL PRESENTATION: We report on the rare case of a 55-year-old male patient with a large supratentorial meningeal melanocytoma mimicking a convexity meningioma and a smaller, similarly dura based lesion in the posterior fossa.
  • INTERVENTION: Tumor control to date was achieved by surgery of the large lesion and radiosurgery of the small lesion.
  • CONCLUSION: Complete tumor resection may be advantageous and second or recurrent lesions may be managed by repeat surgery or stereotactic radiosurgery.
  • [MeSH-major] Melanocytes / pathology. Meningeal Neoplasms / pathology. Meningioma / diagnosis. Neoplasms, Multiple Primary / pathology. Nevus / pathology. Supratentorial Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Diagnostic Errors / prevention & control. Humans. Magnetic Resonance Imaging. Male. Meninges / pathology. Middle Aged. Neurosurgical Procedures. Parietal Lobe / pathology. Parietal Lobe / surgery. Radiosurgery. Rare Diseases. Treatment Outcome

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16391879.001).
  • [ISSN] 0001-6268
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


44. Tseng KY, Chung MH, Sytwu HK, Lee HM, Chen KY, Chang C, Lin CK, Yen CH, Chen JH, Lin GJ, Ma HI, Yeh YS, Ju DT, Liu MY, Hueng DY: Osteopontin expression is a valuable marker for prediction of short-term recurrence in WHO grade I benign meningiomas. J Neurooncol; 2010 Nov;100(2):217-23

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osteopontin expression is a valuable marker for prediction of short-term recurrence in WHO grade I benign meningiomas.
  • Prediction of recurrence remains a challenge in histopathological benign/grade I tumors.
  • In this study, we investigated OPN protein expression by evaluating the differences between recurrent and non-recurrent histologically benign meningiomas.
  • Thirty-two patients were enrolled, and 23 benign non-recurrent meningiomas and 9 benign recurrent meningiomas were followed for a mean of 34 months after complete surgical resection (Simpson grades I and II).
  • We examined clinical biological data, their relationship with tumor recurrence, and the expression of OPN.
  • In comparison, an OPN Allred score from 4 to 8 was indicative of a shorter average recurrence-free time.
  • Moreover, determination of the OPN Allred score is a reliable, quantitative tool for predicting recurrence-free time in benign meningioma patients.
  • [MeSH-major] Biomarkers, Tumor / analysis. Meningeal Neoplasms / pathology. Meningioma / pathology. Neoplasm Recurrence, Local / pathology. Osteopontin / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Neurol. 2004 Feb;61(2):149-55; discussion 155-6 [14751627.001]
  • [Cites] Curr Mol Med. 2001 Nov;1(5):621-32 [11899236.001]
  • [Cites] Neuro Oncol. 2010 Jan;12(1):58-70 [20150368.001]
  • [Cites] J Neurooncol. 2002 Dec;60(3):235-45 [12510775.001]
  • [Cites] J Neurosurg. 1999 Sep;91(3):375-83 [10470810.001]
  • [Cites] Crit Rev Oncog. 2000;11(2):135-46 [11005509.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2001 Oct;6(4):419-29 [12013531.001]
  • [Cites] J Cell Biochem. 2000 Jun 6;78(3):465-75 [10861844.001]
  • [Cites] J Cell Biochem Suppl. 1998;30-31:92-102 [9893260.001]
  • [Cites] Nat Rev Cancer. 2008 Mar;8(3):212-26 [18292776.001]
  • [Cites] Cancer. 2002 Mar 1;94(5):1538-47 [11920512.001]
  • [Cites] J Neurooncol. 2009 Sep;94(3):383-8 [19330289.001]
  • [Cites] Hum Pathol. 2010 Feb;41(2):199-207 [19801161.001]
  • [Cites] Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):184-90 [14734468.001]
  • [Cites] Arch Pathol Lab Med. 1998 Dec;122(12):1087-90 [9870857.001]
  • [Cites] Neuropathol Appl Neurobiol. 1998 Dec;24(6):441-52 [9888154.001]
  • [Cites] Biochim Biophys Acta. 2001 Dec 28;1552(2):61-85 [11825687.001]
  • [Cites] Neuropathology. 2007 Oct;27(5):407-12 [18018472.001]
  • [Cites] J Neurooncol. 2007 Mar;82(1):63-8 [17225937.001]
  • [Cites] Cancer. 2003 Jul 1;98(1):119-27 [12833464.001]
  • [Cites] Curr Mol Med. 2006 Dec;6(8):819-30 [17168734.001]
  • [Cites] Neuropathology. 2007 Apr;27(2):114-20 [17494511.001]
  • [Cites] Pathol Oncol Res. 2009 Jun;15(2):203-7 [19048398.001]
  • (PMID = 20428925.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / SPP1 protein, human; 106441-73-0 / Osteopontin
  •  go-up   go-down


45. Kaynar MY, Sanus GZ, Hnimoglu H, Kacira T, Kemerdere R, Atukeren P, Gumustas K, Canbaz B, Tanriverdi T: Expression of hypoxia inducible factor-1alpha in tumors of patients with glioblastoma multiforme and transitional meningioma. J Clin Neurosci; 2008 Sep;15(9):1036-42
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of hypoxia inducible factor-1alpha in tumors of patients with glioblastoma multiforme and transitional meningioma.
  • There was no statistically significant difference between the two types of tumor (p=0.264).
  • These findings indicate that HIF-1alpha is elevated in both TM and GBM, suggesting that although hypoxia is one of the most important and powerful stimuli for HIF-1alpha elevation and consequently angiogenesis, other mechanisms may play roles in HIF-1alpha stimulation in benign brain tumors such as TM.
  • [MeSH-major] Brain Neoplasms / metabolism. Glioblastoma / metabolism. Hypoxia-Inducible Factor 1, alpha Subunit / metabolism. Meningeal Neoplasms / metabolism. Meningioma / metabolism
  • [MeSH-minor] Adult. Aged. Anoxia / diagnosis. Anoxia / metabolism. Anoxia / physiopathology. Biomarkers, Tumor / analysis. Biomarkers, Tumor / metabolism. Cell Hypoxia / physiology. Enzyme-Linked Immunosorbent Assay. Female. Humans. Male. Middle Aged. Neovascularization, Pathologic / etiology. Neovascularization, Pathologic / metabolism. Neovascularization, Pathologic / physiopathology. Predictive Value of Tests. Up-Regulation / physiology

  • Genetic Alliance. consumer health - Glioblastoma.
  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18621534.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit
  •  go-up   go-down


46. Kwon Y, Bae JS, Kim JM, Lee DH, Kim SY, Ahn JS, Kim JH, Kim CJ, Kwun BD, Lee JK: Visual changes after gamma knife surgery for optic nerve tumors. Report of three cases. J Neurosurg; 2005 Jan;102 Suppl:143-6
MedlinePlus Health Information. consumer health - Vision Impairment and Blindness.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Visual changes after gamma knife surgery for optic nerve tumors. Report of three cases.
  • Tumors involving the optic nerve (optic glioma, optic nerve sheath meningioma) are benign but difficult to treat.
  • [MeSH-major] Cranial Nerve Neoplasms / surgery. Exophthalmos / etiology. Meningeal Neoplasms / surgery. Meningioma / surgery. Optic Nerve Glioma / surgery. Optic Nerve Neoplasms / surgery. Postoperative Complications. Radiosurgery / instrumentation. Vision Disorders / etiology
  • [MeSH-minor] Adult. Child. Female. Humans. Magnetic Resonance Imaging. Male. Radiation Dosage. Tumor Burden / radiation effects. Visual Acuity / physiology

  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15662798.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Nakaya K, Niranjan A, Kondziolka D, Kano H, Khan AA, Nettel B, Koebbe C, Pirris S, Flickinger JC, Lunsford LD: Gamma knife radiosurgery for benign tumors with symptoms from brainstem compression. Int J Radiat Oncol Biol Phys; 2010 Jul 15;77(4):988-95
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gamma knife radiosurgery for benign tumors with symptoms from brainstem compression.
  • PURPOSE: This study evaluated the role of radiosurgery in the management of symptomatic patients with brainstem compression from benign basal tumors.
  • METHODS AND MATERIALS: Over a 17-year, period 246 patients (202 vestibular schwannomas and 44 meningiomas) with brainstem compression from benign skull-base tumors were managed with Gamma Knife radiosurgery.
  • Median tumor volumes were 3.9 cm(3) (range, 0.8-39.0 mL) and 6.6 mL (range, 1.6-25.1 mL) for vestibular schwannomas and meningiomas, respectively.
  • For both tumors, a median marginal dose of 13 Gy was prescribed.
  • Patients were categorized into four groups on the basis of the tumor-brainstem relationship on neuroimaging.
  • The tumor control rate was 100 % for meningioma and 97% for vestibular schwannomas (although 5% required an additional procedure such as a ventriculoperitoneal shunt).
  • Balance improved significantly in patients who had less tumor compression (p = 0.0357) after radiosurgery.
  • CONCLUSION: Radiosurgery is a minimally invasive option for patients with benign basal tumors that indent or distort the brainstem.
  • A high tumor growth control rate and satisfactory rate of neurological preservation and symptom control can be obtained with radiosurgery.
  • [MeSH-major] Brain Stem. Meningeal Neoplasms / surgery. Meningioma / surgery. Neuroma, Acoustic / surgery. Radiosurgery / methods. Skull Base Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20381265.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Bhatnagar AK, Gerszten PC, Ozhasaglu C, Vogel WJ, Kalnicki S, Welch WC, Burton SA: CyberKnife Frameless Radiosurgery for the treatment of extracranial benign tumors. Technol Cancer Res Treat; 2005 Oct;4(5):571-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CyberKnife Frameless Radiosurgery for the treatment of extracranial benign tumors.
  • Limited data exists for the use of radiosurgery for benign extracranial tumors.
  • The purpose of this study was to evaluate the feasibility, toxicity, and local control of patients with benign extracranial lesions treated with the CyberKnife Frameless Radiosurgery System.
  • From September 2001 thru January 2004, 59 benign tumors in 44 patients were treated using the CyberKnife a frameless image-guided radiosurgery system.
  • Of these tumors, there were 21 neurofibromas, ten schwannomas, eight meningiomas, eight hemangioblastomas, seven paragangliomas, two hemangiopericytomas, one pseudotumor, one ependymoma, and one arteriovenous malformation (AVM).
  • The anatomic locations of these tumors were spinal (25 cervical, four thoracic, 14 lumbar, and two sacral), neck (eight), orbital (three), brainstem (one), and foramen magnum (one).
  • The median tumor dose delivered was 16.0 Gy to the 80% isodose line (range 10-31 Gy).
  • The median tumor volume was 4.3 cc (range 0.14-98.6 cc).
  • This study suggests that CyberKnife Radiosurgery is a safe and efficacious treatment modality for benign tumors, even for those patients with recurrent previously irradiated lesions.
  • [MeSH-major] Brain Neoplasms / surgery. Neoplasms / surgery. Radiosurgery / methods
  • [MeSH-minor] Humans. Image Processing, Computer-Assisted. Magnetic Resonance Imaging. Meningeal Neoplasms / surgery. Meningioma / surgery. Neurilemmoma / surgery. Neurofibroma / surgery. Safety. Spinal Cord Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16173828.001).
  • [ISSN] 1533-0346
  • [Journal-full-title] Technology in cancer research & treatment
  • [ISO-abbreviation] Technol. Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Johnson WD, Loredo LN, Slater JD: Surgery and radiotherapy: complementary tools in the management of benign intracranial tumors. Neurosurg Focus; 2008;24(5):E2
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgery and radiotherapy: complementary tools in the management of benign intracranial tumors.
  • Historically, radiation therapy has been used extensively in the treatment of malignant and aggressive intracranial tumors, and the importance of its role has been repeatedly verified by prolonged patient survival rates and increased tumor control.
  • As more modern capabilities are employed in surgery and radiotherapy, attention is being directed to the utility of radiation as either primary or secondary treatment of benign tumors.
  • Specifically, primary treatment encompasses irradiation of small benign tumors without biopsy confirmation of tumor type; secondary treatment involves postoperative radiation therapy, with the possibility that less-aggressive tumor resection may be performed in areas that have a higher probability of resultant neurological deficit.
  • This article provides an overview of factors to consider in the use of radiation therapy and reviews the relationships between radiation and surgery, notably the unique complementary role each plays in the treatment of benign intracranial tumors.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Brain Neoplasms / surgery. Cranial Irradiation
  • [MeSH-minor] Adenoma / radiotherapy. Adenoma / surgery. Combined Modality Therapy. Dose Fractionation. Elementary Particles / therapeutic use. Humans. Meningeal Neoplasms / radiotherapy. Meningeal Neoplasms / surgery. Meningioma / radiotherapy. Meningioma / surgery. Neurilemmoma / radiotherapy. Neurilemmoma / ultrasonography. Pituitary Neoplasms / radiotherapy. Pituitary Neoplasms / surgery. Radioisotopes / therapeutic use. Radiosurgery / instrumentation. Radiosurgery / methods. Radiotherapy, Computer-Assisted / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18447741.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radioisotopes
  • [Number-of-references] 55
  •  go-up   go-down


50. Fagundes-Pereyra WJ, de Sousa L, Carvalho GT, Pittella JE, de Sousa AA: Meningeal melanocytoma of the posterior fossa: case report and literature review. Surg Neurol; 2005 Mar;63(3):269-73; discussion 273-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meningeal melanocytoma of the posterior fossa: case report and literature review.
  • BACKGROUND: Meningeal melanocytomas are rare primary melanotic tumors of the leptomeninges.
  • According to our review of the literature, just 22 cases of meningeal melanocytoma (MM) of the posterior fossa have been previously reported.
  • Some aspects related to diagnosis, radiological appearance, histopathologic features, and management are discussed in this paper.
  • CASE DESCRIPTION: We describe the case of a 42-year-old female presenting with severe headache, nausea, and vomiting.
  • Histopathologic examination showed a highly cellular melanocytic neoplasm with numerous dark pigments in the cytoplasm.
  • Immunoperoxidase staining S-100 protein and HMB 45 demonstrated immunoreactivity for both, confirming the diagnosis of MM.
  • CONCLUSIONS: In conclusion, MMs are rare histologically benign tumors that can be cured by complete surgical resection alone, which should be the goal of the treatment.
  • These lesions, although rare, should be considered in the differential diagnosis of tumors of the posterior fossa.
  • [MeSH-major] Cerebellum / pathology. Cranial Fossa, Posterior / pathology. Infratentorial Neoplasms / pathology. Melanocytes / pathology. Meningeal Neoplasms / pathology
  • [MeSH-minor] Adult. Biomarkers, Tumor. Diagnosis, Differential. Disease-Free Survival. Female. Headache / etiology. Humans. Magnetic Resonance Imaging. Nausea / etiology. Neurosurgical Procedures / methods. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15734524.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 29
  •  go-up   go-down


51. Keller A, Ludwig N, Comtesse N, Hildebrandt A, Meese E, Lenhof HP: A minimally invasive multiple marker approach allows highly efficient detection of meningioma tumors. BMC Bioinformatics; 2006;7:539
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A minimally invasive multiple marker approach allows highly efficient detection of meningioma tumors.
  • BACKGROUND: The development of effective frameworks that permit an accurate diagnosis of tumors, especially in their early stages, remains a grand challenge in the field of bioinformatics.
  • Our approach uses statistical learning techniques applied to multiple antigen tumor antigen markers utilizing the immune system as a very sensitive marker of molecular pathological processes.
  • For validation purposes we choose the intracranial meningioma tumors as model system since they occur very frequently, are mostly benign, and are genetically stable.
  • Detailed analysis revealed that prediction performs particularly well on low-grade (WHO I) tumors, consistent with our goal of early stage tumor detection.
  • For these tumors the best classification result with a specificity of 97.5%, a sensitivity of 91.3%, an accuracy of 95.6%, and an area under the ROC curve of 0.971 was achieved using a set of 12 antigen markers only.
  • Remarkably, our study proves that the inclusion of non-specific antigens, detected not only in tumor but also in normal sera, increases the performance significantly, since non-specific antigens contribute additional diagnostic information.
  • CONCLUSION: Our approach offers the possibility to screen members of risk groups as a matter of routine such that tumors hopefully can be diagnosed immediately after their genesis.
  • [MeSH-major] Algorithms. Antigens, Neoplasm / analysis. Biomarkers, Tumor / analysis. Meningeal Neoplasms / diagnosis. Meningeal Neoplasms / immunology. Meningioma / diagnosis. Meningioma / immunology
  • [MeSH-minor] Diagnosis, Computer-Assisted / methods. Gene Expression Profiling / methods. Humans. Immunoassay / methods. Pattern Recognition, Automated / methods. Reproducibility of Results. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2651-6 [12601173.001]
  • [Cites] Cancer Immun. 2004 Jan 23;4:1 [14738373.001]
  • [Cites] Bioinformatics. 2004 Nov 22;20(17):3034-44 [15226172.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1110-8 [15709178.001]
  • [Cites] J Urol. 2005 May;173(5):1456-62 [15821460.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jul 5;102(27):9601-6 [15983380.001]
  • [Cites] Nat Rev Cancer. 2002 Mar;2(3):210-9 [11990857.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):1181-90 [16424057.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1792-8 [16452240.001]
  • [Cites] Nature. 2006 Aug 17;442(7104):736-8 [16915260.001]
  • [Cites] Lancet. 2002 Feb 16;359(9306):572-7 [11867112.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] Semin Cancer Biol. 2002 Feb;12(1):25-31 [11926408.001]
  • [Cites] N Engl J Med. 2005 Sep 22;353(12):1224-35 [16177248.001]
  • (PMID = 17184519.001).
  • [ISSN] 1471-2105
  • [Journal-full-title] BMC bioinformatics
  • [ISO-abbreviation] BMC Bioinformatics
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC1769403
  •  go-up   go-down


52. Spalice A, Ruggieri M, Grosso S, Verrotti A, Polizzi A, Magro G, Caltabiano R, Pavone P, Del Balzo F, Platania N, Iannetti P: Dysembryoplastic neuroepithelial tumors: a prospective clinicopathologic and outcome study of 13 children. Pediatr Neurol; 2010 Dec;43(6):395-402
MedlinePlus Health Information. consumer health - Seizures.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dysembryoplastic neuroepithelial tumors: a prospective clinicopathologic and outcome study of 13 children.
  • Dysembryoplastic neuroepithelial tumors (DNETs) are benign intracortical masses that are typically observed in children and young adults and are classified as glioneuronal tumors (WHO grade I).
  • Pathology examination revealed cortical dysplasia (n = 8), glial nodules (n = 11), calcification (n = 4), cellular atypia (n = 3), endothelial proliferation (n = 1), perivascular inflammation (n = 3), and meningeal involvement (n = 6).
  • This first prospective study with follow-up monitoring of a childhood population with DNETs confirms, on a long-term basis, that the coupled strategy of extended lesionectomy and neuronavigation has good outcome for long-term seizure control.
  • [MeSH-major] Brain Neoplasms / pathology. Cerebral Cortex / pathology. Neoplasms, Neuroepithelial / pathology. Seizures / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 21093729.001).
  • [ISSN] 1873-5150
  • [Journal-full-title] Pediatric neurology
  • [ISO-abbreviation] Pediatr. Neurol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Aruga J, Nozaki Y, Hatayama M, Odaka YS, Yokota N: Expression of ZIC family genes in meningiomas and other brain tumors. BMC Cancer; 2010;10:79
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of ZIC family genes in meningiomas and other brain tumors.
  • BACKGROUND: Zic zinc finger proteins are present in the developing rodent meninges and are required for cell proliferation and differentiation of meningeal progenitors.
  • METHODS: We examined the mRNA and protein expression of human ZIC1, ZIC2, ZIC3, ZIC4 and ZIC5 genes in meningiomas in comparison to other brain tumors, using RT-PCR, analysis of published microarray data, and immunostaining.
  • The expression level of ZIC1 in public microarray data was greater in meningiomas classified as World Health Organization Grade II (atypical) than those classified as Grade I (benign).
  • In normal meninges, ZIC-like immunoreactivities were detected in vimentin-expressing arachnoid cells both in human and mouse.
  • The pattern of ZIC expression in both of these tumor types may reflect the properties of the tissues from which the tumors are derived.
  • [MeSH-major] Brain Neoplasms / metabolism. Gene Expression Regulation, Neoplastic. Meningioma / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurg Focus. 2007;23(4):E3 [17961040.001]
  • [Cites] Dev Biol. 2007 Jun 15;306(2):669-84 [17490632.001]
  • [Cites] Physiol Genomics. 1999 Aug 31;1(2):83-91 [11015565.001]
  • [Cites] J Neurosci. 2002 Jan 1;22(1):218-25 [11756505.001]
  • [Cites] Neurology. 2002 Dec 24;59(12):1985-7 [12499499.001]
  • [Cites] Mol Cell Neurosci. 2004 Jun;26(2):205-21 [15207846.001]
  • [Cites] Cancer Res. 1996 Jan 15;56(2):377-83 [8542595.001]
  • [Cites] Clin Genet. 2005 Apr;67(4):290-6 [15733262.001]
  • [Cites] Cancer. 2005 Jun 15;103(12):2575-83 [15880380.001]
  • [Cites] Lancet Neurol. 2006 Dec;5(12):1045-54 [17110285.001]
  • [Cites] Nucleic Acids Res. 2007;35(7):e51 [17344319.001]
  • [Cites] J Neuroimmunol. 2008 Sep 15;201-202:163-5 [18639938.001]
  • [Cites] Int J Cancer. 2009 Jan 15;124(2):346-51 [19003955.001]
  • [Cites] J Neurol. 2010 Apr;257(4):509-17 [20035430.001]
  • [Cites] J Neurosci. 2008 Apr 30;28(18):4712-25 [18448648.001]
  • (PMID = 20199689.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / Vimentin; 0 / ZIC1 protein, human; 0 / ZIC2 protein, human; 0 / ZIC5 protein, human
  • [Other-IDs] NLM/ PMC2838823
  •  go-up   go-down


54. Budrukkar A, Jalali R, Dutta D, Sarin R, Devlekar R, Parab S, Kakde A: Prospective assessment of quality of life in adult patients with primary brain tumors in routine neurooncology practice. J Neurooncol; 2009 Dec;95(3):413-419
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective assessment of quality of life in adult patients with primary brain tumors in routine neurooncology practice.
  • The aim of this article is to evaluate and assess the impact of various factors on quality of life (QOL) in adult patients with primary brain tumors seen consecutively in routine neurooncology practice.
  • Two hundred and fifty-seven adult patients, after undergoing surgical intervention and histologically proven primary brain neoplasms were registered in the NeuroOncology Clinic at our centre during 1 full calendar year.
  • In the present analysis, QOL scores before starting adjuvant treatment were measured and impact of patient and tumor related factors were analyzed.
  • Baseline global QOL data of all patients (available in 243) was relatively low including in all histological tumor types.
  • Domains of future uncertainty, visual disorder, motor deficit, communication deficit, headache, seizures and drowsiness scores were 19.6, 18.2, 28.5, 30.7, 21, 31.8 and 16 (lower values better), respectively.
  • Patients with lower performance status (KPS < 70) had a lower global QOL (KPS >or= 80 vs. <or= 70; 37 vs. 67; p = 0.001) including in all histological types of high-grade gliomas (HGG) (p = 0.005), low-grade gliomas (LGG) (p = 0.04) and benign tumors (p = <0.001).
  • Tumor type is an important patient related factor that influences baseline global scores (LGG vs. HGG 62 and 52; p = 0.015).
  • Type of surgery (biopsy/complete excision) (p = 0.284) and site of tumor (p = 0.309) did not show any impact on QOL score.
  • Patients with malignant tumors and poor performance status had significantly lower QOL scores even before starting adjuvant treatment.
  • [MeSH-major] Brain Neoplasms / physiopathology. Brain Neoplasms / therapy. Glioma / physiopathology. Glioma / therapy. Outpatient Clinics, Hospital. Quality of Life
  • [MeSH-minor] Adenoma / physiopathology. Adenoma / therapy. Adolescent. Adult. Educational Status. Female. Health Status. Humans. India. Karnofsky Performance Status. Male. Meningeal Neoplasms / physiopathology. Meningeal Neoplasms / therapy. Middle Aged. Pituitary Neoplasms / physiopathology. Pituitary Neoplasms / therapy. Prospective Studies. Surveys and Questionnaires. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 2002 Sep;38(14):1824-31 [12204663.001]
  • [Cites] Lancet. 2002 Nov 2;360(9343):1361-8 [12423981.001]
  • [Cites] Qual Life Res. 1996 Feb;5(1):139-50 [8901377.001]
  • [Cites] J Neurooncol. 2009 Aug;94(1):103-10 [19255726.001]
  • [Cites] Lancet Oncol. 2005 Dec;6(12 ):937-44 [16321761.001]
  • [Cites] J Neurooncol. 2008 Mar;87(1):111-4 [18004503.001]
  • [Cites] Neuro Oncol. 2000 Oct;2(4):221-8 [11265231.001]
  • [Cites] J Neurooncol. 2006 Feb;76(3):283-91 [16163448.001]
  • [Cites] J Natl Cancer Inst. 1993 Mar 3;85(5):365-76 [8433390.001]
  • [Cites] J Cancer Res Ther. 2006 Oct-Dec;2(4):166-70 [17998699.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):139-44 [9440735.001]
  • [Cites] J Neurooncol. 2008 Dec;90(3):321-8 [18704269.001]
  • [Cites] BMC Cancer. 2007 Jan 25;7:18 [17254350.001]
  • (PMID = 19548070.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


55. Barnholtz-Sloan JS, Kruchko C: Meningiomas: causes and risk factors. Neurosurg Focus; 2007;23(4):E2
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Meningiomas are among the most common primary intracranial tumors.
  • Although the vast majority of these tumors are considered histologically benign, the incidence of complications can be high.
  • [MeSH-major] Meningeal Neoplasms / etiology. Meningioma / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17961039.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Grant] United States / PHS HHS / / 2004-01218
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hormones
  • [Number-of-references] 113
  •  go-up   go-down


56. Ahmadi SA, Samadi N: Evaluation of argyrophilic nucleolar organizer region staining in predicting the behavior of meningiomas. Ann Saudi Med; 2006 Jan-Feb;26(1):38-42

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Comparing nonrecurrent, recurrent, atypical and malignant meningiomas we studied the value of the routine applicability of the AgNOR count in the prognostication of this tumor.
  • Eighty-one cases were selected and arranged in six groups according to clinical data and grading: 14 benign non-recurrent meningiomas; 14 primary benign recurrent meningiomas and their subsequent benign recurrences; 14 atypical; 11 malignant and 14 spinal meningiomas.
  • RESULTS: There was a proportionate increase of AgNOR dots with increasing tumor grade.
  • There was a significant difference between benign non-recurrenttumors versus benign recurrent (P<0.0001) and atypical or malignant (P<0.0001) tumors.
  • A difference was also noted between the recurring tumors versus malignant ones (P = 0.002) but no significant difference was seen between recurrent and atypical; atypical and malignant; intracranial and intraspinal; and primary of recurring meningiomas with their subsequent recurrences.
  • A mean AgNOR count of <2.3 could separate benign tumors from atypical or malignant meningiomas with 93% specificity; and 93% of tumors with benign histology had no recurrence potential if their mean AgNOR count was less than 1.8.
  • CONCLUSION: This study indicates that in meningioma, the AgNOR count has a good correlation with tumor grading and recurrence, which may aid pathologists and clinicians in predicting tumor behavior.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningioma / pathology. Nucleolus Organizer Region / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16521873.001).
  • [ISSN] 0256-4947
  • [Journal-full-title] Annals of Saudi medicine
  • [ISO-abbreviation] Ann Saudi Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Saudi Arabia
  • [Chemical-registry-number] 0 / Coloring Agents
  •  go-up   go-down


57. Lusis EA, Chicoine MR, Perry A: High throughput screening of meningioma biomarkers using a tissue microarray. J Neurooncol; 2005 Jul;73(3):219-23
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Meningiomas are histologically and clinically diverse CNS neoplasms with few available immunohistochemical markers of differentiation and progression.
  • In most cases, frequencies of tumor positivity were similar to those previously reported using whole section IHC.
  • As in prior studies, PR and cathepsin D expression were inversely proportional to tumor grade.
  • However, PR and EGFR were also differentially expressed between symptomatic, surgically resected benign meningiomas and incidental meningiomas found at autopsy.
  • We conclude that (1) TMA-IHC is an accurate and efficient way to rapidly assess biomarkers in meningeal tumors, (2) EMA, E-cadherin, and PDGFR-beta are useful in distinguishing anaplastic meningiomas from HPCs, and (3) the expression patterns for incidental meningiomas differ slightly from their surgically resected symptomatic counterparts.
  • [MeSH-major] Biomarkers, Tumor / analysis. Histocytological Preparation Techniques. Meningeal Neoplasms / diagnosis. Meningioma / diagnosis


58. Nasseri K, Mills JR: Epidemiology of primary brain tumors in the Middle Eastern population in California, USA 2001-2005. Cancer Detect Prev; 2009;32(5-6):363-71
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidemiology of primary brain tumors in the Middle Eastern population in California, USA 2001-2005.
  • The purpose of this study was to compare the epidemiology of primary brain tumors in this ethnic population with the non-Hispanic, non-Middle Eastern White (NHNMW) in California.
  • Data for 683 cases of primary brain tumors (429 benign, 238 malignant, 16 uncertain) in the ME and 15,589 cases (8352 benign, 6812 malignant, 425 uncertain) in the NHNMW were available for this study.
  • RESULTS: ME patients were significantly (p < 0.05) younger and their age-adjusted incidence rates per 100,000 for benign tumors of 10.0 in men and 17.6 in women were higher than similar rates of 7.3 and 10.6 in the NHNMW group (p < 0.05).
  • Rates for malignant tumors were similar.
  • Also increased were benign tumors of the pituitary and pineal glands.
  • The overall mortality in patients with benign tumors was significantly lower than malignant tumors.
  • CONCLUSIONS: This study presents a significantly high incidence of benign meningioma in the ME population in California.
  • This may be due to higher susceptibility or exposure of this ethnic group to the risk factor(s) for this neoplasm.
  • Considering the reported causal association of benign meningioma with childhood radiation exposure from Israel, exposure to this risk factor in this ethnic group needs to be evaluated in future studies.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2005 Dec 15;104(12):2798-806 [16288487.001]
  • [Cites] Radiat Res. 2005 Apr;163(4):424-32 [15799699.001]
  • [Cites] Calif Med. 1949 Mar;70(3):189-93 [18112454.001]
  • [Cites] Asian Pac J Cancer Prev. 2007 Jul-Sep;8(3):405-11 [18159978.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008 Apr;105(4):470-80 [18206397.001]
  • [Cites] Cancer Causes Control. 2008 Dec;19(10):1183-91 [18543070.001]
  • [Cites] Am J Epidemiol. 2000 Feb 1;151(3):266-72 [10670551.001]
  • [Cites] Dermatol Surg. 2001 Jul;27(7):667-9 [11442620.001]
  • [Cites] Neuro Oncol. 1999 Jul;1(3):205-11 [11554389.001]
  • [Cites] Neoplasma. 2001;48(6):442-4 [11949834.001]
  • [Cites] Neuro Oncol. 2002 Oct;4(4):278-99 [12356358.001]
  • [Cites] Cancer Detect Prev. 2003;27(3):203-8 [12787727.001]
  • [Cites] Br J Surg. 1977 Jul;64(7):457-9 [922301.001]
  • [Cites] Neuroepidemiology. 1989;8(6):283-95 [2586698.001]
  • [Cites] Health Inf Manag. 1997 Mar-May;27(1):31-8 [10169442.001]
  • [Cites] Cancer Detect Prev. 2007;31(5):424-9 [18023539.001]
  • (PMID = 19588542.001).
  • [ISSN] 1525-1500
  • [Journal-full-title] Cancer detection and prevention
  • [ISO-abbreviation] Cancer Detect. Prev.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA103457-02; United States / NCI NIH HHS / CA / CA103457; United States / NCI NIH HHS / PC / N01-PC-35139; United States / NCCDPHP CDC HHS / DP / U58 DP000807; United States / NCI NIH HHS / CA / N01PC54404; United States / NCI NIH HHS / CA / R03 CA103457-02; United States / NCI NIH HHS / CA / R03 CA103457; United States / NCI NIH HHS / CA / N01PC35136; United States / NCI NIH HHS / CA / N01PC35139; United States / NCI NIH HHS / PC / N01-PC-54404; United States / NCI NIH HHS / PC / N01-PC-35136; United States / NCCDPHP CDC HHS / DP / 1U58DP00807-01
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS140088; NLM/ PMC2785228
  •  go-up   go-down


59. James MF, Lelke JM, Maccollin M, Plotkin SR, Stemmer-Rachamimov AO, Ramesh V, Gusella JF: Modeling NF2 with human arachnoidal and meningioma cell culture systems: NF2 silencing reflects the benign character of tumor growth. Neurobiol Dis; 2008 Feb;29(2):278-92
Hazardous Substances Data Bank. BROMODEOXYURIDINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modeling NF2 with human arachnoidal and meningioma cell culture systems: NF2 silencing reflects the benign character of tumor growth.
  • Meningiomas, common tumors arising from arachnoidal cells of the meninges, may occur sporadically, or in association with the inherited disorder, neurofibromatosis 2 (NF2).
  • Most sporadic meningiomas result from NF2 inactivation, resulting in loss of tumor suppressor merlin, implicated in regulating membrane-cytoskeletal organization.
  • To investigate merlin function in an authentic target cell type for NF2 tumor formation, we established primary cultures from genetically-matched meningioma and normal arachnoidal tissues.
  • Merlin-deficient meningioma cells displayed cytoskeletal and cell contact defects, altered cell morphology and growth properties, most notably cell senescence, implicating the activation of senescence pathways in limiting benign meningioma growth.

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 1998 Oct 29;17(17):2195-209 [9811451.001]
  • [Cites] Neurobiol Dis. 1998 Jul;5(1):55-64 [9702788.001]
  • [Cites] Oncogene. 1999 Aug 26;18(34):4788-97 [10490812.001]
  • [Cites] J Virol Methods. 2004 Dec 15;122(2):131-9 [15542136.001]
  • [Cites] Oncogene. 2004 Nov 18;23(54):8815-25 [15467741.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):183-202 [15674477.001]
  • [Cites] Int J Biochem Cell Biol. 2005 May;37(5):961-76 [15743671.001]
  • [Cites] Mol Cell Biol. 2005 Mar;25(6):2384-94 [15743831.001]
  • [Cites] Neurobiol Dis. 2005 Jun-Jul;19(1-2):1-9 [15837555.001]
  • [Cites] Nature. 2005 Aug 4;436(7051):642 [16079833.001]
  • [Cites] Nature. 2005 Aug 4;436(7051):725-30 [16079851.001]
  • [Cites] Br J Neurosurg. 2005 Feb;19(1):5-12 [16147576.001]
  • [Cites] Genes Dev. 2005 Oct 1;19(19):2265-77 [16204178.001]
  • [Cites] J Cell Biol. 2005 Oct 24;171(2):361-71 [16247032.001]
  • [Cites] J Neurosci. 2006 Mar 29;26(13):3390-5 [16571745.001]
  • [Cites] Cancer Cell. 2006 Dec;10(6):459-72 [17157787.001]
  • [Cites] J Biol Chem. 1999 Dec 3;274(49):34507-10 [10574907.001]
  • [Cites] Cancer. 1999 Dec 15;86(12):2649-58 [10594860.001]
  • [Cites] Cell. 2000 Jan 21;100(2):209-19 [10660044.001]
  • [Cites] Neurology. 2000 Mar 14;54(5):1132-8 [10720287.001]
  • [Cites] Neuropathol Appl Neurobiol. 2001 Feb;27(1):40-9 [11299001.001]
  • [Cites] Genes Dev. 2001 Apr 15;15(8):968-80 [11316791.001]
  • [Cites] Biochim Biophys Acta. 2001;1471(2):M73-80 [11342186.001]
  • [Cites] Dev Cell. 2001 Jul;1(1):63-72 [11703924.001]
  • [Cites] J Cell Sci. 2001 Oct;114(Pt 20):3583-90 [11707510.001]
  • [Cites] Mol Cell Biol. 2002 Feb;22(4):1150-7 [11809806.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] Genes Dev. 2002 May 1;16(9):1060-5 [12000789.001]
  • [Cites] Neoplasia. 2002 Jul-Aug;4(4):279-90 [12082543.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Aug;3(8):586-99 [12154370.001]
  • [Cites] Oncogene. 2002 Sep 5;21(39):5990-7 [12203111.001]
  • [Cites] J Cell Sci. 2002 Nov 1;115(Pt 21):3991-4000 [12356905.001]
  • [Cites] Int J Cancer. 2003 Feb 10;103(4):483-8 [12478663.001]
  • [Cites] RNA. 2003 Apr;9(4):493-501 [12649500.001]
  • [Cites] Genes Dev. 2003 May 1;17(9):1090-100 [12695331.001]
  • [Cites] Hum Mol Genet. 2003 Jun 1;12(11):1211-21 [12761036.001]
  • [Cites] Mol Biol Cell. 2003 May;14(5):2181-91 [12802084.001]
  • [Cites] Int J Mol Med. 2003 Dec;12(6):943-7 [14612971.001]
  • [Cites] J Neuropathol Exp Neurol. 2004 Apr;63(4):275-86 [15099018.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2004 Jun;75 Suppl 2:ii2-11 [15146033.001]
  • [Cites] J Cell Sci. 2004 Jun 15;117(Pt 14):2951-61 [15161943.001]
  • [Cites] Exp Cell Res. 1983 Jul;146(2):371-6 [6192005.001]
  • [Cites] Lab Invest. 1986 Jul;55(1):71-85 [3724065.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Aug;84(15):5419-23 [3037550.001]
  • [Cites] Cell. 1992 Aug 7;70(3):401-10 [1643658.001]
  • [Cites] Cell. 1993 Mar 12;72(5):791-800 [8453669.001]
  • [Cites] Histopathology. 1993 Feb;22(2):113-25 [7681027.001]
  • [Cites] Nature. 1993 Jun 10;363(6429):515-21 [8379998.001]
  • [Cites] Neurosci Lett. 1994 Jan 3;165(1-2):122-4 [8015711.001]
  • [Cites] Cancer Res. 1995 Jun 1;55(11):2270-4 [7757975.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9363-7 [7568133.001]
  • [Cites] J Cell Biol. 1996 May;133(4):843-52 [8666669.001]
  • [Cites] Oncogene. 1996 Sep 19;13(6):1239-47 [8808698.001]
  • [Cites] Genes Chromosomes Cancer. 1996 Sep;17(1):45-55 [8889506.001]
  • [Cites] JAMA. 1997 Jul 2;278(1):51-7 [9207339.001]
  • [Cites] J Cell Biol. 1997 Aug 25;138(4):913-26 [9265656.001]
  • [Cites] Science. 1998 Jan 23;279(5350):509-14 [9438836.001]
  • [Cites] J Biol Chem. 1998 Mar 27;273(13):7757-64 [9516485.001]
  • [Cites] Genes Dev. 1998 Apr 15;12(8):1121-33 [9553042.001]
  • [Cites] Hum Mol Genet. 1999 Feb;8(2):267-75 [9931334.001]
  • (PMID = 17962031.001).
  • [ISSN] 0969-9961
  • [Journal-full-title] Neurobiology of disease
  • [ISO-abbreviation] Neurobiol. Dis.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / P30 NS045776-04; United States / NINDS NIH HHS / NS / NS024279-15A10010; United States / NINDS NIH HHS / NS / P01 NS024279-130001; United States / NINDS NIH HHS / NS / NS024279-160010; United States / NINDS NIH HHS / NS / P30 NS045776-03; United States / NINDS NIH HHS / NS / NS045776; United States / NINDS NIH HHS / NS / NS045776-05; United States / NINDS NIH HHS / NS / NS045776-019003; United States / NINDS NIH HHS / NS / NS045776-01; United States / NINDS NIH HHS / NS / NS024279-140001; United States / NINDS NIH HHS / NS / NS041917-04; United States / NINDS NIH HHS / NS / P30 NS045776; United States / NINDS NIH HHS / NS / P30 NS045776-019001; United States / NINDS NIH HHS / NS / NS024279; United States / NINDS NIH HHS / NS / NS024279-130001; United States / NINDS NIH HHS / NS / NS041917-02; United States / NINDS NIH HHS / NS / R01 NS041917; United States / NINDS NIH HHS / NS / R01 NS041917-05; United States / NINDS NIH HHS / NS / R01 NS041917-02; United States / NINDS NIH HHS / NS / NS045776-04; United States / NINDS NIH HHS / NS / P01 NS024279-15A10010; United States / NINDS NIH HHS / NS / NS024279-120001; United States / NINDS NIH HHS / NS / NS041917-05; United States / NINDS NIH HHS / NS / P30 NS045776-01; United States / NINDS NIH HHS / NS / NS041917-03; United States / NINDS NIH HHS / NS / P01 NS024279-120001; United States / NINDS NIH HHS / NS / P30 NS045776-019003; United States / NINDS NIH HHS / NS / NS045776-03; United States / NINDS NIH HHS / NS / P30 NS045776-02; United States / NINDS NIH HHS / NS / P30 NS045776-05; United States / NINDS NIH HHS / NS / P01 NS024279; United States / NINDS NIH HHS / NS / R01 NS041917-01; United States / NINDS NIH HHS / NS / NS041917-01; United States / NINDS NIH HHS / NS / R01 NS041917-04; United States / NINDS NIH HHS / NS / NS045776-019001; United States / NINDS NIH HHS / NS / P01 NS024279-140001; United States / NINDS NIH HHS / NS / NS041917; United States / NINDS NIH HHS / NS / R01 NS041917-03; United States / NINDS NIH HHS / NS / P01 NS024279-160010
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / Catenins; 0 / Membrane Proteins; 0 / Neoplasm Proteins; 0 / Neurofibromin 2; 0 / RNA, Small Interfering; G34N38R2N1 / Bromodeoxyuridine
  • [Other-IDs] NLM/ NIHMS39296; NLM/ PMC2266821
  •  go-up   go-down


60. Böthig R, Rogosch KU, Mach P, Mahn B, Burgdörfer H: [Testicular metastases as primary manifestation of malignant melanoma at known melanocytoma]. Aktuelle Urol; 2006 Mar;37(2):138-40
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Secondary tumors of the testes are rare.
  • In about 15 % of the cases they are metastases of a malignant melanoma, there are about 30 reports of such cases in the literature.
  • Most of them describe findings at post-mortem, in only 4 of the previously described cases testicular metastases were the first manifestation of a melanoma.
  • The transformation of a benign, meningeal melanocytoma into a malignant melanoma has only been described once world-wide.
  • The problems in the diagnosis and therapy of this extremely rare tumor are discussed on the basis of a further patient with metastases of the testes as primary manifestation of a malignant melanoma.
  • The case history disclosed operations 10 and 3.5 year earlier for an apparently benign melanocytoma at the level of the 11th and 12th thoracic vertebrae, a local recurrence with paraparesis was known at the time of admission.
  • Sonography revealed an inhomogeneous tumor effecting the entire left testicle.
  • The correct diagnosis was made histologically.
  • CONCLUSION: In the case of a primary manifestation a correct preoperative diagnosis is unusual.
  • Radical orchiectomy is the treatment of choice for a suspected primary testicular tumor.
  • In elderly patients with unclear testicular tumors metastases from an (occult) tumor disease must be taken into consideration.
  • [MeSH-major] Cell Transformation, Neoplastic / pathology. Melanocytes. Melanoma / secondary. Meningeal Neoplasms / diagnosis. Precancerous Conditions / diagnosis. Testicular Neoplasms / secondary
  • [MeSH-minor] Aged. Diagnosis, Differential. Disease Progression. Humans. Magnetic Resonance Imaging. Male. Neoplasm Invasiveness / pathology. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Orchiectomy. Testis / pathology. Ultrasonography

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16625471.001).
  • [ISSN] 0001-7868
  • [Journal-full-title] Aktuelle Urologie
  • [ISO-abbreviation] Aktuelle Urol
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


61. Ritz R, Roser F, Bornemann A, Merkle M, Freudenstein D: Recurrence and increased proliferation rate of a solitary fibrous tumor in the central nervous system--case report and review of the literature. Clin Neuropathol; 2005 Nov-Dec;24(6):252-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrence and increased proliferation rate of a solitary fibrous tumor in the central nervous system--case report and review of the literature.
  • Meningeal solitary fibrous tumors (SFTs) were at first estimated as rare benign tumors which can be cured by total resection.
  • Therefore, the natural history of this tumor entity needs more enlightenment.
  • The authors report a case of a 77-year-old female in whom a SFT with infiltration of the transversal sinus was subtotally resected.
  • After a short time, interval tumor recurrence was seen, 2 years and 6 months later second surgery was performed.
  • In conclusion, consequent long-time follow-up for SFTs are necessary, especially after incomplete tumor resection.
  • [MeSH-major] Meningeal Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Neoplasms, Fibrous Tissue / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16320818.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 30
  •  go-up   go-down


62. Huang CF, Tu HT, Liu WS, Lin LY: Gamma Knife surgery for trigeminal pain caused by benign brain tumors. J Neurosurg; 2008 Dec;109 Suppl:154-9
MedlinePlus Health Information. consumer health - Trigeminal Neuralgia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gamma Knife surgery for trigeminal pain caused by benign brain tumors.
  • OBJECT: The authors report the effects of Gamma Knife surgery (GKS) on benign tumor-related trigeminal pain in patients who underwent follow-up for a mean 57.8 months.
  • METHODS: From 1999 to 2004, 21 patients with benign tumor-related trigeminal pain (12 meningiomas and 9 schwannomas) underwent GKS as a primary or repeated treatment.
  • These patients harbored tumors within the radiosurgical target area.
  • For meningiomas, the mean radiosurgical treatment volume was 8.2 ml (range 1.1-21 ml), and the mean radiosurgical tumor margin dose was 12.7 Gy (range 12-15 Gy); for schwannomas, the mean volume was 5.6 ml (range 2-9.2 ml), and the mean marginal dose was 13 Gy (range 11.5-16 Gy).
  • For all 21 patients (100%), control of tumor growth was documented at a mean of 46 months after GKS.
  • CONCLUSIONS: Gamma Knife surgery appears to be an effective tool to treat benign tumor-related trigeminal pain and control tumor growth.
  • [MeSH-major] Brain Neoplasms / surgery. Meningeal Neoplasms / surgery. Meningioma / surgery. Neurilemmoma / surgery. Radiosurgery. Trigeminal Neuralgia / prevention & control

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19123903.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Montano N, Doglietto F, Lauriola L, Signorelli F, Pallini R: Solitary fibrous tumour of the IV ventricle. Br J Neurosurg; 2010 Aug;24(4):495-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary fibrous tumour of the IV ventricle.
  • BACKGROUND: Solitary Fibrous Tumour (SFT) is a rare tumour occurring mainly in the pleural cavity, with less than 100 cases reported in the Central Nervous System, where it typically presents as a meningeal-based lesion.
  • We describe the case of a SFT located in the fourth ventricle and briefly review the pertinent literature.
  • CONCLUSION: Although uncommon, SFT should always be included in the differential diagnosis of intraventricular tumours.
  • SFTs of the fourth ventricle are usually benign tumours.
  • [MeSH-major] Cerebral Ventricle Neoplasms / diagnosis. Solitary Fibrous Tumors / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20726760.001).
  • [ISSN] 1360-046X
  • [Journal-full-title] British journal of neurosurgery
  • [ISO-abbreviation] Br J Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


64. Ferrer M, Schulze A, Gonzalez S, Ferreiro V, Ciavarelli P, Otero J, Giliberto F, Basso A, Szijan I: Neurofibromatosis type 2: molecular and clinical analyses in Argentine sporadic and familial cases. Neurosci Lett; 2010 Aug 9;480(1):49-54
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most of them are benign however, their location in the nervous system has harmful effects on important cranial and spinal structures.
  • These tumors are developed as the outcome of NF2 gene (22q12) inactivation.
  • The NF2 protein, merlin or schwannomin belongs to the Ezrin, Radixin, Moesin (ERM) family involved in the cytoskeletal network and has a tumor suppressor function.
  • Inactivating mutations occur as "de novo" (more frequently) or as inherited, and most of them are frameshift or nonsense.
  • [MeSH-minor] Adolescent. Adult. Aged. Argentina. Child. Ependymoma / genetics. Ependymoma / physiopathology. Female. Haplotypes. Humans. Male. Meningeal Neoplasms / genetics. Meningeal Neoplasms / physiopathology. Meningioma / genetics. Meningioma / physiopathology. Middle Aged. Molecular Diagnostic Techniques. Mutation. Pedigree. Young Adult

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Neurofibromatosis type 2.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20553997.001).
  • [ISSN] 1872-7972
  • [Journal-full-title] Neuroscience letters
  • [ISO-abbreviation] Neurosci. Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Neurofibromin 2
  •  go-up   go-down


65. Santelli L, Ramondo G, Della Puppa A, Ermani M, Scienza R, d'Avella D, Manara R: Diffusion-weighted imaging does not predict histological grading in meningiomas. Acta Neurochir (Wien); 2010 Aug;152(8):1315-9; discussion 1319
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: This study aims to verify the reliability of diffusion-weighted imaging (DWI) and apparent diffusion coefficient (ADC) measurements to differentiate benign from atypical/malignant meningiomas and among different sub-types.
  • DWI signal intensity of tumors was classified as hypo-, iso- or hyper-intense to grey matter.
  • RESULTS: Meningiomas were histologically graded as malignant (1%), atypical (21.5%) and benign (77.5%).
  • Meningothelial, transitional and fibrous were the most frequent benign sub-types (44, 16 and 10 cases, respectively).
  • [MeSH-major] Diffusion Magnetic Resonance Imaging / methods. Meningeal Neoplasms / pathology. Meningioma / pathology. Neoplasm Invasiveness / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Brain / pathology. Diagnosis, Differential. Female. Humans. Male. Meninges / pathology. Middle Aged. Observer Variation. Predictive Value of Tests. Prognosis. Reproducibility of Results. Severity of Illness Index

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20428902.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Austria
  •  go-up   go-down


66. Drakos SS, Anifantaki F, Zarros A, Liapi C: The role of folate metabolism-related gene polymorphisms in the development of meningiomas. Cancer Genomics Proteomics; 2010 Mar-Apr;7(2):105-9
Hazardous Substances Data Bank. FOLIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Meningiomas are (usually) slow-growing benign tumors, and several factors have been implicated in their development.
  • The complex genetic background supporting the pathogenesis of meningiomas includes a large number of mutations and polymorphisms that might be actively involved in tumor development, progression and recurrence.
  • [MeSH-major] Folic Acid / metabolism. Meningeal Neoplasms / genetics. Meningeal Neoplasms / pathology. Meningioma / genetics. Meningioma / pathology. Polymorphism, Single Nucleotide / genetics

  • MedlinePlus Health Information. consumer health - Folic Acid.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20335525.001).
  • [ISSN] 1790-6245
  • [Journal-full-title] Cancer genomics & proteomics
  • [ISO-abbreviation] Cancer Genomics Proteomics
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Greece
  • [Chemical-registry-number] 935E97BOY8 / Folic Acid
  • [Number-of-references] 38
  •  go-up   go-down


67. Oruckaptan HH, Sarac S, Gedikoglu G: Primary intracranial myxoma of the lateral skull base: a rare entity in clinical practice. Turk Neurosurg; 2010 Jan;20(1):86-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Myxomas are rare benign tumors arising from mesenchymal tissues throughout the body.
  • These tumors are usually seen in the atrium of the heart and the jawbone.
  • The patient underwent a skull base surgery with a pre-diagnosis of possible chondrosarcoma.
  • The tumor pathology revealed a diagnosis of myxoma with bone and meningeal involvement.
  • Despite the radical surgery, the tumor showed a local recurrence in three years.
  • Such a localization and intracranial extension of myxomas is extremely unusual in clinical practice; the diagnosis therefore requires a high degree of suspicion and detailed histopathological examination.
  • The differential diagnosis frequently includes chondrosarcomas, chordoma, metastatic tumors of the skull, hemangiopericytoma, meningioma and other neoplasms of the dura and skull base in this location.
  • [MeSH-major] Myxoma / radiography. Myxoma / surgery. Skull Base Neoplasms / radiography. Skull Base Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20066630.001).
  • [ISSN] 1019-5149
  • [Journal-full-title] Turkish neurosurgery
  • [ISO-abbreviation] Turk Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Turkey
  • [Chemical-registry-number] 68238-35-7 / Keratins
  •  go-up   go-down


68. Norden AD, Raizer JJ, Abrey LE, Lamborn KR, Lassman AB, Chang SM, Yung WK, Gilbert MR, Fine HA, Mehta M, Deangelis LM, Cloughesy TF, Robins HI, Aldape K, Dancey J, Prados MD, Lieberman F, Wen PY: Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. J Neurooncol; 2010 Jan;96(2):211-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The epidermal growth factor receptor (EGFR) is often over-expressed in meningiomas and may promote tumor growth.
  • Patients with recurrent histologically confirmed meningiomas with no more than 2 previous chemotherapy regimens were treated with gefitinib 500 mg/day or erlotinib 150 mg/day until tumor progression or unacceptable toxicity.
  • Eight patients (32%) had benign tumors, 9 (36%) atypical, and 8 (32%) malignant.
  • For benign tumors, the 6-month progression-free survival (PFS6) was 25%, 12-month PFS (PFS12) 13%, 6-month overall survival (OS6) 63%, and 12-month OS (OS12) 50%.
  • For atypical and malignant tumors, PFS6 was 29%, PFS12 18%, OS6 71%, and OS12 65%.

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Gynecol Obstet. 1993 Nov;177(5):488-96 [8211601.001]
  • [Cites] Neurosurg Focus. 2007;23(4):E12 [17961036.001]
  • [Cites] J Neurooncol. 1995 Oct;26(1):45-51 [8583244.001]
  • [Cites] J Neurosurg. 1997 Aug;87(2):315-23 [9254099.001]
  • [Cites] Neuropathol Appl Neurobiol. 1998 Dec;24(6):441-52 [9888154.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):183-202 [15674477.001]
  • [Cites] Br J Neurosurg. 2004 Oct;18(5):495-9 [15799152.001]
  • [Cites] Neurosurgery. 2005 Sep;57(3):538-50; discussion 538-50 [16145534.001]
  • [Cites] Lancet. 2005 Oct 29-Nov 4;366(9496):1527-37 [16257339.001]
  • [Cites] J Clin Oncol. 2009 Mar 10;27(8):1268-74 [19204207.001]
  • [Cites] Neuro Oncol. 2009 Dec;11(6):853-60 [19293394.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] J Clin Oncol. 2004 Jan 1;22(1):133-42 [14638850.001]
  • [Cites] Neurology. 2004 Apr 13;62(7):1210-2 [15079029.001]
  • [Cites] J Neuropathol Exp Neurol. 2004 Apr;63(4):275-86 [15099018.001]
  • [Cites] Acta Neuropathol. 2004 Aug;108(2):135-42 [15148612.001]
  • [Cites] Curr Treat Options Oncol. 2004 Dec;5(6):499-509 [15509483.001]
  • [Cites] Cancer Res. 1987 Apr 15;47(8):2172-6 [3493842.001]
  • [Cites] Cancer. 1990 Jul 1;66(1):152-5 [2354402.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] J Neuropathol Exp Neurol. 2005 Dec;64(12):1029-36 [16319713.001]
  • [Cites] J Neurooncol. 2006 Jul;78(3):271-6 [16628476.001]
  • [Cites] Br J Cancer. 2007 Apr 10;96(7):1047-51 [17353924.001]
  • [Cites] Hum Pathol. 1994 Feb;25(2):146-53 [8119714.001]
  • (PMID = 19562255.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA062407; United States / NCRR NIH HHS / RR / M01 RR000079; United States / NCATS NIH HHS / TR / UL1 TR000005; United States / NCI NIH HHS / CA / U01 CA062421-06; United States / NCI NIH HHS / CA / P30 CA016672; United States / NCRR NIH HHS / RR / M01-RR0865; United States / NCI NIH HHS / CA / U01 CA62399; United States / NCRR NIH HHS / RR / M01 RR003186; United States / NCRR NIH HHS / RR / M01 RR000056; United States / NCRR NIH HHS / RR / M01-RR00079; United States / NCI NIH HHS / CA / U01CA62407-08; United States / NCI NIH HHS / CA / CA16672; United States / NCRR NIH HHS / RR / M01 RR000865; United States / NCI NIH HHS / CA / 5-U01CA62399-09; United States / NCI NIH HHS / CA / CA062421-06; United States / NCI NIH HHS / CA / U01 CA062399; United States / NCRR NIH HHS / RR / M01-RR00056; United States / NCI NIH HHS / CA / U01 CA062405; United States / NCI NIH HHS / CA / U01 CA062412; United States / NCI NIH HHS / CA / U01CA62421-08; United States / NCI NIH HHS / CA / CA62422; United States / NCI NIH HHS / CA / U01 CA062421; United States / NCI NIH HHS / CA / U01CA62405; United States / NCRR NIH HHS / RR / M01 RR03186; United States / NCI NIH HHS / CA / U01 CA062422; United States / NCI NIH HHS / CA / CA62399; United States / NCI NIH HHS / CA / CA62412
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; 0 / Quinazolines; DA87705X9K / Erlotinib Hydrochloride; S65743JHBS / gefitinib
  • [Other-IDs] NLM/ NIHMS511532; NLM/ PMC3786190
  •  go-up   go-down


69. Eyenga VC, Ngah JE, Atangana R, Etom E, Ngowe MN, Bassong Y, Oyono JL, Sosso M: [Central nervous system tumours in Cameroon: histopathology and demography]. Sante; 2008 Jan-Mar;18(1):39-42
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Les tumeurs du système nerveux central au Cameroun: histopathologie, démographie.
  • INCLUSION CRITERIA: All cases undergoing surgery in these units for a histologically-confirmed CNS tumour.
  • The average age of patients with metastatic tumors was 42+/-18.5 years compared with 36.5+/-17.8 years for cases with primary tumors.
  • Primary tumors were malignant in 34.2% (n=12) of the children and benign in 65.8% (n=23); among adults 22.7% (n=30) were malignant and 77.3% (n=102) benign.
  • In conclusion, CNS tumors occurred mainly before the age of 55 years and had a slight predilection for girls and women.
  • Meningiomas were the most frequent tumors in adults while astrocytomas were more prevalent in children.
  • [MeSH-major] Brain Neoplasms / epidemiology. Meningeal Neoplasms / epidemiology. Meningioma / epidemiology
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Astrocytoma / epidemiology. Astrocytoma / pathology. Brain / pathology. Cameroon. Child. Child, Preschool. Female. Humans. Infant. Infant, Newborn. Male. Meninges / pathology. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18684690.001).
  • [ISSN] 1157-5999
  • [Journal-full-title] Santé (Montrouge, France)
  • [ISO-abbreviation] Sante
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


70. Friedman WA, Murad GJ, Bradshaw P, Amdur RJ, Mendenhall WM, Foote KD, Bova FJ: Linear accelerator surgery for meningiomas. J Neurosurg; 2005 Aug;103(2):206-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECT: In this paper the authors review the results of a single-center experience in the use of linear accelerator (LINAC) surgery for radiosurgical treatment of meningiomas.
  • The actuarial local control rate for benign tumors was 100% at both 1 and 2 years, and 96% at 5 years.
  • The actuarial local control rate for atypical tumors was 100% at 1 year, 92% at 2 years, and 77% at 5 years; and that for malignant tumors was 100% at both 1 and 2 years, and only 19% at 5 years.
  • CONCLUSIONS: Linear accelerator surgery produced high local control rates and very low rates of permanent morbidity in patients harboring benign meningiomas.
  • [MeSH-major] Meningeal Neoplasms / surgery. Meningioma / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Neurosurg. 2005 Aug;103(2):203-5; discussion 205 [16175846.001]
  • (PMID = 16175847.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


71. Kao HW, Chen CY, Hsueh CJ, Lo CP, Juan CJ, Chang WC, Huang GS: Typical Meningioma with Atypical MR Imaging Features Masquerading Malignancy. A Case Report. Neuroradiol J; 2007 Oct 31;20(5):541-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Meningiomas are the most common extraaxial tumors of intracranial neoplasms.
  • They are usually benign with characteristic pathologic and imaging features.
  • Unusual imaging features such as large meningeal cysts, ring enhancement, and various metaplastic changes can be particularly misleading.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24299943.001).
  • [ISSN] 1971-4009
  • [Journal-full-title] The neuroradiology journal
  • [ISO-abbreviation] Neuroradiol J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Saraceni C, Harrop JS: Spinal meningioma: chronicles of contemporary neurosurgical diagnosis and management. Clin Neurol Neurosurg; 2009 Apr;111(3):221-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spinal meningioma: chronicles of contemporary neurosurgical diagnosis and management.
  • Notwithstanding their overwhelmingly benign propensity, the occurrence of extramedullary meningioma may nonetheless cause significant morbidity and possible mortality.
  • The rapidity of diagnosis and the first neurosurgical encounter are cornerstones in patient longevity and neurological preservation.
  • However, surgical candidacy may be limited, particularly in those patients with significant preexisting medical comorbidities, aggressive or recurring tumors, or multiple lesions.
  • A review on neurosurgical diagnosis and treatment modalities in the management of spinal meningioma is therefore pertinent.
  • [MeSH-major] Meningeal Neoplasms / diagnosis. Meningeal Neoplasms / surgery. Meningioma / diagnosis. Meningioma / surgery. Microsurgery / methods. Radiosurgery / methods


73. Moradi A, Semnani V, Djam H, Tajodini A, Zali AR, Ghaemi K, Nikzad N, Madani-Civi M: Pathodiagnostic parameters for meningioma grading. J Clin Neurosci; 2008 Dec;15(12):1370-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Meningiomas are usually slow-growing benign tumors, for which complete removal can be difficult and recurrence is an issue.
  • Between January 1997 and December 2006, a total of 4885 intracranial tumors were diagnosed at Shohada Hospital, 378 (7.74%) of which were meningiomas.
  • All slides stained with hematoxylin and eosin were reviewed by two independent pathologists and all the diagnoses reconfirmed; histological anaplasia was classified according to the grading of the WHO Working Group 2000 as benign (Grade I), atypical with incipient signs of anaplasia (Grade II), or overtly anaplastic (Grade III).
  • There was no relationship between the location of the tumor and the histopathological features.
  • Overall, the mitotic count was the most important marker for tumor grade.
  • [MeSH-major] Meningeal Neoplasms / diagnosis. Meningioma / diagnosis

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18819804.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] EC 6.3.2.19 / MIB1 ligase, human; EC 6.3.2.19 / Ubiquitin-Protein Ligases
  •  go-up   go-down


74. Cargioli TG, Ugur HC, Ramakrishna N, Chan J, Black PM, Carroll RS: Establishment of an in vivo meningioma model with human telomerase reverse transcriptase. Neurosurgery; 2007 Apr;60(4):750-9; discussion 759-60
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: The lack of meningioma models has hindered research on the pathogenesis and treatment of this commonly diagnosed primary brain tumor.
  • Animal models of meningioma have been difficult to develop, especially those derived from Grade I tumors, which display very slow growth rates, senesce at early passages, and infrequently survive as explants in vivo.
  • In this study, the authors report the establishment of two benign immortalized meningioma cell lines, Me10T and Me3TSC, that can serve as useful models of human meningioma.
  • In addition, immortalized cell lines were implanted subdurally into mice to confirm their ability to form tumors.
  • RESULTS: Two immortalized benign meningioma cell lines, Me10T and Me3TSC, transduced with catalytic subunit human telomerase reverse transcriptase alone or human telomerase reverse transcriptase and SV40 large T antigen, were established.
  • The meningeal phenotype of the established cell cultures and orthotopic xenografts was confirmed by immunostaining.
  • After subdural injection into athymic nude mice, both cell lines formed identifiable tumors with histological features and immunostaining patterns of human meningioma.
  • [MeSH-major] Cell Line, Tumor / enzymology. Cell Line, Tumor / pathology. Cell Transformation, Neoplastic / genetics. Meningioma / enzymology. Meningioma / genetics. Telomerase / genetics. Transfection / methods

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17415213.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.7.49 / Telomerase
  •  go-up   go-down


75. Kondraganti S, Gondi CS, McCutcheon I, Dinh DH, Gujrati M, Rao JS, Olivero WC: RNAi-mediated downregulation of urokinase plasminogen activator and its receptor in human meningioma cells inhibits tumor invasion and growth. Int J Oncol; 2006 Jun;28(6):1353-60
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] RNAi-mediated downregulation of urokinase plasminogen activator and its receptor in human meningioma cells inhibits tumor invasion and growth.
  • Similar to gliomas, malignant meningiomas also exhibit elevated protease levels in comparison to normal brain and benign meningiomas.
  • Intratumoral injections of the plasmid vector expressing siRNA for uPA and uPAR resulted in regression of pre-established, subcutaneous tumors in mice.
  • In addition, in vivo studies of mice injected with pU2-transfected meningioma cells revealed inhibition of intracranial tumor formation.

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2000 Jun 23;275(25):19382-8 [10777511.001]
  • [Cites] Nat Biotechnol. 2000 Aug;18(8):896-8 [10932163.001]
  • [Cites] Cell Mol Life Sci. 2000 Jan 20;57(1):25-40 [10949579.001]
  • [Cites] Am J Manag Care. 2000 Sep;6(14 Suppl):S746-60 [11184072.001]
  • [Cites] Curr Biol. 2000 Oct 5;10(19):1191-200 [11050387.001]
  • [Cites] Cancer Res. 2000 Oct 15;60(20):5839-47 [11059781.001]
  • [Cites] Cell Mol Life Sci. 1999 Oct 1;56(1-2):104-32 [11213252.001]
  • [Cites] Genes Dev. 2001 Jan 15;15(2):188-200 [11157775.001]
  • [Cites] Oncogene. 2001 Apr 12;20(16):2032-43 [11360187.001]
  • [Cites] Nature. 2001 May 24;411(6836):494-8 [11373684.001]
  • [Cites] Clin Cancer Res. 2001 Aug;7(8):2519-26 [11489835.001]
  • [Cites] J Biol Chem. 2002 Apr 5;277(14):12479-85 [11805108.001]
  • [Cites] Oncogene. 2002 Mar 28;21(14):2245-52 [11948407.001]
  • [Cites] Haemostasis. 2001;31 Suppl 1:59 [11990482.001]
  • [Cites] Oncogene. 2002 Aug 22;21(37):5716-24 [12173041.001]
  • [Cites] FEBS Lett. 2002 Sep 25;528(1-3):212-6 [12297307.001]
  • [Cites] Oncogene. 2002 Nov 7;21(51):7824-30 [12420219.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Dec;3(12):932-43 [12461559.001]
  • [Cites] Int J Oncol. 2003 Feb;22(2):289-94 [12527924.001]
  • [Cites] Nat Med. 2003 Mar;9(3):347-51 [12579197.001]
  • [Cites] Nat Biotechnol. 2003 Jun;21(6):635-7 [12754523.001]
  • [Cites] Oncogene. 2003 Sep 4;22(38):5967-75 [12955075.001]
  • [Cites] Acta Neurochir (Wien). 2003 Sep;145(9):825-38 [14505115.001]
  • [Cites] Chembiochem. 2005 Feb;6(2):441-3 [15651038.001]
  • [Cites] Oncogene. 2004 Jun 10;23(27):4681-9 [15122332.001]
  • [Cites] BMC Biotechnol. 2003 Nov 6;3:21 [14604435.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Oct 12;101(41):14883-8 [15466709.001]
  • [Cites] J Cell Biol. 1990 Aug;111(2):783-92 [2166055.001]
  • [Cites] Cancer Res. 1991 Jan 1;51(1):274-81 [1988089.001]
  • [Cites] Cancer Res. 1993 Sep 15;53(18):4143-7 [8395977.001]
  • [Cites] Ann N Y Acad Sci. 1992 Dec 4;667:13-31 [1339241.001]
  • [Cites] EMBO J. 1994 Sep 1;13(17):3983-91 [8076594.001]
  • [Cites] J Biol Chem. 1994 Dec 23;269(51):32380-8 [7528215.001]
  • [Cites] J Neurosurg. 1995 Jan;82(1):17-27 [7815129.001]
  • [Cites] Invasion Metastasis. 1995;15(1-2):34-45 [7672930.001]
  • [Cites] Cancer Res. 1996 May 15;56(10):2428-33 [8625323.001]
  • [Cites] Clin Exp Metastasis. 1996 May;14(3):297-307 [8674284.001]
  • [Cites] Oncology (Williston Park). 1996 May;10(5):747-56; discussion 756-9 [8738830.001]
  • [Cites] Science. 1996 Sep 13;273(5281):1551-5 [8703217.001]
  • [Cites] J Cell Biol. 1997 May 5;137(3):767-77 [9151680.001]
  • [Cites] J Cell Sci. 1997 May;110 ( Pt 9):1091-8 [9175705.001]
  • [Cites] Oncogene. 1997 Mar 20;14(11):1351-9 [9178895.001]
  • [Cites] Thromb Haemost. 1997 Jul;78(1):285-96 [9198168.001]
  • [Cites] J Clin Invest. 1997 Jul 1;100(1):58-67 [9202057.001]
  • [Cites] Clin Exp Metastasis. 1997 Jul;15(4):440-6 [9219733.001]
  • [Cites] Blood. 1997 Dec 1;90(11):4522-31 [9373263.001]
  • [Cites] J Cell Biol. 1997 Dec 29;139(7):1861-72 [9412478.001]
  • [Cites] Nature. 1998 Feb 19;391(6669):806-11 [9486653.001]
  • [Cites] Clin Exp Metastasis. 1998 May;16(4):353-7 [9626814.001]
  • [Cites] Acta Neurochir (Wien). 1998;140(4):377-85; discussion 385-6 [9689330.001]
  • [Cites] Nature. 1998 Oct 29;395(6705):854 [9804418.001]
  • [Cites] Anticancer Res. 1998 Nov-Dec;18(6A):4499-504 [9891516.001]
  • [Cites] Cancer Res. 1999 Jul 15;59(14):3369-73 [10416596.001]
  • [Cites] Oncogene. 2004 Nov 4;23(52):8486-96 [15378018.001]
  • [Cites] J Cell Sci. 2000 Jan;113 ( Pt 1):123-34 [10591631.001]
  • [Cites] Bioorg Med Chem Lett. 1999 Nov 1;9(21):3147-52 [10560742.001]
  • [Cites] Cancer Res. 1999 Oct 15;59(20):5307-14 [10537314.001]
  • [Cites] Cell. 2000 Mar 31;101(1):25-33 [10778853.001]
  • [Cites] Trends Biochem Sci. 2000 Feb;25(2):53-9 [10664583.001]
  • [Cites] Thromb Haemost. 1999 Aug;82(2):298-304 [10605717.001]
  • [Cites] Nature. 2004 Sep 16;431(7006):371-8 [15372045.001]
  • (PMID = 16685436.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / NS47699; United States / NCI NIH HHS / CA / R01 CA075557; United States / NCI NIH HHS / CA / CA75557; United States / NCI NIH HHS / CA / CA116708; United States / NCI NIH HHS / CA / CA95058; United States / NCI NIH HHS / CA / R01 CA116708; United States / NINDS NIH HHS / NS / R01 NS047699; United States / NCI NIH HHS / CA / R01 CA095058; United States / NCI NIH HHS / CA / R01 CA092393; United States / NCI NIH HHS / CA / CA92393
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / PLAUR protein, human; 0 / Plaur protein, mouse; 0 / RNA, Neoplasm; 0 / Receptors, Cell Surface; 0 / Receptors, Urokinase Plasminogen Activator; EC 3.4.21.73 / Urokinase-Type Plasminogen Activator
  • [Other-IDs] NLM/ NIHMS9142; NLM/ PMC1459538
  •  go-up   go-down


76. Torp SH, Lindboe CF, Grønberg BH, Lydersen S, Sundstrøm S: Prognostic significance of Ki-67/MIB-1 proliferation index in meningiomas. Clin Neuropathol; 2005 Jul-Aug;24(4):170-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Even though tumor grade, subtype, and extent of resection are strong prognostic factors in human meningiomas, the growth of this tumor is still unpredictable, and additional prognostic markers are needed.
  • The aim of this study was to investigate the prognostic role of MIB-1 proliferation index (PI) in a series of meningiomas comprising 23 benign, 17 atypical, and 9 anaplastic tumors.
  • MIB- 1 PI increased with increasing tumor grade and discriminated significantly benign from atypical and anaplastic meningiomas whereas no difference was found between the latter two grades.
  • However, due to the considerable overlap of PI values between the various grades, one should be circumspect before using this criterion for tumor grading.
  • Furthermore, MIB-1 PIs were significantly higher in recurrent tumors compared with non-recurrent and a reliable MIB-1 PI cut-off value of 10% was established.
  • [MeSH-major] Antibodies, Antinuclear / analysis. Antibodies, Monoclonal / analysis. Biomarkers, Tumor / analysis. Ki-67 Antigen / analysis. Meningeal Neoplasms / pathology. Meningioma / pathology. Neoplasm Recurrence, Local / pathology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16033133.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Antinuclear; 0 / Antibodies, Monoclonal; 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / MIB-1 antibody
  •  go-up   go-down


77. Hardell L, Carlberg M, Hansson Mild K: Case-control study on cellular and cordless telephones and the risk for acoustic neuroma or meningioma in patients diagnosed 2000-2003. Neuroepidemiology; 2005;25(3):120-8
MedlinePlus Health Information. consumer health - Acoustic Neuroma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We performed a case-control study on the use of cellular and cordless telephones and the risk for brain tumors.
  • We report the results for benign brain tumors with data from 413 cases (89% response rate), 305 with meningioma, 84 with acoustic neuroma, 24 with other types and 692 controls (84% response rate).
  • [MeSH-major] Cell Phones / utilization. Meningeal Neoplasms / etiology. Meningioma / etiology. Neuroma, Acoustic / etiology

  • Genetic Alliance. consumer health - Acoustic Neuroma.
  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 S. Karger AG, Basel.
  • (PMID = 15956809.001).
  • [ISSN] 0251-5350
  • [Journal-full-title] Neuroepidemiology
  • [ISO-abbreviation] Neuroepidemiology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  •  go-up   go-down


78. Mawrin C, Sasse T, Kirches E, Kropf S, Schneider T, Grimm C, Pambor C, Vorwerk CK, Firsching R, Lendeckel U, Dietzmann K: Different activation of mitogen-activated protein kinase and Akt signaling is associated with aggressive phenotype of human meningiomas. Clin Cancer Res; 2005 Jun 1;11(11):4074-82
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Activation of intracellular signaling cascades has been implicated in the growth control of benign meningiomas, but their role for meningioma progression and outcome is unknown.
  • Here we determined the expression and function of proteins involved in mitogen-activated protein kinase (MAPK) and phosphinositol-3 kinase (PI3K)/Akt signaling in benign, atypical, and malignant meningiomas and studied their association with clinicopathologic data including meningioma recurrence.
  • EXPERIMENTAL DESIGN: Expression of various MAPK and PI3K signaling proteins was determined in 70 primary meningiomas and, if present, in recurrent tumors by immunohistochemistry and Western blotting.
  • The expression patterns in primary and recurrent tumors were related to clinical data.
  • RESULTS: Atypical and malignant meningiomas showed higher levels of phospho-Akt compared with benign tumors, and their proliferation could be inhibited by PI3K blocking using wortmannin.
  • In contrast, expression of phospho-Raf and phospho-MAPK was decreased in aggressive meningiomas compared with benign tumors, but MAPK inhibition by PD98059 resulted in tumor cell apoptosis and decreased proliferation.
  • CONCLUSIONS: Both MAPK and PI3K/Akt pathways are activated at different levels in benign and malignant meningiomas.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningioma / pathology. Mitogen-Activated Protein Kinases / metabolism. Protein-Serine-Threonine Kinases / metabolism. Proto-Oncogene Proteins / metabolism
  • [MeSH-minor] Aged. Androstadienes / pharmacology. Apoptosis / drug effects. Cell Proliferation / drug effects. Cell Survival / drug effects. Enzyme Activation. Female. Flavonoids / pharmacology. Humans. Immunohistochemistry. In Situ Nick-End Labeling. Ki-67 Antigen / analysis. Male. Middle Aged. Phosphatidylinositol 3-Kinases / antagonists & inhibitors. Phosphatidylinositol 3-Kinases / metabolism. Phospholipase C gamma. Platelet-Derived Growth Factor / analysis. Protein Kinase Inhibitors / pharmacology. Proto-Oncogene Proteins c-akt. Signal Transduction. Tumor Cells, Cultured. Type C Phospholipases / analysis. raf Kinases / analysis. ras Proteins / analysis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15930342.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one; 0 / Androstadienes; 0 / Flavonoids; 0 / Ki-67 Antigen; 0 / Platelet-Derived Growth Factor; 0 / Protein Kinase Inhibitors; 0 / Proto-Oncogene Proteins; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.1 / AKT1 protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.11.1 / raf Kinases; EC 2.7.11.24 / Mitogen-Activated Protein Kinases; EC 3.1.4.- / Type C Phospholipases; EC 3.1.4.3 / Phospholipase C gamma; EC 3.6.5.2 / ras Proteins; XVA4O219QW / wortmannin
  •  go-up   go-down


79. Usul H, Kuzeyli K, Cakir E, Caylan R, Sayin OC, Peksoylu B, Karaarslan G: Giant cranial extradural primary fibroxanthoma: a case report. Surg Neurol; 2005 Mar;63(3):281-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Xanthomatous tumors of the central nervous system are occasionally associated with diseases such as Hand-Schuler-Christian disease, malignant fibrous histiocytoma, hyperlipidemia, and a complication of metabolic or storage disorders.
  • [MeSH-major] Dura Mater / pathology. Histiocytoma, Benign Fibrous / pathology. Meningeal Neoplasms / pathology. Skull Neoplasms / pathology. Xanthomatosis / pathology
  • [MeSH-minor] Adult. Cranial Fossa, Posterior / pathology. Cranial Fossa, Posterior / radiography. Cranial Fossa, Posterior / surgery. Craniotomy. Diagnosis, Differential. Epidural Space / pathology. Epidural Space / radiography. Epidural Space / surgery. Facial Nerve Diseases / etiology. Female. Headache / etiology. Hearing Loss / etiology. Humans. Occipital Bone / pathology. Occipital Bone / radiography. Occipital Bone / surgery. Parietal Bone / pathology. Parietal Bone / radiography. Parietal Bone / surgery. Temporal Bone / pathology. Temporal Bone / radiography. Temporal Bone / surgery. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15734528.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Sioka C, Kyritsis AP: Chemotherapy, hormonal therapy, and immunotherapy for recurrent meningiomas. J Neurooncol; 2009 Mar;92(1):1-6
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Meningioma is a common intracranial tumor, originating from the meninges of the skull or spinal canal.
  • Most meningiomas are benign tumors, however atypical or anaplastic tumors can be found in 6% of cases.
  • Patients with asymptomatic small benign meningiomas can be followed without therapy, but in symptomatic patients complete surgical resection should be performed.
  • For recurrent previously resected tumors re-resection is recommended followed by radiotherapy in selected cases.
  • Antiprogesterone treatment can also be considered in recurrent benign meningiomas.
  • Immunotherapy with interferon-alpha and chemotherapy should be reserved for all cases of recurrent meningiomas (benign, atypical, and malignant) when all the standard therapies have failed or contraindicated.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Immunotherapy / methods. Meningeal Neoplasms / therapy. Meningioma / therapy. Neoplasm Recurrence, Local / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurooncol. 2004 Jun;68(2):131-40 [15218949.001]
  • [Cites] J Neurosurg. 1997 May;86(5):840-4 [9126900.001]
  • [Cites] Cancer. 2007 Feb 1;109(3):588-97 [17177201.001]
  • [Cites] Neurosurgery. 1997 Feb;40(2):271-5 [9007858.001]
  • [Cites] J Clin Endocrinol Metab. 1992 Mar;74(3):543-7 [1346787.001]
  • [Cites] Rev Neurol. 1997 Dec;25(148):2002-5 [9528047.001]
  • [Cites] Clin Neuropathol. 2004 Jan-Feb;23(1):21-7 [14986930.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1992 Jun;55(6):486-90 [1619417.001]
  • [Cites] J Neurosurg. 2005 Sep;103(3):508-17 [16235684.001]
  • [Cites] Br J Neurosurg. 2004 Oct;18(5):495-9 [15799152.001]
  • [Cites] Clin Cancer Res. 2000 May;6(5):1865-74 [10815909.001]
  • [Cites] Eur J Cancer. 1991;27(11):1453-7 [1660295.001]
  • [Cites] J Clin Neurosci. 2008 Jun;15(6):721-2; author reply 722-3 [18406141.001]
  • [Cites] J Neurosurg. 1991 Jun;74(6):861-6 [2033444.001]
  • [Cites] J Neurosurg. 2007 Mar;106(3):455-62 [17367069.001]
  • [Cites] Neurosurgery. 1995 Feb;36(2):365-73; discussion 373-4 [7731518.001]
  • [Cites] Neurosurg Focus. 2007;23(4):E10 [17961034.001]
  • [Cites] J Neurooncol. 1993 Jan;15(1):75-7 [8455065.001]
  • [Cites] J Neurooncol. 2004 Jan;66(1-2):155-66 [15015781.001]
  • [Cites] J Neurooncol. 2002 Jan;56(2):133-42 [11995814.001]
  • [Cites] Gan To Kagaku Ryoho. 2007 Feb;34(2):265-8 [17301541.001]
  • [Cites] Neurochirurgie. 2004 Sep;50(4):461-7 [15547484.001]
  • [Cites] Neurology. 2007 Sep 4;69(10):969-73 [17785665.001]
  • [Cites] Cancer. 2005 Apr 1;103(7):1427-30 [15690330.001]
  • [Cites] Neurosurgery. 2006 Nov;59(5):1109-20; discussion 1120-1 [17143245.001]
  • [Cites] Eur J Cancer. 1991;27(4):416-9 [1828169.001]
  • [Cites] Skull Base. 2006 Aug;16(3):157-60 [17268588.001]
  • [Cites] J Neurooncol. 2000 Sep;49(2):165-70 [11206012.001]
  • [Cites] J Neurooncol. 1996 Sep;29(3):269-72 [8858533.001]
  • [Cites] J Neurosurg. 2000 Jul;93(1):132-5 [10883917.001]
  • [Cites] J Neurosurg. 2002 Aug;97(2):341-6 [12186462.001]
  • [Cites] J Neurooncol. 2005 Sep;74(2):157-65 [16193387.001]
  • [Cites] Cancer Invest. 2006 Dec;24(8):727-33 [17162554.001]
  • [Cites] J Neurooncol. 2006 Jul;78(3):271-6 [16628476.001]
  • [Cites] Hum Reprod. 1994 Jun;9 Suppl 1:202-7 [7962466.001]
  • [Cites] Clin Neurol Neurosurg. 2008 Jul;110(7):645-8 [18471956.001]
  • [Cites] Acta Neurol Scand. 1987 Jun;75(6):434-6 [2888257.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2007 Jun;15(2):187-92 [17525632.001]
  • [Cites] Lancet. 1995 Feb 4;345(8945):331 [7837901.001]
  • [Cites] Clin Cancer Res. 2001 Aug;7(8):2269-76 [11489801.001]
  • [Cites] J Neurooncol. 2004 Mar-Apr;67(1-2):221-6 [15072471.001]
  • [Cites] Neurosurgery. 2000 Mar;46(3):692-702; discussion 702-3 [10719866.001]
  • (PMID = 19023520.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Hormonal
  • [Number-of-references] 43
  •  go-up   go-down


81. Alexiou GA, Vartholomatos G, Tsiouris S, Papadopoulos A, Kyritsis AP, Polyzoidis KS, Voulgaris S, Fotopoulos AD: Evaluation of meningioma aggressiveness by (99m)Tc-Tetrofosmin SPECT. Clin Neurol Neurosurg; 2008 Jul;110(7):645-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: Although meningiomas usually have a benign clinical course, atypical and malignant types of this brain tumor are associated with high recurrence rates and poor outcome; thus, DNA ploidy and S-phase -- as determined by DNA flow cytometry -- are useful indicators of their biological behavior.
  • Brain single-photon emission computed tomography (SPECT) has been suggested as a potentially useful modality for the metabolic assessment of various brain tumors.
  • PATIENTS AND METHODS: Ten consecutive patients (3 males, 7 females, mean age 64.6 years) with a diagnosis of a symptomatic intracranial meningioma, planned to undergo surgery, were studied.
  • RESULTS: Benign meningiomas were diagnosed in 8/10 cases, the remaining 2/10 patients had anaplastic lesions.
  • DNA aneuploidy was found in 2 lesions, the remaining tumors were diploid.
  • There was also a positive correlation between tracer uptake and the level of aneuploidy and tumor grade.
  • CONCLUSION: These results imply that (99m)Tc-TF brain SPECT may have the ability to discriminate benign meningiomas from malignant meningiomas pre-operatively, the tracer uptake being a likely indicator of their proliferative activity.
  • [MeSH-major] Meningeal Neoplasms / radionuclide imaging. Meningioma / radionuclide imaging. Organophosphorus Compounds. Organotechnetium Compounds. Tomography, Emission-Computed, Single-Photon / methods
  • [MeSH-minor] Aged. Cell Cycle. Female. Flow Cytometry. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Invasiveness. Reproducibility of Results. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18471956.001).
  • [ISSN] 0303-8467
  • [Journal-full-title] Clinical neurology and neurosurgery
  • [ISO-abbreviation] Clin Neurol Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Organophosphorus Compounds; 0 / Organotechnetium Compounds; 0 / technetium Tc 99m 1,2-bis(bis(2-ethoxyethyl)phosphino)ethane
  •  go-up   go-down


82. Sturges BK, Dickinson PJ, Bollen AW, Koblik PD, Kass PH, Kortz GD, Vernau KM, Knipe MF, Lecouteur RA, Higgins RJ: Magnetic resonance imaging and histological classification of intracranial meningiomas in 112 dogs. J Vet Intern Med; 2008 May-Jun;22(3):586-95
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Intracranial meningiomas are the most common primary brain tumors in dogs.
  • Classification of meningiomas by tumor grade and subtype has not been reported, and the value of magnetic resonance imaging (MRI) characteristics for predicting tumor subtype and grade has not been investigated.
  • HYPOTHESIS: Canine intracranial meningiomas are a heterogenous group of tumors with differing histological subtypes and grades.
  • ANIMALS: One hundred and twelve dogs with a histological diagnosis of intracranial meningioma.
  • The incidence of specific tumor grades was 56% benign (Grade I), 43% atypical (Grade II), and 1% malignant (Grade III).
  • No statistically significant (P < .05) associations were found among tumor subtype or grade and any of the MRI features studied.
  • CONCLUSIONS AND CLINICAL IMPORTANCE: Meningiomas in dogs differ from their counterparts in humans mainly in their higher incidence of atypical (Grade II) tumors observed.
  • MRI characteristics do not allow for prediction of meningioma subtype or grade, emphasizing the necessity of histopathology for antemortem diagnosis.
  • The higher incidence of atypical tumors in dogs may contribute to the poorer therapeutic response in dogs with meningiomas as compared with the response in humans with meningiomas.

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18466258.001).
  • [ISSN] 0891-6640
  • [Journal-full-title] Journal of veterinary internal medicine
  • [ISO-abbreviation] J. Vet. Intern. Med.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Woo KS, Sung KS, Kim KU, Shaffer LG, Han JY: Characterization of complex chromosome aberrations in a recurrent meningioma combining standard cytogenetic and array comparative genomic hybridization techniques. Cancer Genet Cytogenet; 2008 Jan 1;180(1):56-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Meningiomas were among the first solid tumors recognized as having cytogenetic alterations.
  • The vast majority of meningiomas are histologically benign, but the prognosis is determined by risk of recurrence after surgical treatment.
  • Despite important advances in the identification of prognostic factors in the past decade, the exact nature of tumor recurrence remains largely unknown.
  • Cytogenetic analysis at diagnosis revealed the following complex numerical and structural aberrations: 42,XY,der(1)t(1;?
  • )(p12;? ),-6,der(12;15)(q10;q10),-18, -22.
  • The presence of a complex cytogenetic profile and progression-associated chromosomal abnormalities in a benign meningioma suggests the existence of underlying molecular events.
  • [MeSH-major] Brain Neoplasms / genetics. Chromosome Aberrations. Meningeal Neoplasms / genetics

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18068535.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


84. Ragel BT, Jensen RL, Gillespie DL, Prescott SM, Couldwell WT: Celecoxib inhibits meningioma tumor growth in a mouse xenograft model. Cancer; 2007 Feb 1;109(3):588-97
Hazardous Substances Data Bank. CELECOXIB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Celecoxib inhibits meningioma tumor growth in a mouse xenograft model.
  • METHODS: Meningioma cell lines (IOMM-Lee, CH157-MN, WHO grade I primary cultured tumor) were transplanted into flanks of nude mice fed mouse chow with celecoxib at varying concentrations (0, 500, 1000, 1500 ppm) ad libitum.
  • Tumors were measured biweekly and processed for MIB-1, Factor VIII, COX-2, and VEGF, and assayed with transferase-mediated dUTP-biotin nick-end labeling (TUNEL).
  • RESULTS: Celecoxib reduced growth of mean tumor volume by 66% (P < .05), 25% (P > .05), and 65% (P < .05) compared with untreated controls in IOMM-Lee, CH157-MN, and benign tumors, respectively.
  • IOMM-Lee tumors removed from celecoxib treatment regained a growth rate similar to the control.
  • Blood vessel density decreased and apoptotic cells increased in treated flank tumors.
  • Diminished COX-2 expression and VEGF were observed in treated IOMM-Lee tumors.
  • Celecoxib-treated tumors were less vascular with increased apoptosis.
  • IOMM-Lee tumors treated with celecoxib showed decreased COX-2 and VEGF expression.
  • [MeSH-major] Cyclooxygenase Inhibitors / therapeutic use. Meningeal Neoplasms / prevention & control. Meningioma / prevention & control. Pyrazoles / therapeutic use. Sulfonamides / therapeutic use
  • [MeSH-minor] Animals. Apoptosis. Celecoxib. Cyclooxygenase 2 / metabolism. Factor VIII / metabolism. Humans. Immunoenzyme Techniques. In Situ Nick-End Labeling. Ki-67 Antigen / metabolism. Mice. Mice, Nude. Survival Rate. Tumor Cells, Cultured. Vascular Endothelial Growth Factor A / metabolism. Xenograft Model Antitumor Assays

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 American Cancer Society.
  • (PMID = 17177201.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclooxygenase Inhibitors; 0 / Ki-67 Antigen; 0 / Pyrazoles; 0 / Sulfonamides; 0 / Vascular Endothelial Growth Factor A; 9001-27-8 / Factor VIII; EC 1.14.99.1 / Cyclooxygenase 2; JCX84Q7J1L / Celecoxib
  •  go-up   go-down


85. Chang CW, Wang LC, Lee JS, Tai SH, Huang CY, Chen HH: Orbitozygomatic approach for excisions of orbital tumors with 1 piece of craniotomy bone flap: 2 case reports. Surg Neurol; 2007;68 Suppl 1:S56-9; discussion S59

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Orbitozygomatic approach for excisions of orbital tumors with 1 piece of craniotomy bone flap: 2 case reports.
  • BACKGROUND: Orbital tumors are classified as primary and secondary.
  • For primary entities, there are variable pathologies with benign and malignant natures.
  • Many of the orbital tumors should be excised through neurosurgical approaches.
  • We reported 2 cases of orbital tumors, which were clearly disclosed by magnetic resonance imaging.
  • This approach assures maximum exposure for successful en bloc excisions of these tumors with minimal bone loss, so the cosmetic results are satisfactory.
  • CONCLUSIONS: Even though most orbital tumors are diagnosed by ophthalmologists, most of them should be operated on by neurosurgeons because neurosurgical approaches offer wide and safe surgical windows.
  • [MeSH-major] Craniotomy / methods. Neurosurgical Procedures / methods. Orbit / surgery. Orbital Neoplasms / surgery. Surgical Flaps / standards. Zygoma / surgery
  • [MeSH-minor] Adenoma / pathology. Adenoma / surgery. Aged. Female. Hemangioma, Cavernous, Central Nervous System / pathology. Hemangioma, Cavernous, Central Nervous System / surgery. Humans. Lacrimal Apparatus / pathology. Lacrimal Apparatus / surgery. Lacrimal Apparatus Diseases / pathology. Lacrimal Apparatus Diseases / surgery. Meningeal Neoplasms / pathology. Meningeal Neoplasms / surgery. Meningioma / pathology. Meningioma / surgery. Middle Aged. Postoperative Complications. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Surg Neurol. 2008 Dec;70 Suppl 1:S1:91-2 [18614213.001]
  • [CommentIn] Surg Neurol. 2009 Dec;72 Suppl 2:S86 [19944830.001]
  • (PMID = 17963927.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Vogelbaum MA, Leland Rogers C, Linskey MA, Mehta MP: Opportunities for clinical research in meningioma. J Neurooncol; 2010 Sep;99(3):417-22
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Meningiomas, when benign, are commonly treated with surgical resection alone.
  • However, the optimal treatment for patients with subtotally resected or recurrent World Health Organization (WHO) grade I tumors, or WHO grade II and III tumors, regardless of the extent of resection, is not well defined, with both a paucity of high quality published evidence as well as a perceived minimal clinical effect for currently available interventions, specifically in terms of prolonging survival.
  • In consideration of the size of the patient population with incompletely treated or non-benign meningiomas, there are opportunities for conducting high quality, prospective, multicenter clinical trials.
  • [MeSH-major] Biomedical Research. Meningeal Neoplasms / pathology. Meningioma / pathology

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurgery. 2009 Jan;64(1):56-60; discussion 60 [19145156.001]
  • [Cites] J Neurosurg. 2000 May;92(5):766-70 [10794289.001]
  • [Cites] J Neurooncol. 1992 Jun;13(2):157-64 [1432033.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jul 1;56(3):801-6 [12788188.001]
  • [Cites] Neuro Oncol. 2009 Dec;11(6):853-60 [19293394.001]
  • [Cites] Br J Neurosurg. 2007 Dec;21(6):588-92 [18071986.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1957 Feb;20(1):22-39 [13406590.001]
  • [Cites] Neuropathol Appl Neurobiol. 2005 Apr;31(2):141-9 [15771707.001]
  • [Cites] Neurosurgery. 1993 Sep;33(3):394-9; discussion 399 [8413869.001]
  • [Cites] J Neurooncol. 1993 Jan;15(1):75-7 [8455065.001]
  • [Cites] Acta Neurochir (Wien). 1999;141(9):921-32 [10526073.001]
  • [Cites] Neurosurgery. 2005 Dec;57(6):1088-95; discussion 1088-95 [16331155.001]
  • [Cites] Neurosurgery. 2000 Mar;46(3):567-74; discussion 574-5 [10719852.001]
  • [Cites] Cancer. 1999 May 1;85(9):2046-56 [10223247.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Sep 1;39(2):427-36 [9308947.001]
  • [Cites] J Neurooncol. 2010 Jan;96(2):211-7 [19562255.001]
  • [Cites] Neurosurg Focus. 2008;24(5):E3 [18447742.001]
  • [Cites] Neurosurg Focus. 2003 May 15;14 (5):e4 [15669815.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 Aug;15(2):299-304 [3403313.001]
  • [Cites] Surg Neurol. 1986 Nov;26(5):461-9 [3764651.001]
  • [Cites] Mayo Clin Proc. 1998 Oct;73(10):936-42 [9787740.001]
  • [Cites] Lancet Neurol. 2006 Dec;5(12):1045-54 [17110285.001]
  • (PMID = 20835750.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


87. Jolapara M, Kesavadas C, Radhakrishnan VV, Thomas B, Gupta AK, Bodhey N, Patro S, Saini J, George U, Sarma PS: Role of diffusion tensor imaging in differentiating subtypes of meningiomas. J Neuroradiol; 2010 Dec;37(5):277-83
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Meningiomas are the most common extraaxial intracranial type of tumor, and their management and prognosis depend on their grade and histology.
  • Diffusion-weighted imaging (DWI) and diffusion tensor imaging (DTI) are two new imaging techniques that have proved helpful in elucidating the microarchitecture of brain tumors.
  • METHODS AND MATERIALS: A total of 21 consecutive patients with meningioma were included in this retrospective study, of whom 16 had benign meningiomas (three fibroblastic, 11 transitional/mixed, two meningothelial) and five had atypical meningiomas.
  • Tumor mean diffusivity (Dav), fractional anisotropy (FA), linear anisotropy (CL), planar anisotropy (CP), spherical anisotropy (CS) and eigenvalues (e1, e2, e3) were measured in all cases, and differences in diffusion tensor metrics between atypical, fibroblastic and other benign (transitional, meningothelial) meningiomas were statistically analyzed using the Mann-Whitney test.
  • RESULTS: No statistically significant differences were found among the mean Dav values for atypical, fibroblastic and other benign meningiomas.
  • Atypical meningiomas showed higher CL values compared with fibroblastic and other benign meningiomas but, again, the difference was not statistically significant.
  • CONCLUSION: These results suggest that diffusion tensor metrics may be helpful in the differentiation of atypical, fibroblastic and other benign meningiomas.
  • [MeSH-major] Diffusion Tensor Imaging. Meningeal Neoplasms / pathology. Meningioma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20381865.001).
  • [ISSN] 0150-9861
  • [Journal-full-title] Journal of neuroradiology. Journal de neuroradiologie
  • [ISO-abbreviation] J Neuroradiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  •  go-up   go-down


88. Stremenová J, Mares V, Lisá V, Hilser M, Krepela E, Vanicková Z, Syrucek M, Soula O, Sedo A: Expression of dipeptidyl peptidase-IV activity and/or structure homologs in human meningiomas. Int J Oncol; 2010 Feb;36(2):351-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Meningiomas are tumors derived from arachnoid cap cells that represent approximately 30% of all intracranial tumors.
  • DPP-IV-like enzymatic activity, including all enzymatically-active DASH molecules, was found in all 18 benign meningiomas WHO grade I and IV atypical meningiomas WHO grade II by continuous rate fluorimetric assay in tissue homogenates and catalytic enzyme histochemistry in situ.
  • Expression of CXCR4, the receptor of pro-proliferative chemokine stromal cell-derived factor-1alpha (SDF-1alpha), DPP-IV substrate, was found in all tumors, suggesting higher values in atypical grade II samples.
  • In addition, the study suggests an increase of DPP-IV-like enzymatic activity in these tumors of WHO grade II.
  • [MeSH-major] Dipeptidases / metabolism. Dipeptidyl Peptidase 4 / metabolism. Dipeptidyl-Peptidases and Tripeptidyl-Peptidases / metabolism. Meningeal Neoplasms / enzymology. Meningioma / enzymology
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Female. Gelatinases / genetics. Gelatinases / metabolism. Gene Expression. Gene Expression Profiling. Humans. Immunohistochemistry. Isoenzymes / genetics. Isoenzymes / metabolism. Male. Membrane Proteins / genetics. Membrane Proteins / metabolism. Middle Aged. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction. Serine Endopeptidases / genetics. Serine Endopeptidases / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20043068.001).
  • [ISSN] 1791-2423
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Isoenzymes; 0 / Membrane Proteins; 0 / RNA, Messenger; EC 3.4.13.- / Dipeptidases; EC 3.4.14.- / DPP9 protein, human; EC 3.4.14.- / Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; EC 3.4.14.5 / DPP8 protein, human; EC 3.4.14.5 / Dipeptidyl Peptidase 4; EC 3.4.21.- / Serine Endopeptidases; EC 3.4.21.- / fibroblast activation protein alpha; EC 3.4.24.- / Gelatinases
  •  go-up   go-down


89. Durand A, Labrousse F, Jouvet A, Bauchet L, Kalamaridès M, Menei P, Deruty R, Moreau JJ, Fèvre-Montange M, Guyotat J: WHO grade II and III meningiomas: a study of prognostic factors. J Neurooncol; 2009 Dec;95(3):367-375
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Meningiomas represent one of the largest subgroups of intracranial tumors.
  • They are generally benign, but may show a histological progression to malignancy.
  • [MeSH-major] Meningeal Neoplasms / mortality. Meningeal Neoplasms / pathology. Meningioma / mortality. Meningioma / pathology. World Health Organization
  • [MeSH-minor] Adult. Aged. Cause of Death. Databases, Factual. Disease Progression. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Multivariate Analysis. Neoplasm Recurrence, Local / mortality. Prognosis. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] J Neurooncol. 2000 Jun;48(2):151-60 [11083080.001]
  • [Cites] Virchows Arch. 2006 Nov;449(5):529-38 [17016718.001]
  • [Cites] Neurosurg Rev. 2003 Jul;26(3):221-8 [12690530.001]
  • [Cites] J Neurosurg. 1992 Oct;77(4):616-23 [1527622.001]
  • [Cites] Hum Mutat. 2006 Apr;27(4):297-306 [16521120.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1957 Feb;20(1):22-39 [13406590.001]
  • [Cites] Br J Neurosurg. 2008 Aug;22(4):520-8 [18803079.001]
  • [Cites] Acta Neurochir (Wien). 1999;141(9):921-32 [10526073.001]
  • [Cites] Neurosurgery. 2005 Sep;57(3):538-50; discussion 538-50 [16145534.001]
  • [Cites] Neurosurgery. 2005 Dec;57(6):1088-95; discussion 1088-95 [16331155.001]
  • [Cites] Cancer. 2002 Mar 1;94(5):1538-47 [11920512.001]
  • [Cites] J Clin Neurosci. 2007 Aug;14(8):747-53 [17499508.001]
  • [Cites] Acta Neurochir (Wien). 2004 Jan;146(1):37-44; discussion 44 [14740263.001]
  • [Cites] Neurosurgery. 2007 Dec;61(6):1194-8; discussion 1198 [18162898.001]
  • [Cites] Neurosurgery. 1993 Dec;33(6):955-63 [8134008.001]
  • [Cites] Surg Neurol. 1986 Mar;25(3):233-42 [3945904.001]
  • [Cites] Cancer. 1999 May 1;85(9):2046-56 [10223247.001]
  • [Cites] Lancet. 2004 May 8;363(9420):1535-43 [15135603.001]
  • [Cites] Curr Opin Neurol. 2004 Dec;17(6):687-92 [15542977.001]
  • [Cites] J Neurooncol. 1998 Apr;37(2):177-88 [9524097.001]
  • [Cites] J Neurooncol. 2009 Mar;92(1):1-6 [19023520.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Aug 1;71(5):1388-93 [18294779.001]
  • [Cites] Cancer. 2000 Sep 1;89(5):1102-10 [10964341.001]
  • [Cites] Neurosurg Focus. 2008;24(5):E3 [18447742.001]
  • [Cites] J Neuropathol Exp Neurol. 2004 Apr;63(4):275-86 [15099018.001]
  • [Cites] Neurosurg Focus. 1997 Apr 15;2(4):e3 [15096007.001]
  • [Cites] Neuropathology. 2007 Apr;27(2):114-20 [17494511.001]
  • (PMID = 19562258.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


90. Asthagiri AR, Helm GA, Sheehan JP: Current concepts in management of meningiomas and schwannomas. Neurol Clin; 2007 Nov;25(4):1209-30, xi
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Meningiomas and schwannomas are the two most common extra-axial intracranial tumors in adults.
  • Since their initial discovery, these often-benign lesions have shared a parallel metamorphosis in their management.
  • [MeSH-major] Brain Neoplasms / therapy. Meningeal Neoplasms / therapy. Meningioma / therapy. Neurilemmoma / therapy

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17964032.001).
  • [ISSN] 0733-8619
  • [Journal-full-title] Neurologic clinics
  • [ISO-abbreviation] Neurol Clin
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 126
  •  go-up   go-down


91. Ketter R, Urbschat S, Henn W, Feiden W, Beerenwinkel N, Lengauer T, Steudel WI, Zang KD, Rahnenführer J: Application of oncogenetic trees mixtures as a biostatistical model of the clonal cytogenetic evolution of meningiomas. Int J Cancer; 2007 Oct 1;121(7):1473-80

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Meningiomas are mostly benign tumors that originate from the coverings of brain and spinal cord.
  • We calculated an oncogenetic tree model that estimates the most likely cytogenetic pathways of 661 meningioma patients in terms of accumulation of somatic chromosome changes in tumor cells.
  • The genetic progression score (GPS) estimates the genetic status of a tumor as progression in the corresponding tumor cells along this model.
  • We show that tumor location also has an impact on genetic progression.
  • Clinical relevance of the GPS is thus demonstrated with respect to origin, WHO grade and recurrence of the tumor.
  • [MeSH-major] Chromosome Aberrations. Meningeal Neoplasms / pathology. Meningioma / pathology. Models, Genetic
  • [MeSH-minor] Adult. Aged. Chromosomes, Human, Pair 22. Clone Cells. Cytogenetics / methods. Disease Progression. Female. Follow-Up Studies. Gene Deletion. Humans. Karyotyping. Male. Middle Aged. Multivariate Analysis. Neoplasm Recurrence, Local / genetics. Retrospective Studies. Sex Factors. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17557299.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


92. von Randow AJ, Schindler S, Tews DS: Expression of extracellular matrix-degrading proteins in classic, atypical, and anaplastic meningiomas. Pathol Res Pract; 2006;202(5):365-72

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although the majority of meningiomas, commonly benign tumors (WHO I), are amenable to surgical resection, a percentage of up to 3% will recur as higher-grade meningiomas with potential brain invasion.
  • There was a significant increase in positive tumor cells from WHO grade I to II and III for MMP-2 (p<0.001), but not for cathepsin D (p=0.099).
  • MMP-9 displayed an increased number of positive tumor cells from WHO grade I to II, but a decrease in WHO III meningiomas (p<0.002).
  • [MeSH-major] Cathepsin D / metabolism. Matrix Metalloproteinase 2 / metabolism. Matrix Metalloproteinase 9 / metabolism. Meningeal Neoplasms / metabolism. Meningioma / metabolism
  • [MeSH-minor] Extracellular Matrix Proteins / metabolism. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16563650.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Extracellular Matrix Proteins; EC 3.4.23.5 / Cathepsin D; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


93. Schaller B: Spinal meningioma: relationship between histological subtypes and surgical outcome? J Neurooncol; 2005 Nov;75(2):157-61
Genetic Alliance. consumer health - Meningioma, spinal.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Intraspinal meningiomas are slow growing benign tumors that produce indolent neurological deficits, which are often reversible following operation.
  • Mean age of the 30 women (91%) and the 3 men (9%) was 63+/-20 years (range 22-88).
  • Tumor position was laterally in 19 (58%), posteriorly in 8 (24%) and anteriorly in 6 (18%) patients.
  • Following tumor resection, neurological deficits resolved in 26 of 33 patients (79%) and worsened in 7 of 33 patients (21%) all of the latter had meningiomas of the psammomatous type.
  • Posterior or lateral tumor position in the spinal canal, location below C4, age less than 60 years, and duration of preoperative symptoms seem to be correlated with a good outcome.
  • [MeSH-major] Meningeal Neoplasms / diagnosis. Meningeal Neoplasms / pathology. Meningeal Neoplasms / surgery. Meningioma / diagnosis. Meningioma / pathology. Meningioma / surgery
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Angiography. Chi-Square Distribution. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Myelography. Neoplasm Recurrence, Local. Neurologic Examination. Prognosis. Regression Analysis. Retrospective Studies. Sex Factors. Time Factors. Tomography, X-Ray Computed. Treatment Outcome. Tumor Burden. X-Rays

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] J Neurosurg. 1982 Dec;57(6):804-12 [7143063.001]
  • [Cites] J Neurosurg. 1986 Feb;64(2):253-6 [3003263.001]
  • [Cites] J Neurosurg. 1979 Mar;50(3):353-60 [422988.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1957 Feb;20(1):22-39 [13406590.001]
  • [Cites] Acta Neurol Scand. 1988 Jan;77(1):27-30 [3354308.001]
  • [Cites] Acta Neurochir (Wien). 1999;141(5):465-71 [10392201.001]
  • [Cites] Neurosurgery. 1990 Oct;27(4):629-31 [2234369.001]
  • [Cites] Otolaryngol Head Neck Surg. 1995 Feb;112(2):228-34 [7838543.001]
  • [Cites] J Neurosurg. 1989 Apr;70(4):646-8 [2926506.001]
  • [Cites] Ann Surg. 1940 Apr;111(4):513-30 [17857556.001]
  • [Cites] J Neurosurg. 1987 May;66(5):695-700 [3572496.001]
  • [Cites] Neurosurgery. 1989 Aug;25(2):153-60 [2671779.001]
  • [Cites] Neurology. 1975 Aug;25(8):705-12 [1171403.001]
  • (PMID = 16132511.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


94. Tabernero MD, Espinosa AB, Maíllo A, Sayagués JM, Alguero Mdel C, Lumbreras E, Díaz P, Gonçalves JM, Onzain I, Merino M, Morales F, Orfao A: Characterization of chromosome 14 abnormalities by interphase in situ hybridization and comparative genomic hybridization in 124 meningiomas: correlation with clinical, histopathologic, and prognostic features. Am J Clin Pathol; 2005 May;123(5):744-51

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cases with gain or monosomy corresponded more frequently to histologically malignant tumors (P = .009).
  • The 2 patients with loss limited to 14q31-q32 had histologically benign tumors and no relapse after more than 5 years' follow-up.
  • [MeSH-major] Chromosome Aberrations. Chromosomes, Human, Pair 14. In Situ Hybridization, Fluorescence / methods. Meningeal Neoplasms / genetics. Meningioma / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Humans. Interphase. Male. Middle Aged. Neoplasm Recurrence, Local / genetics. Neoplasm Recurrence, Local / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15981814.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


95. Kalamarides M, Peyre M, Giovannini M: Meningioma mouse models. J Neurooncol; 2010 Sep;99(3):325-31
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Meningiomas, although mostly benign, may sometimes present aggressive features and raise issues concerning alternative treatment options besides surgery.
  • As rodents very rarely develop spontaneous meningiomas, animal models have been first developed by implanting human meningioma cells derived from a primary tumor and meningioma cell lines subcutaneously into athymic mice.
  • Induction of de novo meningiomas in rodents with mutagens, such as nitrosourea, has also been reported.
  • Advances in our understanding of molecular genetics of meningioma have pinpointed the central role of NF2 tumor suppressor gene in the pathogenesis of those tumors.
  • These discoveries have led to the creation of a genetically engineered model utilizing conditional mutagenesis to specifically inactivate the mouse Nf2 gene in arachnoidal cells, resulting in the formation of intracranial meningothelial hyperplasia and meningiomas and thus reproducing the main mechanism of human meningeal tumorigenesis.
  • [MeSH-major] Disease Models, Animal. Meningeal Neoplasms / pathology. Meningioma / pathology

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurgery. 2009 Jan;64(1):56-60; discussion 60 [19145156.001]
  • [Cites] J Neurosurg. 2008 Feb;108(2):304-10 [18240927.001]
  • [Cites] Mod Pathol. 2001 Mar;14(3):197-201 [11266526.001]
  • [Cites] Brain Pathol. 2002 Apr;12(2):183-90 [11958372.001]
  • [Cites] J Neurosurg. 1989 Oct;71(4):545-50 [2477514.001]
  • [Cites] Neurosurgery. 2007 Apr;60(4):750-9; discussion 759-60 [17415213.001]
  • [Cites] Cancer. 2007 Feb 1;109(3):588-97 [17177201.001]
  • [Cites] Genes Dev. 2000 Jul 1;14(13):1617-30 [10887156.001]
  • [Cites] Proc Soc Exp Biol Med. 1977 May;155(1):85-8 [193127.001]
  • [Cites] Int J Mol Med. 2003 Dec;12(6):943-7 [14612971.001]
  • [Cites] Brain Pathol. 2008 Jan;18(1):62-70 [17924978.001]
  • [Cites] J Neurosurg. 1995 May;82(5):864-73 [7714613.001]
  • [Cites] Br J Cancer. 1978 Apr;37(4):644-7 [646935.001]
  • [Cites] Neurosurgery. 1998 Jan;42(1):130-5; discussion 135-6 [9442514.001]
  • [Cites] Neurosurgery. 2007 May;60(5):787-98; discussion 787-98 [17460514.001]
  • [Cites] J Neurosurg. 2007 Mar;106(3):455-62 [17367069.001]
  • [Cites] J Med Genet. 1992 Dec;29(12 ):841-6 [1479598.001]
  • [Cites] Am J Pathol. 2001 Aug;159(2):661-9 [11485924.001]
  • [Cites] Surg Neurol. 2001 May;55(5):275-83 [11516467.001]
  • [Cites] Genes Dev. 2002 May 1;16(9):1060-5 [12000789.001]
  • [Cites] J Neuropathol Exp Neurol. 2000 Oct;59(10):872-9 [11079777.001]
  • [Cites] Br J Neurosurg. 2001 Aug;15(4):328-34 [11599449.001]
  • [Cites] Toxicol Pathol. 2007 Oct;35(6):780-7 [17943659.001]
  • [Cites] J Neurosci. 1997 Apr 1;17(7):2376-82 [9065498.001]
  • [Cites] J Neurosurg. 2004 Feb;100(2):303-9 [15098535.001]
  • [Cites] J Neurosurg. 1987 Apr;66(4):584-7 [3559725.001]
  • [Cites] Can J Neurol Sci. 2003 Nov;30(4):326-32 [14672264.001]
  • [Cites] Clin Neuropathol. 1994 Mar-Apr;13(2):82-7 [8205731.001]
  • [Cites] Hum Pathol. 1997 Apr;28(4):416-20 [9104940.001]
  • [Cites] J Neurosurg. 2001 Mar;94(3):487-92 [11235955.001]
  • [Cites] Exp Toxicol Pathol. 2008 Aug;60(4-5):247-51 [18524558.001]
  • [Cites] Neurosurgery. 1990 Sep;27(3):389-95; discussion 396 [2234331.001]
  • [Cites] Neurology. 2004 Apr 13;62(7):1210-2 [15079029.001]
  • [Cites] Neoplasia. 2002 Jul-Aug;4(4):304-11 [12082546.001]
  • [Cites] J Neurosurg. 2000 Feb;92(2):306-14 [10659019.001]
  • [Cites] Nature. 1995 Dec 14;378(6558):720-4 [7501018.001]
  • [Cites] J Neurooncol. 2006 Jun;78(2):113-21 [16554968.001]
  • [Cites] Brain Tumor Pathol. 1997;14 (2):139-43 [15726793.001]
  • [Cites] Cell. 1987 Nov 6;51(3):503-12 [2822260.001]
  • [Cites] Neurology. 1997 Jul;49(1):267-70 [9222206.001]
  • [Cites] Cancer Res. 1994 Dec 1;54(23):6090-3 [7954452.001]
  • [Cites] Brain Pathol. 2005 Jan;15(1):55-65 [15779237.001]
  • [Cites] Genes Dev. 1998 Apr 15;12(8):1121-33 [9553042.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2008 May;79(5):574-80 [17766430.001]
  • [Cites] Surg Neurol. 2008 Sep;70(3):295-307; discussion 307 [18261772.001]
  • [Cites] Cell Prolif. 2005 Feb;38(1):3-12 [15679862.001]
  • [Cites] Toxicol Pathol. 2000 Jan-Feb;28(1):202-14 [10669008.001]
  • [Cites] Brain Pathol. 2008 Apr;18(2):172-9 [18093250.001]
  • [Cites] Lab Invest. 2005 Sep;85(9):1163-71 [15965488.001]
  • (PMID = 20734219.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


96. Pérez-Magán E, Rodríguez de Lope A, Ribalta T, Ruano Y, Campos-Martín Y, Pérez-Bautista G, García JF, García-Claver A, Fiaño C, Hernández-Moneo JL, Mollejo M, Meléndez B: Differential expression profiling analyses identifies downregulation of 1p, 6q, and 14q genes and overexpression of 6p histone cluster 1 genes as markers of recurrence in meningiomas. Neuro Oncol; 2010 Dec;12(12):1278-90

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The majority of meningiomas are probably benign but a number of tumors display considerable histological and/or clinical aggressivity, sometimes with unexpectedly high recurrence rates after radical removal.
  • Understanding the potential behavior of these tumors in individual patients is critical for rational therapeutic decision-making.
  • [MeSH-major] Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 14 / genetics. Chromosomes, Human, Pair 6 / genetics. Histones / genetics. Meningeal Neoplasms / genetics. Meningioma / genetics. Neoplasm Recurrence, Local / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Female. Gene Expression Profiling. Humans. Immunoenzyme Techniques. In Situ Hybridization, Fluorescence. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. Prognosis. Survival Rate. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 Feb;18(3):636-45 [10653879.001]
  • [Cites] Cancer Genet Cytogenet. 2000 Jul 1;120(1):30-6 [10913674.001]
  • [Cites] J Neurosurg. 2001 Feb;94(2):293-300 [11213968.001]
  • [Cites] Am J Pathol. 2002 Aug;161(2):665-72 [12163391.001]
  • [Cites] Mod Pathol. 2003 Jul;16(7):708-15 [12861068.001]
  • [Cites] Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3606-14 [14506147.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):883-8 [14871816.001]
  • [Cites] J Neurooncol. 2004 Jan;66(1-2):9-16 [15015765.001]
  • [Cites] Oncol Rep. 2004 Oct;12(4):939-43 [15375526.001]
  • [Cites] J Neurosurg. 1985 Jan;62(1):18-24 [3964853.001]
  • [Cites] J Neurosurg. 1989 Nov;71(5 Pt 1):665-72 [2809720.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14719-24 [9405679.001]
  • [Cites] Am J Surg Pathol. 1997 Dec;21(12):1455-65 [9414189.001]
  • [Cites] Cancer. 1998 Jul 15;83(2):360-6 [9669820.001]
  • [Cites] Mayo Clin Proc. 1998 Oct;73(10):936-42 [9787740.001]
  • [Cites] J Neurooncol. 1999 Jan;41(2):167-74 [10222437.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1957 Feb;20(1):22-39 [13406590.001]
  • [Cites] Curr Opin Neurol. 2004 Dec;17(6):687-92 [15542977.001]
  • [Cites] Int J Cancer. 2005 Mar 20;114(2):249-56 [15540215.001]
  • [Cites] Cancer Res. 2005 Apr 1;65(7):2653-61 [15805262.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 May 24;102(21):7659-64 [15897450.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):5070-5 [15958550.001]
  • [Cites] Am J Clin Pathol. 2005 May;123(5):744-51 [15981814.001]
  • [Cites] Neurosurgery. 2005 Sep;57(3):538-50; discussion 538-50 [16145534.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50 [16199517.001]
  • [Cites] Cell. 2005 Dec 29;123(7):1199-212 [16377562.001]
  • [Cites] Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):772-80 [16467088.001]
  • [Cites] Oncogene. 2006 May 11;25(20):2920-30 [16331278.001]
  • [Cites] Lancet Neurol. 2006 Dec;5(12):1045-54 [17110285.001]
  • [Cites] Neuro Oncol. 2007 Oct;9(4):438-46 [17704362.001]
  • [Cites] Mol Cancer. 2007;6:64 [17937814.001]
  • [Cites] J Biol Chem. 2008 Apr 4;283(14):9113-26 [18258596.001]
  • [Cites] Neoplasia. 2008 Jun;10(6):604-12 [18516297.001]
  • [Cites] Int J Cancer. 2009 Jan 15;124(2):346-51 [19003955.001]
  • [Cites] Mol Cancer. 2008;7:93 [19099607.001]
  • [Cites] Gynecol Oncol. 2009 Mar;112(3):646-53 [19095296.001]
  • [Cites] Biofactors. 2009 Mar-Apr;35(2):200-8 [19449449.001]
  • [Cites] Brain Pathol. 2009 Jul;19(3):409-20 [18637901.001]
  • [Cites] Int J Oncol. 2009 Dec;35(6):1395-407 [19885562.001]
  • [Cites] Int J Cancer. 2010 Jun 1;126(11):2584-93 [19847810.001]
  • [Cites] Cancer Genet Cytogenet. 2005 Oct 1;162(1):63-7 [16157202.001]
  • (PMID = 20685720.001).
  • [ISSN] 1523-5866
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Histones
  • [Other-IDs] NLM/ PMC3018937
  •  go-up   go-down


97. Haase D, Schmidl S, Ewald C, Kalff R, Huebner C, Firsching R, Keilhoff G, Evert M, Paulus W, Gutmann DH, Lal A, Mawrin C: Fatty acid synthase as a novel target for meningioma therapy. Neuro Oncol; 2010 Aug;12(8):844-54
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • High levels of fatty acid synthase (FAS) expression have been reported in hormone receptor-positive tumors, including prostate, breast, and ovarian cancers, and its inhibition reduces tumor growth in vitro and in vivo.
  • Similar to other hormone receptor-positive tumor types, meningiomas are progesterone receptor- and estrogen receptor-immunoreactive brain tumors.
  • To define the role of FAS in human meningioma growth control, we first analyzed the FAS expression using a tissue microarray containing 38 meningiomas and showed increased FAS expression in 70% of atypical WHO grade II and anaplastic WHO grade III meningiomas compared with 10% of benign WHO grade I tumors.
  • Fourth, we demonstrated that Cer treatment of mice bearing meningioma xenografts resulted in significantly reduced tumor volumes associated with increased meningioma cell death.
  • [MeSH-major] Cerulenin / pharmacology. Fatty Acid Synthases / metabolism. Fatty Acid Synthesis Inhibitors / pharmacology. Meningeal Neoplasms / enzymology. Meningioma / enzymology
  • [MeSH-minor] Animals. Apoptosis / drug effects. Blotting, Western. Cell Line, Tumor. Cell Survival / drug effects. DNA Fragmentation / drug effects. Enzyme-Linked Immunosorbent Assay. Female. Humans. Immunohistochemistry. In Situ Nick-End Labeling. Mice. Mice, SCID. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction. Tissue Array Analysis. Xenograft Model Antitumor Assays

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Histochem Cytochem. 2000 May;48(5):613-22 [10769045.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3450-4 [10716717.001]
  • [Cites] Clin Cancer Res. 2001 Jan;7(1):153-7 [11205903.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1493-9 [11245456.001]
  • [Cites] Am J Pathol. 2001 Aug;159(2):661-9 [11485924.001]
  • [Cites] Cancer. 2002 Mar 15;94(6):1626-35 [11920521.001]
  • [Cites] Exp Cell Res. 2003 Jan 15;282(2):132-7 [12531699.001]
  • [Cites] Histopathology. 2003 Sep;43(3):280-90 [12940781.001]
  • [Cites] Mol Cell Biol. 2003 Nov;23(21):7794-808 [14560023.001]
  • [Cites] Cancer Res. 2003 Nov 1;63(21):7330-7 [14612531.001]
  • [Cites] Oncol Rep. 2004 Aug;12(2):411-22 [15254710.001]
  • [Cites] Ann Neurol. 2004 Aug;56(2):295-8 [15293284.001]
  • [Cites] J Biol Chem. 2004 Aug 27;279(35):36608-15 [15220355.001]
  • [Cites] J Biochem. 1989 May;105(5):751-5 [2666407.001]
  • [Cites] Cancer. 1989 Dec 1;64(11):2243-9 [2804914.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Jul 5;91(14):6379-83 [8022791.001]
  • [Cites] Cancer Res. 1996 Mar 15;56(6):1189-93 [8640795.001]
  • [Cites] Int J Gynecol Pathol. 1997 Jan;16(1):45-51 [8986532.001]
  • [Cites] Neurology. 1997 Jul;49(1):267-70 [9222206.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14719-24 [9405679.001]
  • [Cites] Anticancer Res. 1997 Nov-Dec;17(6D):4589-93 [9494573.001]
  • [Cites] Am J Physiol. 1999 Aug;277(2 Pt 1):L381-90 [10444533.001]
  • [Cites] Lab Invest. 2005 Jan;85(1):99-108 [15543204.001]
  • [Cites] Oncogene. 2005 Jan 6;24(1):39-46 [15489885.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):183-202 [15674477.001]
  • [Cites] J Pathol. 2005 Jun;206(2):214-9 [15880754.001]
  • [Cites] Clin Cancer Res. 2005 Jun 1;11(11):4074-82 [15930342.001]
  • [Cites] Oncogene. 2005 May 19;24(22):3574-82 [15806173.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):5070-5 [15958550.001]
  • [Cites] Clin Neuropathol. 2005 Jul-Aug;24(4):175-83 [16033134.001]
  • [Cites] Lab Invest. 2005 Sep;85(9):1163-71 [15965488.001]
  • [Cites] Cancer Res. 2006 Jun 15;66(12):5977-80 [16778164.001]
  • [Cites] Br J Cancer. 2006 Oct 9;95(7):869-78 [16969344.001]
  • [Cites] Cancer Res. 2007 Jan 15;67(2):735-45 [17234785.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Nat Rev Cancer. 2007 Oct;7(10):763-77 [17882277.001]
  • [Cites] Biomed Pharmacother. 2007 Oct;61(9):578-87 [17904792.001]
  • [Cites] Cancer Res. 2008 Jan 1;68(1):314-22 [18172325.001]
  • [Cites] J Neuropathol Exp Neurol. 2000 Oct;59(10):872-9 [11079777.001]
  • (PMID = 20511185.001).
  • [ISSN] 1523-5866
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fatty Acid Synthesis Inhibitors; 0 / RNA, Messenger; 17397-89-6 / Cerulenin; EC 2.3.1.85 / Fatty Acid Synthases
  • [Other-IDs] NLM/ PMC2940685
  •  go-up   go-down


98. Norden AD, Drappatz J, Wen PY: Advances in meningioma therapy. Curr Neurol Neurosci Rep; 2009 May;9(3):231-40
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Meningiomas are the most common primary brain tumors in adults.
  • Most of them are benign (World Health Organization grade I), slow-growing lesions, but some are classified as atypical (WHO grade II) or malignant (WHO grade III).
  • Surgical resection is curative when complete removal of a benign meningioma is possible.
  • Incompletely resected tumors and high-grade lesions are frequently treated with fractionated radiotherapy or stereotactic radiosurgery.
  • [MeSH-major] Meningeal Neoplasms / therapy. Meningioma / therapy

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Zentralbl Neurochir. 2005 Feb;66(1):17-23 [15744624.001]
  • [Cites] Eur J Endocrinol. 2005 Jan;152(1):161-2 [15762200.001]
  • [Cites] J Biomed Opt. 2005 Nov-Dec;10(6):064026 [16409091.001]
  • [Cites] N Engl J Med. 2007 Dec 6;357(23):2411-2 [18057351.001]
  • [Cites] Neurosurgery. 2007 Nov;61(5):1048-59; discussion 1060-1 [18091281.001]
  • [Cites] J Clin Oncol. 2008 Jan 10;26(2):279-82 [18182668.001]
  • [Cites] Neuro Oncol. 2007 Oct;9(4):438-46 [17704362.001]
  • [Cites] J Neurooncol. 2008 Jul;88(3):251-9 [18365142.001]
  • [Cites] Cancer. 2007 Aug 1;110(3):471-6 [17580362.001]
  • [Cites] Cancer Res. 2006 May 15;66(10):5295-303 [16707455.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Aug;16(8):1655-61 [17684142.001]
  • [Cites] Nat Genet. 1994 Feb;6(2):180-4 [8162072.001]
  • [Cites] Neurosurgery. 2007 May;60(5):787-98; discussion 787-98 [17460514.001]
  • [Cites] Neurosurgery. 2005 Jul;57(1 Suppl):107-13; discussion 107-13 [15987576.001]
  • [Cites] Brain. 2008 Mar;131(Pt 3):606-15 [17940085.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1957 Feb;20(1):22-39 [13406590.001]
  • [Cites] Neurosurg Focus. 2007;23(4):E9 [17961046.001]
  • [Cites] Neurosurg Focus. 2007;23(4):E11 [17961035.001]
  • [Cites] Int J Cancer. 2009 Jan 15;124(2):346-51 [19003955.001]
  • [Cites] J Neurooncol. 1993 Jan;15(1):75-7 [8455065.001]
  • [Cites] J Neurooncol. 2004 Jan;66(1-2):155-66 [15015781.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):858-63 [17379447.001]
  • [Cites] J Neuropathol Exp Neurol. 2005 Dec;64(12):1029-36 [16319713.001]
  • [Cites] J Neurooncol. 2007 May;83(1):33-8 [17245625.001]
  • [Cites] Neoplasia. 2008 Nov;10(11):1204-12 [18953429.001]
  • [Cites] Cancer Genet Cytogenet. 2008 Nov;187(1):25-7 [18992637.001]
  • [Cites] Cancer Genet Cytogenet. 2008 Jul 15;184(2):87-93 [18617056.001]
  • [Cites] J Neuropathol Exp Neurol. 2000 Oct;59(10):872-9 [11079777.001]
  • [Cites] Neurosurgery. 1997 May;40(5):1016-26 [9149260.001]
  • [Cites] J Neurol. 2008 Jun;255(6):891-5 [18350353.001]
  • [Cites] Curr Med Chem. 2008;15(8):826-33 [18393851.001]
  • [Cites] Neurology. 2007 Sep 4;69(10):969-73 [17785665.001]
  • [Cites] Neurosurgery. 2000 Apr;46(4):938-47; discussion 947-8 [10764269.001]
  • [Cites] J Neurosurg. 2001 Mar;94(3):487-92 [11235955.001]
  • [Cites] N Engl J Med. 2008 May 8;358(19):2039-49 [18463380.001]
  • [Cites] Crit Rev Oncol Hematol. 2008 Aug;67(2):153-71 [18342535.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Oct;17 (10 ):2663-70 [18843008.001]
  • [Cites] J Clin Oncol. 2001 Aug 1;19(15):3547-53 [11481362.001]
  • [Cites] J Neurosurg. 2007 Jun;106(6):1034-40 [17564176.001]
  • [Cites] Hybridoma. 2001 Apr;20(2):131-6 [11394532.001]
  • [Cites] J Neurosurg. 1994 Feb;80(2):195-201 [8283256.001]
  • [Cites] Neurology. 2004 Apr 13;62(7):1210-2 [15079029.001]
  • [Cites] J Neurosurg. 1996 May;84(5):733-6 [8622144.001]
  • [Cites] Neurosurgery. 2008 Jun;62(6 Suppl 3):1115-21; discussion 1121-3 [18695533.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):147-56 [17594108.001]
  • [Cites] J Neurooncol. 2005 Jul;73(3):219-23 [15980972.001]
  • [Cites] J Natl Cancer Inst. 2008 Feb 20;100(4):270-6 [18270339.001]
  • [Cites] Neurosurgery. 2008 Mar;62(3 Suppl 1):102-3; discussion 103-4 [18424972.001]
  • [Cites] Eur J Endocrinol. 2002 May;146(5):707-16 [11980628.001]
  • [Cites] Neoplasia. 2008 Jun;10(6):604-12 [18516297.001]
  • [Cites] Neurosurgery. 2001 Nov;49(5):1029-37; discussion 1037-8 [11846894.001]
  • [Cites] J Neurooncol. 2006 Jul;78(3):271-6 [16628476.001]
  • [Cites] J Neurooncol. 1998 Apr;37(2):177-88 [9524097.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jan 1;46(1):57-61 [10656373.001]
  • [Cites] Neurosurg Focus. 2007;23(4):E5 [17961042.001]
  • [Cites] Cancer Genet Cytogenet. 2008 May;183(1):14-20 [18474292.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Aug 1;71(5):1388-93 [18294779.001]
  • [Cites] Neurosurgery. 2008 Jan;62(1):61-9; discussion 69-70 [18300892.001]
  • [Cites] Surg Neurol. 2003 Oct;60(4):298-305; discussion 305 [14505844.001]
  • [Cites] J Neurosurg. 2000 Dec;93 Suppl 3:62-7 [11143265.001]
  • [Cites] Cancer. 2008 Oct 15;113(8):2146-51 [18756531.001]
  • [Cites] Int J Cancer. 2005 Dec 20;117(6):996-1001 [15986431.001]
  • [Cites] Neurosurg Focus. 2008;24(5):E2 [18447741.001]
  • [Cites] Neurosurgery. 2007 Sep;61(3):495-503; discussion 503-4 [17881961.001]
  • [Cites] Cancer Res. 2008 Jan 1;68(1):314-22 [18172325.001]
  • [Cites] J Neuropathol Exp Neurol. 2004 Apr;63(4):275-86 [15099018.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2008 May;79(5):574-80 [17766430.001]
  • [Cites] BMC Cancer. 2006 Jun 07;6:152 [16759391.001]
  • [Cites] Neurosurg Focus. 2007;23(4):E4 [17961041.001]
  • [Cites] BMC Genomics. 2007 Jan 12;8:16 [17222329.001]
  • [Cites] Neurology. 1975 Aug;25(8):705-12 [1171403.001]
  • [Cites] Surg Neurol. 1986 Nov;26(5):461-9 [3764651.001]
  • [Cites] Int J Cancer. 2007 Oct 1;121(7):1473-80 [17557299.001]
  • [Cites] Clin Cancer Res. 2001 Aug;7(8):2269-76 [11489801.001]
  • [Cites] Neurosurg Focus. 2003 May 15;14(5):e5 [15669816.001]
  • (PMID = 19348712.001).
  • [ISSN] 1534-6293
  • [Journal-full-title] Current neurology and neuroscience reports
  • [ISO-abbreviation] Curr Neurol Neurosci Rep
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 81
  •  go-up   go-down


99. Terzi A, Saglam EA, Barak A, Soylemezoglu F: The significance of immunohistochemical expression of Ki-67, p53, p21, and p16 in meningiomas tissue arrays. Pathol Res Pract; 2008;204(5):305-14
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We analyzed the immunohistochemical expression of Ki-67, p53, p21, p16, and PTEN proteins in 130 meningiomas (64 benign, 39 atypical, and 27 malignant meningiomas) using tissue microarray.
  • The tumors were graded according to the World Health Organization classification.
  • In contrast, multivariate analysis revealed that only tumor grade is an independent factor for predicting meningioma recurrence.
  • We conclude that the Ki-67 and p53 labeling indices are useful additional tools in discriminating atypical from benign or anaplastic meningiomas, especially in histological borderline cases.
  • [MeSH-major] Cyclin-Dependent Kinase Inhibitor p16 / analysis. Cyclin-Dependent Kinase Inhibitor p21 / analysis. Immunohistochemistry. Ki-67 Antigen / analysis. Meningeal Neoplasms / chemistry. Meningioma / chemistry. Tissue Array Analysis. Tumor Suppressor Protein p53 / analysis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Infant. Logistic Models. Male. Middle Aged. Neoplasm Staging. Neurofibromatosis 2 / immunology. Neurofibromatosis 2 / metabolism. PTEN Phosphohydrolase / analysis. Recurrence. Risk Assessment. Time Factors. Treatment Outcome

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18374497.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / CDKN1A protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Ki-67 Antigen; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


100. Nakasu S, Fukami T, Jito J, Matsuda M: Microscopic anatomy of the brain-meningioma interface. Brain Tumor Pathol; 2005;22(2):53-7
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The other 19 tumors showed partial disruption of the arachnoid membrane.
  • The degree of arachnoid disruption correlated with the tumor grade, perifocal edema, pial blood supply on angiography, and tumor size.
  • The existence of brain invasion correlated with the tumor grade and partially with tumor size.
  • In case of invasive tumor, GFAP-positive cells were found deep in the tumor, usually in contact with blood vessels.
  • In two benign meningiomas that looked like an invasive growth, Col4 staining was seen above the brain.
  • A pia mater-like structure covered the tumor surface in both cases.
  • [MeSH-major] Brain / ultrastructure. Meningeal Neoplasms / ultrastructure. Meningioma / ultrastructure
  • [MeSH-minor] Amyloid beta-Protein Precursor / analysis. Arachnoid / ultrastructure. Brain Edema / etiology. Collagen Type IV / analysis. Glial Fibrillary Acidic Protein / analysis. Humans. Immunoenzyme Techniques. Matrix Metalloproteinase 2 / analysis. Matrix Metalloproteinase 9 / analysis. Mucin-1 / analysis. Neoplasm Invasiveness. Neoplasm Proteins / analysis. Neurofilament Proteins / analysis. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18095106.001).
  • [ISSN] 1861-387X
  • [Journal-full-title] Brain tumor pathology
  • [ISO-abbreviation] Brain Tumor Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Amyloid beta-Protein Precursor; 0 / Collagen Type IV; 0 / Glial Fibrillary Acidic Protein; 0 / Mucin-1; 0 / Neoplasm Proteins; 0 / Neurofilament Proteins; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down






Advertisement